<!DOCTYPE drug_guide PUBLIC "-//ES//DTD drug_guide DTD version 3.1//EN//XML" "Y:\WWW1\tools\Drugs\3_1_drug.dtd">
<drug_guide isbn="9780323448260">
	<alpha letter="n">
		<monograph id="1" status="active" ru="yes">
			<mono_name>nabumetone (Rx)</mono_name>
			<info>
				<pronunciation>(na-byoo′me-tone)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x230">Relafen</tradename>
				</tradenames>
				<class type="func"> Nonsteroidal antiinflammatory</class>
				<class type="chem"> Acetic acid derivative</class>
			</info>
			<section type="uses" id="sidelem4x33">
				<sec_title>Uses:</sec_title>
				<para>Osteoarthritis, rheumatoid arthritis, acute or chronic treatment</para>
			</section>
			<section type="contra" id="sidelem4x38">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or aspirin, NSAIDs</para>
				<para>
					<bbw>Perioperative pain with CABG surgery</bbw>
				</para>
			</section>
			<section type="doses" id="sidelem4x53">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x61">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x61">
							<item>
								<label>•</label>
								<para> 1 g as single dose or divided bid; max 2 g/day if needed</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x65">
					<section type="none" id="sidelem4x66">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x74">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 31-49 ml/min, 750 mg daily, max 1500 mg/day; CCr &lt;30 ml/min 500 mg daily, max 1000 mg/day</route></sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="2" status="active">
			<mono_name>nadolol (Rx)</mono_name>
			<info>
				<pronunciation>(nay-doe′lole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x821">Corgard</tradename>
					<tradename id="tnidelem4x820">
						<country code="CAN">Syn-Nadol</country>
					</tradename>
				</tradenames>
				<class type="func"> Antihypertensive, antianginal</class>
				<class type="chem"> β-Adrenergic receptor blocker</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x94">
				<para>
					<confusion>
						<tradename id="tnidelem4x940">Corgard</tradename>
						<drug type="generic" refid="idelem4x940">Cognex/Coreg</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x101">
				<sec_title>Action:</sec_title>
				<para>Long-acting, nonselective β-adrenergic receptor blocking agent, blocks β<emphasis style="inf">1</emphasis> in the heart and β<emphasis style="inf">2</emphasis> in the lungs, uterus, and circulatory system; mechanism is similar to that of propranolol</para>
			</section>
			<section type="uses" id="sidelem4x112">
				<sec_title>Uses:</sec_title>
				<para>Chronic stable angina pectoris, mild to moderate hypertension</para>
				<section type="none" id="sidelem4x117">
					<section type="none" id="sidelem4x118">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Tachydysrhythmias, anxiety, tremors, esophageal varices (rebleeding only), prophylaxis of migraine headaches, portal hypertension, atrial fibrillation</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x123">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, cardiac failure, cardiogenic shock, 2nd/3rd-degree heart block, bronchospastic disease, sinus bradycardia, CHF, COPD</para>
				<section type="none" id="sidelem4x128">
					<section type="none" id="sidelem4x129">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, diabetes mellitus, renal disease, hyperthyroidism, peripheral vascular disease, myasthenia gravis, major surgery, nonallergic bronchospasm</para>
						<para>
							<bbw>Abrupt discontinuation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x144">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x152">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x152">
							<item>
								<label>•</label>
								<para> 40 mg/day, increase by 40-80 mg q2-14days; maintenance 40-240 mg/day for angina, 40-320 mg/day for hypertension</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x159">
					<label>•</label>
					<sec_title>Geriatric<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x159">
							<item>
								<label>•</label>
								<para> 20 mg/day, may increase by 20 mg until desired dose</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x163">
					<section type="none" id="sidelem4x164">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x172">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 31-50 ml/min, give q24-36hr; CCr 10-30 ml/min, give q24-48hr; CCr &lt;10 ml/min, give q40-60hr</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x175">
						<sec_title>Migraine prevention (unlabeled)</sec_title>
						<section type="none" id="sidelem4x183">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x183">
									<item>
										<label>•</label>
										<para> 40-240 mg/day × 2-18 mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x187">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 20, 40, 80 mg</para>
					</section>
					<section type="none" id="sidelem4x192">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x196">
								<item>
									<label>•</label>
									<para>With 8 oz water, check apical pulse before use, if &lt;50 bpm, withhold; notify prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>Give without regard to food</para>
								</item>
								<item>
									<label>•</label>
									<para>Tabs may be crushed and mixed with food</para>
								</item>
								<item>
									<label>•</label>
									<para>Discontinue other antihypertensives gradually</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x217">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x220">
					<section type="none" id="sidelem4x221">
						<sec_title>CNS:</sec_title>
						<para> Depression, <emphasis style="italic">dizziness, fatigue,</emphasis> lethargy, paresthesias, headache, <emphasis style="italic">weakness,</emphasis> insomnia, memory loss, nightmares</para>
					</section>
					<section type="none" id="sidelem4x233">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Bradycardia, hypotension,</emphasis><emphasis style="bold">CHF,</emphasis> palpitations, <emphasis style="bold">AV block,</emphasis> chest pain, peripheral ischemia, flushing, edema, vasodilation, conduction disturbances</para>
					</section>
					<section type="none" id="sidelem4x246">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, dry eyes, nasal congestion</para>
					</section>
					<section type="none" id="sidelem4x251">
						<sec_title>ENDO:</sec_title>
						<para> Hyperglycemia, hypoglycemia</para>
					</section>
					<section type="none" id="sidelem4x256">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, diarrhea, colitis, constipation, cramps, dry mouth, flatulence, hepatomegaly, <emphasis style="bold">pancreatitis,</emphasis> taste distortion</para>
					</section>
					<section type="none" id="sidelem4x264">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Impotence,</emphasis> decreased libido</para>
					</section>
					<section type="none" id="sidelem4x272">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x279">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, fever, alopecia</para>
					</section>
					<section type="none" id="sidelem4x284">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea, respiratory dysfunction, <emphasis style="bold">bronchospasm,</emphasis> cough, wheezing, <emphasis style="bold">pulmonary edema,</emphasis> pharyngitis, <emphasis style="bold">laryngospasm</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x297">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x300">
					<section type="none" id="sidelem4x301">
						<sec_title>PO:</sec_title>
						<para> Onset variable, peak 3-4 hr, duration 10-24 hr; half-life 20-24 hr; not metabolized; excreted in urine (unchanged), bile, breast milk; protein binding 30%</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x306">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x314">
					<label>•</label>
					<sec_title>
						<route>Do not use with MAOIs; bradycardia may occur</route>
					</sec_title>
				</section>
				<para>
					<list id="lidelem4x317">
						<item>
							<label>•</label>
							<para>Peripheral ischemia: ergots</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bradycardia—digoxin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension, bradycardia—cloNIDine, EPINEPHrine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotensive effects—other hypotensive agents, phenothiazines</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> β-blocking effect—thyroid hormones</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—NSAIDs</para>
				<section type="none" id="sidelem4x342">
					<section type="none" id="sidelem4x343">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> serum potassium, serum uric acid, ALT, AST, alk phos, LDH, blood glucose, cholesterol, ANA, triglycerides</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x350">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x353">
					<section type="none" id="sidelem4x354">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x359">
								<item>
									<label>•</label>
									<para>B/P, pulse, respirations during beginning therapy and periodically thereafter; orthostatic hypotension may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x364">
								<item>
									<label>•</label>
									<para>Weight daily; report gain of 5 lb</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x369">
								<item>
									<label>•</label>
									<para>I&amp;O ratio, CCr if kidney damage diagnosed; crackles, jugular venous distention, fatigue, dyspnea</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x379">
							<label>•</label>
							<sec_title>Pain</sec_title>
							<para>
								<list id="lidelem4x379">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pain:</emphasis> duration, time started, activity being performed, character</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x386">
							<label>•</label>
							<sec_title>Hypertension</sec_title>
							<para>
								<list id="lidelem4x386">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypertension:</emphasis> check that prescriptions have been filled</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x393">
							<label>•</label>
							<sec_title>Angina</sec_title>
							<para>
								<list id="lidelem4x393">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Angina:</emphasis> monitor frequency of angina, alleviating factors; duration, time started, activity being performed, character</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x397">
								<item>
									<label>•</label>
									<para>Headache, light-headedness, decreased B/P; may indicate a need for decreased dosage
<bbw>Abrupt discontinuation: can result in MI, myocardial ischemia, ventricular dysrhythmias, severe hypertension; withdraw slowly by tapering</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x411">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x415">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased B/P, heart rate, symptoms of angina</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x421">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x426">
								<item>
									<label>•</label>
									<para>That product may mask signs of hypoglycemia or alter blood glucose in diabetics</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x431">
								<item>
									<label>•</label>
									<para>To avoid OTC products unless prescriber approves, to take as prescribed, at same time each day, do not double, take missed dose as soon as remembered if before 8 hr before next dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x436">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities if dizziness occurs</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x444">
							<label>•</label>
							<sec_title>Hypertension</sec_title>
							<para>
								<list id="lidelem4x444">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypertension:</emphasis> to comply with complete medical regimen; to report weight gain of &gt;5 lb, swelling, unusual bruising, bleeding</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x448">
								<item>
									<label>•</label>
									<para>To rise slowly to prevent orthostatic hypotension</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x453">
								<item>
									<label>•</label>
									<para>About how and when to check B/P, pulse; to hold dose, contact prescriber if pulse ≤60 bpm, systolic B/P &lt;90 mm Hg; to take missed dose as soon as possible if less than 8 hr
<bbw>Not to discontinue abruptly; may cause life-threatening cardiac changes</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="3" status="active">
			<mono_name>nafcillin (Rx)</mono_name>
			<info>
				<pronunciation>(naf-sill′in)</pronunciation>
				<class type="func"> Antiinfective, broad-spectrum</class>
				<class type="chem"> Penicillinase-resistant penicillin</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x480">
				<sec_title>Action:</sec_title>
				<para>Bacteriocidal, interferes with cell-wall replication of susceptible organisms; cell lysis mediated by cell wall autolytic enzymes</para>
			</section>
			<section type="uses" id="sidelem4x485">
				<sec_title>Uses:</sec_title>
				<para>Effective for gram-positive cocci <emphasis style="italic">(Staphylococcus aureus, Streptococcus viridans, Streptococcus pneumoniae),</emphasis> infections caused by penicillinase-producing <emphasis style="italic">Staphylococcus</emphasis></para>
			</section>
			<section type="contra" id="sidelem4x495">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to penicillins or corn</para>
				<section type="none" id="sidelem4x500">
					<section type="none" id="sidelem4x501">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, neonates; hypersensitivity to cephalosporins or carbapenems; GI disease, asthma, electrolyte imbalances, hepatic/renal disease, pseudomembranous colitis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x506">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x514">
					<label>•</label>
					<sec_title>Adult<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x514">
							<item>
								<label>•</label>
								<para> 500-2000 mg q4hr; IM 500 mg q6-8hr, max 12 g/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x521">
					<label>•</label>
					<sec_title>Child and infant &gt;1 mo<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x521">
							<item>
								<label>•</label>
								<para> 150-200 mg/kg/day in divided doses</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x528">
					<label>•</label>
					<sec_title>Neonates &gt;7 days (weight &gt;2000 g)<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x528">
							<item>
								<label>•</label>
								<para> 25 mg/kg q6hr</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x535">
					<label>•</label>
					<sec_title>Neonates ≤7 days (weight &lt;2000 g)<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x535">
							<item>
								<label>•</label>
								<para> 25 mg/kg q8hr</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x539">
					<section type="none" id="sidelem4x540">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj 1 g, premixed or Add-Vantage vials</para>
					</section>
					<section type="none" id="sidelem4x545">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x549">
								<item>
									<label>•</label>
									<para>Product after C&amp;S has been drawn, begin therapy while waiting for results</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x555">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x559">
									<item>
										<label>•</label>
										<para>Reconstitute vials: add 1.7 (1.8 nafcil), 3, 4, or 6.4 ml (6.6 ml NaCl) (sterile water for inj, 0.9% NaCl, bacteriostatic water for inj with benzyl alcohol or parabens) to vials with 1 g, 2 g of nafcillin, respectively (250 mg/ml)</para>
									</item>
									<item>
										<label>•</label>
										<para>No further dilution needed; after reconstitution, inject in deep muscle mass</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x570">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x575">
									<item>
										<label>•</label>
										<para>Reconstitute vials: add 1.7 (1.8 nafcil), 3, 4, or 6.4 ml (6.6 ml NaCl) sterile water for inj, 0.9% NaCl, bacteriostatic water for inj with benzyl alcohol or parabens to vials with 1 g, 2 g of nafcillin, respectively (250 mg/ml); pharmacy bulk pack reconstitute 10 g/93 ml sterile water inj or 0.9% NaCl (100 mg/ml)</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x583">
								<label>•</label>
								<sec_title>Nallpen piggyback units</sec_title>
								<para>
									<list id="lidelem4x583">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Nallpen piggyback units:</emphasis> reconstitute 1 or 2 g with 50-100 ml or 99 ml, respectively, of sterile water for inj, 0.45% NaCl, 0.9% NaCl</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x590">
								<label>•</label>
								<sec_title>Unipen piggyback units</sec_title>
								<para>
									<list id="lidelem4x590">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Unipen piggyback units:</emphasis> reconstitute according to manufacturer</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x594">
								<sec_title>Direct Intermittent IV INJ route</sec_title>
								<para>
									<list id="lidelem4x598">
										<item>
											<label>•</label>
											<para>Further dilute reconstituted sol in 15-30 ml sterile water inj, 0.45% NaCl, 0.9% NaCl; inj slowly over 5-10 min into tubing of free-flowing compatible IV solution</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x604">
								<sec_title>Intermittent IV INFUSION route</sec_title>
								<para>
									<list id="lidelem4x608">
										<item>
											<label>•</label>
											<para>Vials, further dilute reconstituted sol to 2-40 mg/ml for peripheral vein infusion ≤20 mg/ml (preferred); piggyback unit, no further dilution needed; infuse ≥30-60 min, make sure entire dose is given before ≥10% of sol is inactivated</para>
										</item>
										<item>
											<label>•</label>
											<para>Extravasation management: stop infusion and disconnect, leave needle/cannula in place, gently aspirate extravasated solution, do not flush line, use hyaluronidase, remove cannula/needle, apply dry cold compresses, elevate extremity</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfentanil, amikacin, aminophylline, amphotericin B lipid complex (Abelcet), anidulafungin, argatroban, ascorbic acid injection, atenolol, atracurium, atropine, aztreonam, benztropine, bivalirudin, bleomycin, bretylium, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, carmustine, cefamandole, ceFAZolin, cefoperazone, cefotaxime, cefoTEtan, cef OXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chlorproMAZINE, cimetidine, CISplatin, clindamycin, cyanocobalamin, cyclophosphamide, cycloSPORINE, DACTINomycin, DAPTOmycin, DAUNOrubicin liposome, dexamethasone, digoxin, DOBUTamine, DOCEtaxel, DOPamine, DOXOrubicin liposomal, enalaprilat, EPHEDrine, EPINEPHrine, epoetin alfa, erythromycin, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, foscarnet, furosemide, gallium, ganciclovir, gatifloxacin, gemtuzumab, gentamicin, glycopyrrolate, granisetron, heparin, hydrocortisone, HYDROmorphone, imipenem-cilastatin, indomethacin, isoproterenol, ketorolac, lactated Ringer’s, lepirudin, leucovorin, lidocaine, linezolid injection, LORazepam, magnesium sulfate, mannitol, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, milrinone, morphine, multiple vitamins injection, naloxone, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, PACLitaxel (solvent/surfactant), pamidronate, pancuronium, pantoprazole, PEMEtrexed, penicillin G potassium/sodium, PENTobarbital, perphenazine, PHENobarbital, phentolamine, phenylephrine, phytonadione, piperacillin, polymyxin B, potassium acetate/chloride, procainamide, prochlorperazine, propofol, propranolol, ranitidine, Ringer’s injection, sodium bicarbonate, SUFentanil, tacrolimus, teniposide, theophylline, thiamine, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, TNA (3-in-1), tobramycin, tolazoline, TPN (2-in-1), urokinase, vasopressin, vinBLAStine, voriconazole, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x625">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x628">
					<section type="none" id="sidelem4x629">
						<sec_title>CNS:</sec_title>
						<para> Lethargy, hallucinations, anxiety, depression, twitching, <emphasis style="bold">coma, seizures</emphasis></para>
					</section>
					<section type="none" id="sidelem4x636">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea,</emphasis> increased AST, ALT, abdominal pain, glossitis, <emphasis style="bold">pseudomembranous colitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x646">
						<sec_title>GU:</sec_title>
						<para> Oliguria, <emphasis style="bold">proteinuria, hematuria,</emphasis> vaginitis, moniliasis, <emphasis style="bold">glomerulonephritis, interstitial nephritis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x656">
						<sec_title>HEMA:</sec_title>
						<para> Anemia, increased bleeding time, <emphasis style="bold">bone marrow depression, neutropenia, agranulocytosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x663">
						<sec_title>INTEG:</sec_title>
						<para> Tissue necrosis, extravasation injury at inj site, <emphasis style="bold">rash, pruritus, exfoliative dermatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x670">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, serum sickness, Stevens-Johnson syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x677">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 30-90 min; metabolized by liver; excreted in bile, urine; 70%-90% protein bound; peak 30-120 min (PO); peak 30-60 min (IM)</para>
			</section>
			<section type="interactions" id="sidelem4x682">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x686">
						<item>
							<label>•</label>
							<para>Avoid use with tetracyclines</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> nafcillin concentrations—probenecid</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of cycloSPORINE—warfarin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> nafcillin effect—chloramphenicol, macrolides, sulfonamides, tetracyclines, aminoglycosides</para>
				<section type="none" id="sidelem4x704">
					<section type="none" id="sidelem4x705">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> absorption—food, carbonated drinks, citrus fruit juices</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb/HcT, neutrophils</para>
					</section>
					<section type="none" id="sidelem4x716">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">False positive:</emphasis> urine glucose, urine protein</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> potassium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x727">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x730">
					<section type="none" id="sidelem4x731">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x736">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; report hematuria, oliguria, high doses are nephrotoxic</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x744">
							<label>•</label>
							<sec_title>Pseudomembranous colitis<route> assess for diarrhea, abdominal pain, fever, fatigue, anorexia; possible anemia, elevated WBC, low serum albumin; stop product; usually either vancomycin or IV metroNIDAZOLE given</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x747">
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x752">
								<item>
									<label>•</label>
									<para>Blood studies: CBC with differential bleeding time, electrolytes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x758">
								<item>
									<para>
										<emphasis alert="nurse">Renal studies: urinalysis, BUN, creatinine; abnormal urinalysis may indicate nephrotoxicity</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x763">
								<item>
									<label>•</label>
									<para>C&amp;S before product therapy; product may be given as soon as culture is taken</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x768">
								<item>
									<label>•</label>
									<para>Respiratory status: rate, character, wheezing, tightness in chest</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x775">
								<item>
									<para>
										<emphasis alert="nurse">Allergies before initiation of treatment; monitor for anaphylaxis, dyspnea, rash, laryngeal edema; stop product; keep emergency equipment nearby; skin eruptions after administration of penicillin to 1 wk after discontinuing product; cross-sensitivity with cephalosporins may occur</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x780">
								<item>
									<label>•</label>
									<para>Differential WBC 2× per wk in patients receiving long-term therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x785">
								<item>
									<label>•</label>
									<para>IV site: for redness, swelling, pain at site</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x790">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x794">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of fever, draining wounds</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x800">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x806">
								<item>
									<para>
										<emphasis alert="nurse">To report sore throat, fever, fatigue (may indicate superinfection); CNS reactions; pseudomembraneous colitis (diarrhea, fever, abdominal pain, fatigue)</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x811">
								<item>
									<label>•</label>
									<para>To wear or carry emergency ID if allergic to penicillins</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x816">
								<item>
									<label>•</label>
									<para>To avoid use with other products unless approved by prescriber</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="4" status="active" ha="yes">
			<mono_name>nalbuphine (Rx)</mono_name>
			<info>
				<pronunciation>(nal′byoo-feen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x8360">
						<country code="CAN">Nubain</country>
					</tradename>
				</tradenames>
				<class type="func"> Opioid analgesic</class>
				<class type="chem"> Synthetic opioid agonist, antagonist</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x848">
				<sec_title>Action:</sec_title>
				<para>Depresses pain impulse transmission at the spinal cord level by interacting with opioid receptors</para>
			</section>
			<section type="uses" id="sidelem4x853">
				<sec_title>Uses:</sec_title>
				<para>Moderate to severe pain, supplement to anesthesia</para>
			</section>
			<section type="contra" id="sidelem4x858">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or parabens, addiction (opiate)</para>
				<section type="none" id="sidelem4x863">
					<section type="none" id="sidelem4x864">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, addictive personality, increased intracranial pressure, MI (acute), severe heart disease, respiratory depression, renal/hepatic disease, bowel impaction, abrupt discontinuation</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x869">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x872">
					<section type="none" id="sidelem4x873">
						<sec_title>Analgesic</sec_title>
						<section type="none" id="sidelem4x881">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT/IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x881">
									<item>
										<label>•</label>
										<para> 10 mg q3-6hr prn (based on 70-kg body weight), max 160 mg/day (IV/IM/SUBCUT); max 20 mg/dose if opiate naïve (IV/IM/SUBCUT)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x885">
						<sec_title>Balanced anesthesia adjunct</sec_title>
						<section type="none" id="sidelem4x893">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x893">
									<item>
										<label>•</label>
										<para> 0.3-3 mg/kg given over 10-15 min; may give 0.25-0.5 mg/kg as needed for maintenance</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x897">
						<sec_title>Available forms:</sec_title>
						<para> Inj 10, 20 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x902">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x906">
								<item>
									<label>•</label>
									<para>With antiemetic if nausea, vomiting occur</para>
								</item>
								<item>
									<label>•</label>
									<para>When pain beginning to return; determine dosage interval by response</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in light-resistant area at room temperature</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x922">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x926">
									<item>
										<label>•</label>
										<para>IM deep in large muscle mass, rotate inj sites, protect from light</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x932">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x936">
									<item>
										<label>•</label>
										<para>Undiluted ≤10 mg over 3-5 min into free-flowing IV line of D<emphasis style="inf">5</emphasis>W, NS, or LR</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Syringe compatibilities:</emphasis> Atropine, cimetidine, diphenhydrAMINE, droperidol, glycopyrrolate, hydrOXYzine, lidocaine, midazolam, prochlorperazine, ranitidine, scopolamine, trimethobenzamide</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Amifostine, aztreonam, cisatracurium, cladribine, filgrastim, fludarabine, granisetron, melphalan, PACLitaxel, propofol, remifentanil, teniposide, thiotepa, vinorelbine</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x953">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x956">
					<section type="none" id="sidelem4x957">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Drowsiness, dizziness, confusion, headache, sedation, euphoria,</emphasis> dysphoria (high doses), hallucinations, dreaming, tolerance, physical, psychologic dependency</para>
					</section>
					<section type="none" id="sidelem4x965">
						<sec_title>CV:</sec_title>
						<para> Bradycardia, change in B/P, <emphasis style="bold">cardiac arrest</emphasis></para>
					</section>
					<section type="none" id="sidelem4x972">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, miosis, diplopia</para>
					</section>
					<section type="none" id="sidelem4x977">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, constipation, cramps,</emphasis> abdominal pain, dyspepsia, xerostomia, bitter taste</para>
					</section>
					<section type="none" id="sidelem4x986">
						<sec_title>GU:</sec_title>
						<para> Urinary urgency</para>
					</section>
					<section type="none" id="sidelem4x991">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> urticaria, flushing, diaphoresis, pruritus</para>
					</section>
					<section type="none" id="sidelem4x999">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Respiratory depression/arrest,</emphasis> pulmonary edema</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1007">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x1010">
					<section type="none" id="sidelem4x1011">
						<sec_title>SUBCUT/IM/IV:</sec_title>
						<para> Peak 30 min, onset 2-15 min, IV 2-3 min, duration 3-6 hr, metabolized by liver, excreted by kidneys, half-life 3-6 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x1016">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects with other CNS depressants—alcohol, opiates, sedative/hypnotics, antipsychotics, skeletal muscle relaxants</para>
				<para>
					<emphasis alert="lifethreat">Increase: severe reactions—MAOIs</emphasis>
				</para>
				<section type="none" id="sidelem4x1026">
					<section type="none" id="sidelem4x1027">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS depression, kava, valerian, hops, chamomile</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1034">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1037">
					<section type="none" id="sidelem4x1038">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x1046">
							<label>•</label>
							<sec_title>Pain</sec_title>
							<para>
								<list id="lidelem4x1046">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pain:</emphasis> type, location, intensity before and 30-60 min after administration; titrate upward with 25%-50% until 50% of pain reduced; need for pain medication by pain sedation scoring, physical dependency</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1050">
								<item>
									<label>•</label>
									<para>Bowel status; constipation is common; may need laxative or stool softener</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1056">
								<item>
									<para>
										<emphasis alert="nurse">Withdrawal reactions in opiate-dependent individuals: PE, vascular occlusion; abscesses, ulcerations, nausea, vomiting, seizures; low potential for dependence</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1064">
							<label>•</label>
							<sec_title>CNS changes</sec_title>
							<para>
								<list id="lidelem4x1064">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">CNS changes:</emphasis> dizziness, drowsiness, hallucinations, euphoria, LOC, pupil reaction</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1068">
								<item>
									<label>•</label>
									<para>Allergic reactions: rash, urticaria</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1076">
							<label>•</label>
							<sec_title>Respiratory dysfunction<route> respiratory depression,</route></sec_title>
							<para>
								<list id="lidelem4x1076">
									<item>
										<label>•</label>
										<para> character, rate, rhythm; notify prescriber if respirations are &lt;10/min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1080">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1084">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in pain without respiratory depression</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1090">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1095">
								<item>
									<label>•</label>
									<para>To report any symptoms of CNS changes, allergic reactions</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1100">
								<item>
									<label>•</label>
									<para>That physical dependency may result from long-term use; low potential for dependency</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1108">
							<label>•</label>
							<sec_title>That withdrawal symptoms may occur<route> nausea, vomiting, cramps, fever, faintness, anorexia, profuse sweating, twitching; without treatment symptoms resolve in 5-14 days, chronic abstinence syndrome may last 2-6 mo</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x1111">
								<item>
									<label>•</label>
									<para>To avoid CNS depressants, alcohol</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1116">
								<item>
									<label>•</label>
									<para>To avoid driving, operating machinery if drowsiness occurs</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="5" status="active">
			<mono_name>naloxone (Rx)</mono_name>
			<info>
				<pronunciation>(nal-oks′one)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x11341">Evzio</tradename>
					<tradename id="tnidelem4x11340">Narcan</tradename>
				</tradenames>
				<class type="func"> Opioid antagonist, antidote</class>
				<class type="chem"> Thebaine derivative</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x1144">
				<para>
					<confusion>
						<tradename id="tnidelem4x11440">naloxone</tradename>
						<drug type="generic" refid="idelem4x11440">naltrexone</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x1148">
				<sec_title>Action:</sec_title>
				<para>Competes with opioids at opiate receptor sites</para>
			</section>
			<section type="uses" id="sidelem4x1153">
				<sec_title>Uses:</sec_title>
				<para>Respiratory depression induced by opioids, opiate agonist overdose</para>
				<section type="none" id="sidelem4x1158">
					<section type="none" id="sidelem4x1159">
						<sec_title>Unlabeled uses:</sec_title>
						<para> IBS, opiate agonist dependence, opiate agonist-induced constipation, pruritus, urinary retention, coma, nausea, vomiting</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x1164">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x1169">
					<section type="none" id="sidelem4x1170">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, neonates, CV disease, opioid dependency, seizure disorder, drug dependency, hepatic disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1175">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1178">
					<section type="none" id="sidelem4x1179">
						<sec_title>Opioid-induced respiratory depression (known for suspected opiate agonist overdose)</sec_title>
						<section type="none" id="sidelem4x1187">
							<label>•</label>
							<sec_title>Adult<route> IV/SUBCUT/IM</route></sec_title>
							<para>
								<list id="lidelem4x1187">
									<item>
										<label>•</label>
										<para> 0.4-2 mg, repeat q2-3min if needed, max 10 mg; infusion loading dose 0.005 mg/kg, then 0.0025 mg/kg/hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1198">
							<label>•</label>
							<sec_title>Child &lt;5 yr or ≤20 kg<route> IV/INTRAOSSEOUS</route></sec_title>
							<para>
								<list id="lidelem4x1198">
									<item>
										<label>•</label>
										<para> 0.01 mg/kg slowly followed by 0.1 mg/kg if needed; IV infusion (PALS) 0.04-0.16 mg/kg/hr, titrate</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1205">
							<label>•</label>
							<sec_title>Adult/Adolescent/Child<route> Nasal</route></sec_title>
							<para>
								<list id="lidelem4x1205">
									<item>
										<label>•</label>
										<para> 1 spray, may repeat q2-3min if needed</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1209">
						<sec_title>Postoperative opioid-induced respiratory depression</sec_title>
						<section type="none" id="sidelem4x1217">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x1217">
									<item>
										<label>•</label>
										<para> 0.1-0.2 mg q2-3min prn</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1224">
							<label>•</label>
							<sec_title>Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x1224">
									<item>
										<label>•</label>
										<para> 0.005-0.01 mg/kg q2-3min prn</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1228">
						<sec_title>Diagnosis of opiate-agonist dependence (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1236">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x1236">
									<item>
										<label>•</label>
										<para> 0.16 mg; if no withdrawal symptoms after 20-30 min, give 0.24 mg </para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1242">
						<sec_title>Nausea/vomiting from continuous morphine infusion/urinary retention (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1250">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x1250">
									<item>
										<label>•</label>
										<para> 0.2 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1254">
						<sec_title>Available forms:</sec_title>
						<para> Inj 0.4, 1 mg/ml; nasal spray 4 mg/0.1 ml</para>
					</section>
					<section type="none" id="sidelem4x1259">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x1263">
								<item>
									<label>•</label>
									<para>Only with resuscitative equipment, O<emphasis style="inf">2</emphasis> nearby</para>
								</item>
								<item>
									<label>•</label>
									<para>Only sol prepared within 24 hr</para>
								</item>
								<item>
									<label>•</label>
									<para>Dark storage at room temperature</para>
								</item>
								<item>
									<label>•</label>
									<para>Double-check dose, those taking opioids longer term are sensitive to this product</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1287">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x1291">
									<item>
										<label>•</label>
										<para>Undiluted (suspected opioid overdose) with sterile water for inj; give ≤0.4 mg over 15 sec</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1297">
							<sec_title>Continuous IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x1301">
									<item>
										<label>•</label>
										<para>Dilute 2 mg/500 ml 0.9% NaCl or D<emphasis style="inf">5</emphasis>W (4 mcg/ml), titrate to response</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfen-tanil, amikacin, aminocaproic acid, aminophylline, anidulafungin, ascorbic acid, atenolol, atracurium, atropine, azaTHIOprine, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, caspofungin, cefamandole, ceFAZolin, cefmetazole, cefonicid, cefoperazone, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, cephalothin, cephapirin, chloramphenicol, chlorproMAZINE, cimetidine, CIS platin, clindamycin, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCE taxel, DOPamine, doxacurium, DOXOrubicin, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, ertapenem, erythromycin, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, fluorouracil, folic acid, furosemide, ganciclovir, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, heparin, hydrocortisone, hydrOXYzine, IDArubicin, ifosfamide, imipenem-cilastatin, inamrinone, indomethacin, insulin (regular), irinotecan, isoproterenol, ketorolac, labetalol, levofloxacin, lidocaine, linezolid, LORazepam, mannitol, mechloreth amine, meperidine, metaraminol, methicillin, methotrexate, methoxamine, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, mezlocillin, miconazole, midazolam, milrinone, minocycline, mitoXANtrone, morphine, moxalactam, multiple vitamins, mycophenolate, nafcillin, nalbuphine, nesiritide, netilmicin, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, papaverine, PEMEtrexed, penicillin G potassium/sodium, pentamidine, pentazocine, PENTobarbital, PHENobarbital, phentolamine, phenylephrine, phytonadione, piperacillin, piperacillin-tazobactam, polymyxin B, potassium chloride, procainamide, prochlorperazine, promethazine, propofol, propranolol, protamine, pyridoxine, quiNIDine, quinupristin-dalfopristin, ranitidine, ritodrine, rocuronium, sodium acetate/bicarbonate, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiamine, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, tobramycin, tolazoline, trimetaphan, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, voriconazole, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1316">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1319">
					<section type="none" id="sidelem4x1320">
						<sec_title>CNS:</sec_title>
						<para> Nervousness, <emphasis style="bold">seizures,</emphasis> tremor, opioid withdrawal symptoms</para>
					</section>
					<section type="none" id="sidelem4x1328">
						<sec_title>CV:</sec_title>
						<para> Rapid pulse, increased systolic B/P (high doses), <emphasis style="bold">ventricular tachycardia, fibrillation, hypo/hypertension, cardiac arrest, sinus tachycardia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1335">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting</para>
					</section>
					<section type="none" id="sidelem4x1340">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Pulmonary edema, dyspnea</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1347">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Well absorbed IM, SUBCUT; metabolized by liver, crosses placenta; excreted in urine, breast milk; half-life 30-81 min</para>
				<section type="none" id="sidelem4x1352">
					<section type="none" id="sidelem4x1353">
						<sec_title>IM/SUBCUT:</sec_title>
						<para> Onset 2-5 min, duration 45-60 min</para>
					</section>
					<section type="none" id="sidelem4x1358">
						<sec_title>IV:</sec_title>
						<para> Onset 1 min, duration 45 min</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x1363">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: seizures—traMADol overdose</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of opioid analgesics</para>
			</section>
			<section type="considerations" id="sidelem4x1373">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1376">
					<section type="none" id="sidelem4x1377">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x1385">
							<label>•</label>
							<sec_title>Withdrawal<route> cramping, hypertension, anxiety, vomiting, signs of withdrawal in drug-dependent individuals may occur ≤2 hr after administration</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x1388">
								<item>
									<label>•</label>
									<para>VS q3-5min</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1393">
								<item>
									<label>•</label>
									<para>ABGs including P<emphasis style="smallcaps">o</emphasis><emphasis style="inf">2</emphasis>, P<emphasis style="smallcaps">co</emphasis><emphasis style="inf">2</emphasis></para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1407">
								<item>
									<label>•</label>
									<para>Cardiac status: tachycardia, hypertension; monitor ECG</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1415">
							<label>•</label>
							<sec_title>Respiratory dysfunction<route> respiratory depression, character, rate, rhythm; if respirations are &lt;10/min, administer naloxone; probably due to opioid overdose; monitor LOC</route></sec_title>
						</section>
						<section type="none" id="sidelem4x1421">
							<label>•</label>
							<sec_title>Pain</sec_title>
							<para>
								<list id="lidelem4x1421">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pain:</emphasis> duration, intensity, location before and after administration; may be used for respiratory depression</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1425">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1429">
								<item>
									<label>•</label>
									<para>Therapeutic response: reversal of respiratory depression; LOC—alert</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1435">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1439">
								<item>
									<label>•</label>
									<para>When patient is lucid, about reasons for, expected results of product</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="6" status="active">
			<mono_name>naltrexone (Rx)</mono_name>
			<info>
				<pronunciation>(nal-trex′one)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x14501">ReVia</tradename>
					<tradename id="tnidelem4x14500">Vivitrol</tradename>
				</tradenames>
				<class type="func"> Opioid antagonist</class>
				<class type="chem"> Thebaine derivative</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x1460">
				<para>
					<confusion>
						<tradename id="tnidelem4x14600">naloxone</tradename>
						<drug type="generic" refid="idelem4x14600">naltrexone</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x1464">
				<sec_title>Action:</sec_title>
				<para>Competes with opioids at opioid-receptor sites</para>
			</section>
			<section type="uses" id="sidelem4x1469">
				<sec_title>Uses:</sec_title>
				<para>Blockage of opioid analgesics; used for treatment of opiate addiction, alcoholism, opiate agonist overdose</para>
				<section type="none" id="sidelem4x1474">
					<section type="none" id="sidelem4x1475">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Nicotine withdrawal, opiate-agonist withdrawal, pruritus</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x1480">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, opioid dependence</para>
				<para>
					<bbw>Hepatic failure, hepatitis</bbw>
				</para>
				<section type="none" id="sidelem4x1495">
					<section type="none" id="sidelem4x1496">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, renal disease, depression, suicidal ideation, coagulopathy, respiratory depression, IV use</para>
						<para>
							<bbw>Hepatic disease</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1511">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1514">
					<section type="none" id="sidelem4x1515">
						<sec_title>Adjunct in opiate-agonist dependence</sec_title>
						<section type="none" id="sidelem4x1523">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1523">
									<item>
										<label>•</label>
										<para> 25 mg; if no withdrawal symptoms in 1 hr, then 25 mg additionally; if no withdrawal symptoms, then 50-150 mg/day or in divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1527">
						<sec_title>Adjunct in alcoholism treatment</sec_title>
						<section type="none" id="sidelem4x1535">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1535">
									<item>
										<label>•</label>
										<para> 50 mg/day with food × 12 wk;  (Vivitrol) 380 mg q4wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1542">
						<sec_title>Pruritus (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1550">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1550">
									<item>
										<label>•</label>
										<para> 50 mg/day × 7 days to 4 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1554">
						<sec_title>Nicotine withdrawal (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1562">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1562">
									<item>
										<label>•</label>
										<para> 50 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1567">
						<sec_title>Ultrarapid opiate detoxification (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1575">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1575">
									<item>
										<label>•</label>
										<para> 50 mg before sedation with midazolam</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1579">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 50 mg; powder for inj 380 mg</para>
					</section>
					<section type="none" id="sidelem4x1584">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x1587">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x1591">
									<item>
										<label>•</label>
										<para>Give with food or after meals, antacid to prevent nausea, vomiting</para>
									</item>
									<item>
										<label>•</label>
										<para>Store in tight container</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1602">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x1607">
									<item>
										<label>•</label>
										<para>Do not give until opioid-free for 7-10 days to prevent opioid withdrawal (relapse only)</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x1612">
									<item>
										<label>•</label>
										<para>IM deep in gluteal, alternate inj sites; use supplied needle to prevent inj-site reaction; aspirate before inj</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x1617">
									<item>
										<label>•</label>
										<para>Only if resuscitative equipment is nearby</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x1625">
								<label>•</label>
								<sec_title>
									<route>Not to use IV or SUBCUT</route>
								</sec_title>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1628">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1631">
					<section type="none" id="sidelem4x1632">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Stimulation, drowsiness,</emphasis> dizziness, confusion, <emphasis style="bold">seizures,</emphasis> headache, flushing, hallucinations, nervousness, irritability, <emphasis style="bold">suicidal ideation,</emphasis> syncope, anxiety</para>
					</section>
					<section type="none" id="sidelem4x1646">
						<sec_title>CV:</sec_title>
						<para> Rapid pulse, <emphasis style="bold">pulmonary edema,</emphasis> hypertension, <emphasis style="bold">DVT</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1656">
						<sec_title>EENT:</sec_title>
						<para> Tinnitus, hearing loss, blurred vision</para>
					</section>
					<section type="none" id="sidelem4x1661">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea, heartburn,</emphasis><emphasis style="bold">hepatotoxicity,</emphasis> constipation, abdominal pain</para>
					</section>
					<section type="none" id="sidelem4x1671">
						<sec_title>GU:</sec_title>
						<para> Delayed ejaculation, impotence</para>
					</section>
					<section type="none" id="sidelem4x1676">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> urticaria, bruising, oily skin, acne, pruritus, inj-site reactions</para>
					</section>
					<section type="none" id="sidelem4x1684">
						<sec_title>MISC:</sec_title>
						<para> Increased thirst, chills, fever</para>
					</section>
					<section type="none" id="sidelem4x1689">
						<sec_title>MS:</sec_title>
						<para> Joint and muscle pain</para>
					</section>
					<section type="none" id="sidelem4x1694">
						<sec_title>RESP:</sec_title>
						<para> Wheezing, hyperpnea, nasal congestion, rhinorrhea, sneezing, sore throat, pneumonia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1699">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by liver, excreted by kidneys; crosses placenta, excreted in breast milk; half-life 4 hr; IM half-life 5-10 days; extensive first-pass metabolism; protein binding 21%-28%</para>
				<section type="none" id="sidelem4x1704">
					<section type="none" id="sidelem4x1705">
						<sec_title>PO:</sec_title>
						<para> Onset 15-30 min, peak 1 hr</para>
					</section>
					<section type="none" id="sidelem4x1710">
						<sec_title>IM:</sec_title>
						<para> Peak 2-3 days, duration &gt;1 month</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x1715">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> lethargy—phenothiazines</para>
				<para>
					<emphasis alert="lifethreat">Increase: hepatotoxicity—disulfiram</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—anticoagulants</para>
			</section>
			<section type="considerations" id="sidelem4x1729">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1732">
					<section type="none" id="sidelem4x1733">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Hepatic status: LFTs, jaundice, hepatitis, hepatic failure</bbw>
						</para>
						<para>
							<list id="lidelem4x1747">
								<item>
									<label>•</label>
									<para>ABGs including P<emphasis style="smallcaps">o</emphasis><emphasis style="inf">2</emphasis>, P<emphasis style="smallcaps">co</emphasis><emphasis style="inf">2</emphasis>, LFTs, VS q3-5min</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1765">
							<label>•</label>
							<sec_title>
								<route>Signs of withdrawal in drug-dependent individuals, use naltrexone challenge to test opioid dependence; must be free of opioids for 7-10 days before using this product, or withdrawal symptoms can occur</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x1768">
								<item>
									<label>•</label>
									<para>Cardiac status: tachycardia, hypertension</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1776">
							<label>•</label>
							<sec_title>Respiratory dysfunction<route> respiratory depression,</route></sec_title>
							<para>
								<list id="lidelem4x1776">
									<item>
										<label>•</label>
										<para> character, rate, rhythm; if respirations &lt;10/min, respiratory stimulant should be administered</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1783">
							<label>•</label>
							<sec_title>
								<route>suicidal ideation</route>
							</sec_title>
							<para>
								<list id="lidelem4x1783">
									<item>
										<label>•</label>
										<para>Mental status: depression, </para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1787">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1791">
								<item>
									<label>•</label>
									<para>Therapeutic response: blocking opiate ingestion; successful nicotine, alcohol withdrawal</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1797">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1802">
								<item>
									<label>•</label>
									<para>That patient must be drug-free to start treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1808">
								<item>
									<para>
										<emphasis alert="nurse">That using opioid while taking this product could prove fatal because high dose is needed to overcome this antagonist; not to self-dose with OTC products unless approved by prescriber</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1813">
								<item>
									<label>•</label>
									<para>To carry emergency ID stating product used</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1818">
								<item>
									<label>•</label>
									<para>That, if surgery is needed, all involved should be aware of this product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1823">
								<item>
									<label>•</label>
									<para>To use caution while driving or performing other hazardous tasks until effect is known</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1830">
								<item>
									<para>
										<emphasis alert="nurse">That suicidal thoughts/behaviors may occur; to report these immediately</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="7" status="active">
			<mono_name>naphazoline (ophthalmic)</mono_name>
			<info>
				<pronunciation>(na-faz′oh-leen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x18406">Advanced Eye Relief</tradename>
					<tradename id="tnidelem4x18405">Redness Maximum Relief</tradename>
					<tradename id="tnidelem4x18404">Ak-Con</tradename>
					<tradename id="tnidelem4x18403">All Clear</tradename>
					<tradename id="tnidelem4x18402">Clear Eyes</tradename>
					<tradename id="tnidelem4x18401">
						<country code="CAN">Naphcon Forte </country>
					</tradename>
					<tradename id="tnidelem4x18400">VasoClear</tradename>
				</tradenames>
				<class type="func"> Ophthalmic vasoconstrictor</class>
				<class type="chem"> Sympathomimetic</class>
			</info>
			<section type="actions" id="sidelem4x1853">
				<sec_title>Action:</sec_title>
				<para>Acts on the blood vessels in the eye to produce vasoconstriction</para>
			</section>
			<section type="uses" id="sidelem4x1858">
				<sec_title>Uses:</sec_title>
				<para>Ocular congestion, irritation, itching of the eye</para>
			</section>
			<section type="contra" id="sidelem4x1863">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, acute angle-closure glaucoma, 0.1% solution in children/infants</para>
				<section type="none" id="sidelem4x1868">
					<section type="none" id="sidelem4x1869">
						<sec_title>Precautions:</sec_title>
						<para> Hyperthyroidism, diabetes mellitus, hypertension, cardiac conditions</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1874">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1882">
					<label>•</label>
					<sec_title>Adult<route> OPHTH</route></sec_title>
					<para>
						<list id="lidelem4x1882">
							<item>
								<label>•</label>
								<para> instill 1-2 drops in affected eye in the conjunctival sac every 3-4 hr, up to qid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1886">
					<section type="none" id="sidelem4x1887">
						<sec_title>Available forms:</sec_title>
						<para> ophthalmic solution 0.012%, 0.1%, 0.02%</para>
					</section>
					<section type="none" id="sidelem4x1892">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x1896">
								<item>
									<label>•</label>
									<para>Store at room temperature; keep tightly closed</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1902">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1905">
					<section type="none" id="sidelem4x1906">
						<sec_title>CNS:</sec_title>
						<para> Headache</para>
					</section>
					<section type="none" id="sidelem4x1911">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, irritation, photophobia, dilation, stinging, elevated IOP, keratitis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1916">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset 10 min, duration up to 6 hr</para>
			</section>
			<section type="interactions" id="sidelem4x1921">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> Systemic effects—β-blockers<list id="lidelem4x1928">
						<item>
							<label>•</label>
							<para>Do not use within 14 days of MAOIs</para>
						</item>
					</list></para>
			</section>
			<section type="considerations" id="sidelem4x1934">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1937">
					<section type="none" id="sidelem4x1938">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x1942">
								<item>
									<label>•</label>
									<para>Ocular itching, congestion, irritation: should show improvement quickly; avoid using more than 3 days; long-term use or exceeding dosage can lead to rebound congestion; report eye pain, blurred vision</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1948">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1952">
								<item>
									<label>•</label>
									<para>Decreasing ocular itching, congestion, irritation</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1958">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1963">
								<item>
									<label>•</label>
									<para>Method for instilling drops</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1971">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber of eye pain, blurred vision</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x1974">
								<item>
									<label>•</label>
									<para>That ocular itching, congestion, irritation should show improvement quickly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1979">
								<item>
									<label>•</label>
									<para>To avoid using longer than 3 days; that long-term use or exceeding dosage can lead to rebound congestion</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1984">
								<item>
									<label>•</label>
									<para>To wait for at least 15 min before wearing contact lenses</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="8" status="active">
			<mono_name>naproxen (Rx, <emphasis style="smallcaps">otc</emphasis>)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x19959">Aleve</tradename>
					<tradename id="tnidelem4x19958">Anaprox</tradename>
					<tradename id="tnidelem4x19957">Anaprox DS</tradename>
					<tradename id="tnidelem4x19956">
						<country code="CAN">Apo-Napro-Na </country>
					</tradename>
					<tradename id="tnidelem4x19955">Midol Extended Relief</tradename>
					<tradename id="tnidelem4x19954">Naprelan</tradename>
					<tradename id="tnidelem4x19953">
						<country code="CAN">Novo-Naprox </country>
					</tradename>
					<tradename id="tnidelem4x19952">
						<country code="CAN">Novo-Naprox Sodium </country>
					</tradename>
					<tradename id="tnidelem4x19951">
						<country code="CAN">Nu-Naprox </country>
					</tradename>
					<tradename id="tnidelem4x19950">TH Naproxen</tradename>
				</tradenames>
				<class type="func"> Nonsteroidal antiinflammatory, nonopioid analgesic</class>
				<class type="chem"> Propionic acid derivative</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg> <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x2017">
				<para>
					<confusion>
						<tradename id="tnidelem4x20170">Naprosyn</tradename>
						<drug type="generic" refid="idelem4x20170">Natacyn/Naprelan</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x2021">
				<sec_title>Action:</sec_title>
				<para>Inhibits COX-1, COX-2 by blocking arachidonate; analgesic, antiinflammatory, antipyretic</para>
			</section>
			<section type="uses" id="sidelem4x2026">
				<sec_title>Uses:</sec_title>
				<para>Osteoarthritis; rheumatoid, gouty arthritis; primary dysmenorrhea; ankylosing spondylitis, bursitis, tendinitis, myalgia, dental pain, juvenile rheumatoid arthritis</para>
				<section type="none" id="sidelem4x2033">
					<section type="none" id="sidelem4x2034">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Bone pain, migraine/migraine prophylaxis, heterotropic ossification</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x2039">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>) 3rd trimester, hypersensitivity to NSAIDs, salicylates</para>
				<para>
					<bbw>Perioperative pain in CABG surgery</bbw>
				</para>
				<section type="none" id="sidelem4x2054">
					<section type="none" id="sidelem4x2055">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>) breastfeeding, children &lt;2 yr, geriatric patients, bleeding disorders, GI disorders, cardiac disorders, hypersensitivity to other antiinflammatory agents, CCr &lt;30 ml/min, asthma, renal failure, hepatic disease</para>
						<para>
							<bbw>MI, GI bleeding, stroke</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2070">
				<sec_title>Dosage and routes</sec_title>
				<para>200 mg base = 220 mg naproxen sodium</para>
				<section type="none" id="sidelem4x2082">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x2082">
							<item>
								<label>•</label>
								<para> 250-500 mg bid, max 1500 mg/day;  375-500 mg bid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2092">
					<label>•</label>
					<sec_title>Child ≥2 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x2092">
							<item>
								<label>•</label>
								<para> 7 mg/kg q12hr</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2096">
					<section type="none" id="sidelem4x2097">
						<sec_title>Antigout</sec_title>
						<section type="none" id="sidelem4x2105">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2105">
									<item>
										<label>•</label>
										<para> 750 mg, then 250 mg q8hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2109">
						<sec_title>OTC use</sec_title>
						<section type="none" id="sidelem4x2117">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2117">
									<item>
										<label>•</label>
										<para> 220 mg q8-12hr or 440 mg, then 220 mg q12hr; max 660 mg/24hr taken ≤10 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2124">
							<label>•</label>
							<sec_title>Geriatric &gt;65 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2124">
									<item>
										<label>•</label>
										<para> max 220 mg q12hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2128">
						<sec_title>Available forms:</sec_title>
						<para> <emphasis style="bold">Naproxen:</emphasis> tabs 250, 375, 500 mg; del rel tabs (EC-Naprosyn, Naprosyn-E) 250 <country code="CAN">FIX_STRUCTUREtabs 250, 375, 500 mg; del rel tabs (EC-Naprosyn, Naprosyn-E) 250 </country>, 375, 500 mg; oral susp 125 mg/5 ml; ext rel tabs (CR) 375, 500, 750 mg; <emphasis style="bold">naproxen sodium:</emphasis> tabs 220, 275, 550 mg tab, ext rel 220 mg</para>
					</section>
					<section type="none" id="sidelem4x2142">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x2147">
								<item>
									<label>•</label>
									<para>Store at room temperature</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2152">
								<item>
									<label>•</label>
									<para>With food to decrease GI symptoms; take on empty stomach to facilitate absorption; give with full glass of liquid</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2157">
								<item>
									<label>•</label>
									<para>Do not crush, break, or chew ext rel tabs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2162">
								<item>
									<label>•</label>
									<para>OTC for ≤10 days unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2167">
								<item>
									<label>•</label>
									<para>Adequately hydrate in those taking angiotensin receptor blockers/angiotensin-converting enzyme inhibitors</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2175">
							<label>•</label>
							<sec_title>Oral susp</sec_title>
							<para>
								<list id="lidelem4x2175">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Oral susp:</emphasis> shake well; use measuring cup provided or other calibrated device</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2179">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2182">
					<section type="none" id="sidelem4x2183">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, drowsiness, fatigue, tremors, confusion, insomnia, anxiety, depression</para>
					</section>
					<section type="none" id="sidelem4x2188">
						<sec_title>CV:</sec_title>
						<para> Tachycardia, peripheral edema, palpitations, dysrhythmias, <emphasis style="bold">MI, stroke</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2195">
						<sec_title>EENT:</sec_title>
						<para> Tinnitus, hearing loss, blurred vision</para>
					</section>
					<section type="none" id="sidelem4x2200">
						<sec_title>GI:</sec_title>
						<para> Nausea, anorexia, vomiting, diarrhea, jaundice, <emphasis style="bold">hepatitis,</emphasis> constipation, flatulence, cramps, peptic ulcer, <emphasis style="bold">GI ulceration, bleeding, perforation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2210">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Nephrotoxicity: dysuria, hematuria, oliguria, azotemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2217">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Blood dyscrasias</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2224">
						<sec_title>INTEG:</sec_title>
						<para> Purpura, rash, pruritus, sweating</para>
					</section>
					<section type="none" id="sidelem4x2229">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, Stevens-Johnson syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2236">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x2239">
					<section type="none" id="sidelem4x2240">
						<sec_title>PO:</sec_title>
						<para> Peak 2-4 hr, half-life 12-17 hr; metabolized in liver; excreted in urine (metabolites), breast milk; 99% protein binding</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x2245">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x2253">
					<label>•</label>
					<sec_title>
						<route>Do not use with adefovir, cidofovir; nephrotoxicity is increased</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> renal impairment—ACE inhibitors</para>
				<para>
					<emphasis alert="nurse">Increase: toxicity risk—methotrexate, lithium, antineoplastics, probenecid, radiation treatment</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—oral anticoagulants, thrombolytic agents, eptifibatide, tirofiban, clopidogrel, ticlopidine, plicamycin, SSRIs, SNRIs, tricyclics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> GI side effects risk—aspirin, corticosteroids, alcohol, NSAIDs</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of antihypertensives, diuretics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption of naproxen—antacids, sucralfate, cholestyramine</para>
				<section type="none" id="sidelem4x2282">
					<section type="none" id="sidelem4x2283">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x2287">
								<item>
									<label>•</label>
									<para>Bleeding risk: feverfew, garlic, ginger, ginkgo, ginseng <emphasis style="italic">(Panax)</emphasis></para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2295">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> BUN, alk phos, LFTs, potassium, glucose, cholesterol</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> potassium, sodium</para>
						<para>
							<emphasis style="bold">False increase:</emphasis> 5-HIAA, 17KS</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2310">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2313">
					<section type="none" id="sidelem4x2314">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Cardiac status: CV thrombotic events, MI, stroke; may be fatal; not to be used with CABG</bbw>
						</para>
						<para>
							<bbw>GI status: ulceration, bleeding, perforation; may be fatal; obtain stool guaiac</bbw>
						</para>
						<section type="none" id="sidelem4x2341">
							<label>•</label>
							<sec_title>Pain</sec_title>
							<para>
								<list id="lidelem4x2341">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pain:</emphasis> frequency, characteristics, intensity; relief before and 1-2 hr after product</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2348">
							<label>•</label>
							<sec_title>Arthritis</sec_title>
							<para>
								<list id="lidelem4x2348">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Arthritis:</emphasis> range of motion, pain, swelling before and 1-2 hr after use</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2355">
							<label>•</label>
							<sec_title>Fever</sec_title>
							<para>
								<list id="lidelem4x2355">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Fever:</emphasis> before, 1 hr after use</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x2360">
								<item>
									<para>
										<emphasis alert="nurse">Asthma, aspirin hypersensitivity or nasal polyps, increased risk of hypersensitivity</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2368">
							<label>•</label>
							<sec_title>Renal, hepatic blood studies</sec_title>
							<para>
								<list id="lidelem4x2368">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Renal, hepatic blood studies:</emphasis> BUN, creatinine, AST, ALT, Hgb, LDH, blood glucose, Hct, WBC, platelets, CCr before treatment, periodically thereafter during long-term therapy</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x2372">
								<item>
									<label>•</label>
									<para>Audiometric, ophthalmic exam before, during, after treatment; if taking long term, eye, ear problems: blurred vision, tinnitus (may indicate toxicity)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2377">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2381">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased pain, stiffness, swelling in joints; ability to move more easily</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2387">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2392">
								<item>
									<label>•</label>
									<para>To report blurred vision, ringing, roaring in ears (may indicate toxicity)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2397">
								<item>
									<label>•</label>
									<para>To avoid driving, other hazardous activities if dizziness or drowsiness occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2403">
								<item>
									<para>
										<emphasis alert="nurse">To report change in urine pattern, weight increase, edema (face, lower extremities), pain increase in joints, fever, blood in urine (indicates nephrotoxicity); black stools, flulike symptoms, signs of MI, stroke</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2408">
								<item>
									<label>•</label>
									<para>That therapeutic effects may take up to 1 mo in arthritis</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2413">
								<item>
									<label>•</label>
									<para>To avoid ASA, alcohol, steroids, or other OTC medications without prescriber approval</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2418">
								<item>
									<label>•</label>
									<para>To report use to all health care providers</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2423">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is planned or suspected, pregnancy (C); to avoid breastfeeding</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="9" status="active">
			<mono_name>naratriptan (Rx)</mono_name>
			<info>
				<pronunciation>(nair′ah-trip-tan)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x24330">Amerge</tradename>
				</tradenames>
				<class type="func"> Antimigraine agent</class>
				<class type="chem"> 5-HT receptor agonist</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x2446">
				<para>
					<confusion>
						<tradename id="tnidelem4x24460">Amerge</tradename>
						<drug type="generic" refid="idelem4x24460">Altace/Amaryl</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x2450">
				<sec_title>Action:</sec_title>
				<para>Binds selectively to the vascular 5-HT<emphasis style="inf">1</emphasis> B/D receptor subtype; exerts antimigraine effect; causes vasoconstriction in cranial arteries</para>
			</section>
			<section type="uses" id="sidelem4x2458">
				<sec_title>Uses:</sec_title>
				<para>Acute treatment of migraine with/without aura</para>
			</section>
			<section type="contra" id="sidelem4x2463">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, angina pectoris, history of MI, documented silent ischemia, ischemic heart disease, concurrent ergotamine-containing preparations, uncontrolled hypertension, CV syndromes, hemiplegic or basilar migraines, severe renal disease (CCr &lt;15 ml/min); severe hepatic disease (Child-Pugh grade C)</para>
				<section type="none" id="sidelem4x2468">
					<section type="none" id="sidelem4x2469">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, postmenopausal women, men &gt;40 yr, CAD risk, hypercholesterolemia, obesity, diabetes, impaired renal/hepatic function, peripheral vascular disease overuse</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2476">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2484">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x2484">
							<item>
								<label>•</label>
								<para> 1 or 2.5 mg with fluids; if headache returns, repeat 1× after 4 hr; max 5 mg/24 hr</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2488">
					<section type="none" id="sidelem4x2489">
						<sec_title>Hepatic/renal dose</sec_title>
						<section type="none" id="sidelem4x2497">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 15-39 ml/min or mild to moderate hepatic disease max 2.5 mg/24 hr</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2500">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 1, 2.5 mg</para>
					</section>
					<section type="none" id="sidelem4x2505">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x2509">
								<item>
									<label>•</label>
									<para>With fluids as soon as symptoms appear; may take another dose after 4 hr; do not take &gt;5 mg during any 24-hr period</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2515">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2518">
					<section type="none" id="sidelem4x2519">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, sedation, fatigue</para>
					</section>
					<section type="none" id="sidelem4x2524">
						<sec_title>CV:</sec_title>
						<para> Increased B/P, palpitations, <emphasis style="bold">tachydysrhythmias, PR, QTc prolongation, ST/T wave changes, PVCs, atrial flutter/fibrillation, coronary vasospasm</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2531">
						<sec_title>EENT:</sec_title>
						<para> EENT infections, photophobia</para>
					</section>
					<section type="none" id="sidelem4x2536">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2543">
						<sec_title>MISC:</sec_title>
						<para> Temperature change sensations; tightness, pressure sensations</para>
					</section>
					<section type="none" id="sidelem4x2548">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="italic">Weakness, neck stiffness,</emphasis> myalgia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2556">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset 2-3 hr; peak 2-3 hr; 28%-31% protein binding; half-life 6 hr; metabolized in liver (metabolite); excreted in urine, feces; may be excreted in breast milk</para>
			</section>
			<section type="interactions" id="sidelem4x2561">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: serotonin syndrome, neuroleptic malignant syndrome—SSRIs (FLUoxetine, fluvoxaMINE, PARoxetine, sertraline), SNRIs, serotonin receptor agonists, sibutramine</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> vasospastic effects—ergot, ergot derivatives, other 5-HT<emphasis style="inf">1</emphasis> agonists</para>
				<para>
					<emphasis alert="lifethreat">Increase: adverse reactions risk—MAOIs; do not use together</emphasis>
				</para>
				<section type="none" id="sidelem4x2577">
					<section type="none" id="sidelem4x2578">
						<sec_title>Drug/Herb</sec_title>
						<section type="none" id="sidelem4x2586">
							<label>•</label>
							<sec_title>Serotonin syndrome<route> SAM-e, St. John’s wort</route></sec_title>
						</section>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2589">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2592">
					<section type="none" id="sidelem4x2593">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x2601">
							<label>•</label>
							<sec_title>Migraine symptoms</sec_title>
							<para>
								<list id="lidelem4x2601">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Migraine symptoms:</emphasis> aura, duration, effect on lifestyle, aggravating/alleviating factors</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x2606">
								<item>
									<para>
										<emphasis alert="nurse">Serotonin syndrome, neuroleptic malignant syndrome: increased heart rate, shivering sweating, dilated pupils, tremors, high B/P, hyperthermia, headache, confusion; if these occur, stop product, administer serotonin antagonist if needed; at least 2 wk should elapse between discontinuation of serotonergic agents and start of product</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2612">
								<item>
									<para>
										<emphasis alert="nurse">Cardiac status: ECG, increased B/P, dysrhythmias, monitor for PR, QT prolongation, ST-T wave changes, PVCs in those with cardiac disease</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2617">
								<item>
									<label>•</label>
									<para>Stress level, activity, recreation, coping mechanisms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2622">
								<item>
									<label>•</label>
									<para>Neurologic status: LOC blurred vision, nausea, vomiting, tingling in extremities preceding headache</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2627">
								<item>
									<label>•</label>
									<para>Quiet, calm environment with decreased stimulation (noise, bright light, excessive talking)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2632">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2636">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in frequency, severity of headache</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2642">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2648">
								<item>
									<para>
										<emphasis alert="nurse">To report pain, tightness in chest, neck, throat, or jaw; to notify prescriber immediately if sudden, severe abdominal pain occurs</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2653">
								<item>
									<label>•</label>
									<para>Not to use if another 5-HT<emphasis style="inf">1</emphasis> agonist or ergot preparation has been used during past 24 hr; to avoid using &gt;2 days/wk because rebound headache may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2661">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is planned or suspected; to avoid breastfeeding</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="10" status="active">
			<mono_name>natalizumab (Rx)</mono_name>
			<info>
				<pronunciation>(na-ta-liz′u-mab)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x26710">Tysabri</tradename>
				</tradenames>
				<class type="func"> Biologic response modifier, immunoglobulins, monoclonal antibody</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x2677">
				<sec_title>Action:</sec_title>
				<para>Biologic-response-modifying properties mediated through specific receptors on cells; may be secondary to blockade of the interaction of inflammatory cells with vascular endothelial cells</para>
			</section>
			<section type="uses" id="sidelem4x2684">
				<sec_title>Uses:</sec_title>
				<para>Ambulatory patients with relapsing/remitting MS who have not responded to other treatment; those with moderate to severe Crohn’s disease</para>
			</section>
			<section type="contra" id="sidelem4x2689">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, immunocompromised individuals (HIV, AIDS, leukemia, lymphoma, transplants), PML, murine (mouse) protein allergy</para>
				<para>
					<bbw>Progressive multifocal leukoencephalopathy</bbw>
				</para>
				<section type="none" id="sidelem4x2704">
					<section type="none" id="sidelem4x2705">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, chronic progressive MS, depression, mental disorders, diabetes, TB, active infections, hepatotoxicity</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2710">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2718">
					<label>•</label>
					<sec_title>Adult<route> IV INFUSION</route></sec_title>
					<para>
						<list id="lidelem4x2718">
							<item>
								<label>•</label>
								<para> 300 mg q4wk; give over 1 hr q4wk; observe during and for 1 hr after infusion</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2725">
					<label>•</label>
					<sec_title>Adolescent and child ≥11 yr (unlabeled)<route> IV INFUSION</route></sec_title>
					<para>
						<list id="lidelem4x2725">
							<item>
								<label>•</label>
								<para> pediatric Crohn’s disease activity index (PCDAI) &gt;30, 3 mg/kg q4wk</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2729">
					<section type="none" id="sidelem4x2730">
						<sec_title>Available forms:</sec_title>
						<para> Single-use vial, 300 mg/100 ml 0.9% NaCl</para>
					</section>
					<section type="none" id="sidelem4x2735">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x2739">
								<item>
									<label>•</label>
									<para>Acetaminophen for fever, headache</para>
								</item>
								<item>
									<label>•</label>
									<para>Only after being enrolled in the TOUCH Prescribing Program</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2750">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x2754">
									<item>
										<label>•</label>
										<para>Use only clear, colorless solution, without particulates</para>
									</item>
									<item>
										<label>•</label>
										<para>Withdraw 15 ml from the vial using aseptic technique: inj concentration into 100 ml 0.9% NaCl; do not use other diluents; mix completely; do not shake; infusion immediately or refrigerate for ≤8 hr; warm to room temperature before using; flush with 0.9% NaCl before, after infusion; do not admix or use in same line with other agents</para>
									</item>
									<item>
										<label>•</label>
										<para>Withhold product at first sign of PML</para>
									</item>
									<item>
										<label>•</label>
										<para>Prescribers must be registered in the TOUCH Prescribing Program (1-800-456-2255)</para>
									</item>
									<item>
										<label>•</label>
										<para>Store sol in refrigerator; do not freeze or shake; protect from light</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2780">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2783">
					<section type="none" id="sidelem4x2784">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, fatigue,</emphasis> rigors, syncope, tremors, <emphasis style="italic">depression,</emphasis><emphasis style="bold">progressive multifocal leukoencephalopathy (PML), suicidal ideation,</emphasis> anxiety</para>
					</section>
					<section type="none" id="sidelem4x2797">
						<sec_title>CV:</sec_title>
						<para> Chest discomfort, hypo/hypertension, tachycardia</para>
					</section>
					<section type="none" id="sidelem4x2802">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Abdominal discomfort,</emphasis> abnormal LFT, gastroentritis, <emphasis style="bold">severe hepatic injury</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2812">
						<sec_title>GU:</sec_title>
						<para> Amenorrhea, <emphasis style="italic">UTI, irregular menses,</emphasis> vaginitis, urinary frequency</para>
					</section>
					<section type="none" id="sidelem4x2820">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> dermatitis, pruritus, <emphasis style="bold">skin melanoma,</emphasis> infusion-related reactions</para>
					</section>
					<section type="none" id="sidelem4x2831">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="italic">Arthralgia,</emphasis> myalgia</para>
					</section>
					<section type="none" id="sidelem4x2839">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Lower respiratory tract infection,</emphasis> dyspnea</para>
					</section>
					<section type="none" id="sidelem4x2847">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, angioedema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2854">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life approximately 11 days</para>
			</section>
			<section type="interactions" id="sidelem4x2859">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x2867">
					<label>•</label>
					<sec_title>
						<route>Do not use with vaccines</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> infection—immunosuppressants, antineoplastics, immunomodulators, tumor necrosis factors</para>
			</section>
			<section type="considerations" id="sidelem4x2874">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2877">
					<section type="none" id="sidelem4x2878">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Progressive multifocal leukoencephalopathy (weakness, paralysis, vision loss, impaired speech, cognitive deterioration; obtain gadolinium-enhanced MRI scan of the brain, possibly cerebrospinal fluid for JC viral DNA; signs, symptoms of PML (decreased cognition, vision; ataxia, dysphagia), incidences increase with number of doses, over 2 yr immunosuppressants and anti-JC virus antibody; consider testing for the anti-JC virus and periodically retest</bbw>
						</para>
						<section type="none" id="sidelem4x2895">
							<label>•</label>
							<sec_title>Infection<route> report serious opportunistic infections to the manufacturer; those with Crohn’s disease and chronic oral corticosteroids may be at greater risk of infection</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x2898">
								<item>
									<label>•</label>
									<para>Blood, renal, hepatic studies: CBC, differential, platelet counts, BUN, creatinine, ALT, urinalysis, antibody testing</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2904">
								<item>
									<label>•</label>
									<para>CNS symptoms: headache, fatigue, depression, rigors, tremors</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2909">
								<item>
									<label>•</label>
									<para>GI status: abdominal discomfort, gastroenteritis, severe hepatic injury, abnormal LFTs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2914">
								<item>
									<label>•</label>
									<para>Mental status: depression, depersonalization, suicidal thoughts, insomnia</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2922">
							<label>•</label>
							<sec_title>
								<route>MS symptoms;</route>
							</sec_title>
							<para>
								<list id="lidelem4x2922">
									<item>
										<label>•</label>
										<para> product should only be used by patients who have not responded to other treatments</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x2927">
								<item>
									<para>
										<emphasis alert="nurse">Anaphylaxis: SOB, hives; swelling, tightness in throat, chest pain; usually within 2 hr of infusion</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2932">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2936">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased symptoms of MS, Crohn’s disease</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2942">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2947">
								<item>
									<label>•</label>
									<para>Provide patient or family member with written, detailed information about product (med guide)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2952">
								<item>
									<label>•</label>
									<para>That female patients may experience irregular menses, amenorrhea; may worsen over several days; to notify prescriber if pregnancy is suspected; to avoid breastfeeding while taking this product; if pregnant, call the Tysabri Pregnancy Exposure Registry (1-800-456-2255)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2958">
								<item>
									<para>
										<emphasis alert="nurse">To notify prescriber of possible infection: sore throat, cough, increased temperature, infusion-site reactions</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2963">
								<item>
									<label>•</label>
									<para>That continuing follow-up will be needed at 3, 6 mo after first dose, then every 6 mo</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2968">
								<item>
									<label>•</label>
									<para>To inform all prescribers of product use</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="11" status="active">
			<mono_name>natamycin ophthalmic</mono_name>
			<section type="none" id="sidelem4x2976">
				<para>
					<see refid="tra">See Appendix B</see>
				</para>
			</section>
		</monograph>
<monograph id="12" status="active">
			<mono_name>nebivolol (Rx)</mono_name>
			<info>
				<pronunciation>(ne-biv′oh-lol)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x29840">Bystolic</tradename>
				</tradenames>
				<class type="func"> Antihypertensive</class>
				<class type="chem"> β-blocker</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x2997">
				<sec_title>Action:</sec_title>
				<para>Competitively blocks stimulation of β-adrenergic receptors within vascular smooth muscle; decreases rate of SA node discharge; increases recovery time; slows conduction of AV node, thereby resulting in decreased heart rate (negative chronotropic effect), which decreases O<emphasis style="inf">2</emphasis> consumption in myocardium due to β<emphasis style="inf">1</emphasis>-receptor antagonism; decreases renin-aldosterone-angiotensin system at high doses; inhibits β<emphasis style="inf">2</emphasis>-receptors in bronchial system at high doses</para>
			</section>
			<section type="uses" id="sidelem4x3011">
				<sec_title>Uses:</sec_title>
				<para>Hypertension alone or in combination</para>
				<section type="none" id="sidelem4x3016">
					<section type="none" id="sidelem4x3017">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Heart failure</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x3022">
				<sec_title>Contraindications:</sec_title>
				<para>Cardiogenic shock, acute heart failure, severe hepatic disease, severe bradycardia, sick sinus syndrome, AV heart block; hypersensitivity to product, β-blockers</para>
				<section type="none" id="sidelem4x3027">
					<section type="none" id="sidelem4x3028">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, major surgery, peripheral vascular disease, diabetes mellitus, thyrotoxicosis disease, COPD, asthma, well-compensated heart failure, renal/hepatic disease, abrupt discontinuation, acute bronchospasm</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3033">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3036">
					<section type="none" id="sidelem4x3037">
						<sec_title>Hypertension</sec_title>
						<section type="none" id="sidelem4x3045">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3045">
									<item>
										<label>•</label>
										<para> 5 mg/day, may be increased to desired response q2wk; max 40 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3052">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3052">
									<item>
										<label>•</label>
										<para> max 40 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3056">
						<sec_title>Renal/hepatic dose</sec_title>
						<section type="none" id="sidelem4x3064">
							<label>•</label>
							<sec_title>Adult<route> PO CCr &lt;30 ml/min, 2.5 mg/day; may increase cautiously; (Child-Pugh class B) 2.5 mg daily, use dose escalation cautiously</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x3067">
						<sec_title>Heart failure (unlabeled)</sec_title>
						<section type="none" id="sidelem4x3075">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3075">
									<item>
										<label>•</label>
										<para> 1.25 mg titrated to max 10 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3079">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 2.5, 5, 10, 20 mg</para>
					</section>
					<section type="none" id="sidelem4x3084">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x3087">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x3091">
									<item>
										<label>•</label>
										<para>Without regard to meals; tab may be crushed or swallowed whole; give with food to prevent GI upset</para>
									</item>
									<item>
										<label>•</label>
										<para>Taper over 1-2 wk when discontinuing, minimize physical exertion, if angina recurs, give nebivolol</para>
									</item>
									<item>
										<label>•</label>
										<para>Store protected from light, moisture; place in cool environment</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3108">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3111">
					<section type="none" id="sidelem4x3112">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Insomnia, fatigue, dizziness, mental changes,</emphasis> drowsiness, <emphasis style="italic">headache</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3122">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Bradycardia, MI,</emphasis> AV heart block, edema</para>
					</section>
					<section type="none" id="sidelem4x3130">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, diarrhea,</emphasis> vomiting, abdominal pain</para>
					</section>
					<section type="none" id="sidelem4x3138">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Impotence</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3145">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3152">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, vasculitis, urticaria, psoriasis, <emphasis style="bold">angioedema</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3159">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Renal failure, pulmonary edema,</emphasis> hyperuricemia, hypercholesterolemia, withdrawal symptoms</para>
					</section>
					<section type="none" id="sidelem4x3167">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Bronchospasm,</emphasis> dyspnea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3175">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 1.5-4 hr; half-life 12 hr; metabolized in liver by CYP2D6; 38% excreted in urine, 44% in feces</para>
			</section>
			<section type="interactions" id="sidelem4x3180">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Do not give with other β-blockers, mefloquine</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> nebivolol action—CYP2D6 inhibitors (amiodarone, buPROPion, chloroquine, chlorpheniramine, chlorproMAZINE, cinacalcet, diphenhydrAMINE, DULoxetine, FLUoxetine, haloperidol, imatinib, PARoxetine, promethazine, propoxyphene, quiNIDine, quiNINE, ritonavir, terbinafine, thioridazine), cimetidine, calcium channel blockers (nondihydropyridine)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> nebivolol action—CYP2D6 inducers (rifampin), sildenafil</para>
				<section type="none" id="sidelem4x3196">
					<section type="none" id="sidelem4x3197">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x3201">
								<item>
									<label>•</label>
									<para>May increase nebivolol effect—hawthorn</para>
								</item>
								<item>
									<label>•</label>
									<para>May decrease nebivolol effect—ephedra</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3212">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> serum lipoprotein levels, BUN, potassium, triglycerides, uric acid, LDH, AST, ALT, alk phos</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> platelets</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3223">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3226">
					<section type="none" id="sidelem4x3227">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x3235">
							<label>•</label>
							<sec_title>Hypertension</sec_title>
							<para>
								<list id="lidelem4x3235">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypertension:</emphasis> B/P during beginning treatment, periodically thereafter; apical/radial pulse before administration; notify prescriber of any significant changes (pulse &lt;50 bpm);  (dyspnea, crackles, weight gain, jugular venous distention)</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3242">
								<item>
									<label>•</label>
									<para>Blood glucose in diabetics</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3250">
							<label>•</label>
							<sec_title>
								<route>do not use in Child-Pugh class &gt;B</route>
							</sec_title>
							<para>
								<list id="lidelem4x3250">
									<item>
										<label>•</label>
										<para>Baselines of renal, hepatic function tests before therapy begins and periodically, </para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3254">
								<item>
									<label>•</label>
									<para>Edema in feet, legs daily: monitor I&amp;O</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3259">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3263">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased B/P after 1-2 wk; decreased dysrhythmias</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3269">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3275">
								<item>
									<para>
										<emphasis alert="nurse">Not to discontinue product abruptly because severe cardiac reactions may occur; to taper over 2 wk; not to double dose; if dose is missed, to take as soon as remembered up to 4 hr before next dose</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3280">
								<item>
									<label>•</label>
									<para>That product may mask signs of hypoglycemia or alter blood glucose levels</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3285">
								<item>
									<label>•</label>
									<para>Not to use OTC products containing α-adrenergic stimulants (nasal decongestants, OTC cold preparations) unless directed by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3290">
								<item>
									<label>•</label>
									<para>To report low pulse, dizziness, confusion, depression, fever</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3295">
								<item>
									<label>•</label>
									<para>To take pulse, B/P at home; advise patient when to notify prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3300">
								<item>
									<label>•</label>
									<para>To comply with weight control, dietary adjustments, modified exercise program</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3305">
								<item>
									<label>•</label>
									<para>To carry emergency ID to identify product, allergies</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3310">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities if dizziness, drowsiness present</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3318">
							<label>•</label>
							<sec_title>To report symptoms of CHF</sec_title>
							<para>
								<list id="lidelem4x3318">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">To report symptoms of CHF:</emphasis> difficulty breathing, especially on exertion or when lying down, night cough, swelling of extremities</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3322">
								<item>
									<label>•</label>
									<para>To continue with required lifestyle changes (exercise, diet, weight loss, stress reduction)</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="13" status="active">
			<mono_name>nelfinavir (Rx)</mono_name>
			<info>
				<pronunciation>(nell-fin′a-ver)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x33410">Viracept</tradename>
				</tradenames>
				<class type="func"> Antiretroviral</class>
				<class type="chem"> Protease inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x3351">
				<sec_title>Action:</sec_title>
				<para>Inhibits human immunodeficiency virus (HIV-1) protease, which prevents maturation of the infectious virus</para>
				<section type="none" id="sidelem4x3356">
					<section type="none" id="sidelem4x3357">
						<sec_title>Uses:</sec_title>
						<para> HIV-1 in combination with other antiretrovirals</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x3362">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to protease inhibitors</para>
				<section type="none" id="sidelem4x3367">
					<section type="none" id="sidelem4x3368">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, renal/hepatic disease, hemophilia, PKU, pancreatitis, diabetes, infection, immune reconstitution syndrome</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3373">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3376">
					<section type="none" id="sidelem4x3377">
						<sec_title>HIV infection</sec_title>
						<section type="none" id="sidelem4x3385">
							<label>•</label>
							<sec_title>Adult and child &gt;13 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3385">
									<item>
										<label>•</label>
										<para> 750 mg tid or 1250 mg bid, max 2500 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3392">
							<label>•</label>
							<sec_title>Child 2-13 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3392">
									<item>
										<label>•</label>
										<para> 25-35 mg/kg tid, max 2500 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3396">
						<sec_title>Prevention of HIV infection after exposure (unlabeled)</sec_title>
						<section type="none" id="sidelem4x3404">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3404">
									<item>
										<label>•</label>
										<para> 1250 mg bid with 2 other antiretroviral agents × 4 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3408">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 250, 625 mg; powder, oral 50 mg/g/scoop</para>
					</section>
					<section type="none" id="sidelem4x3413">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x3416">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x3421">
									<item>
										<label>•</label>
										<para>Do not mix with juice or acidic fluids</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x3429">
								<label>•</label>
								<sec_title>Oral powder</sec_title>
								<para>
									<list id="lidelem4x3429">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Oral powder:</emphasis> mixed with fluids if desired; stable mixed for 6 hr; may use in child unable to take tabs; do not mix with water in original bottle</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x3436">
								<label>•</label>
								<sec_title>
									<route>Tabs</route>
								</sec_title>
								<para>
									<list id="lidelem4x3436">
										<item>
											<label>•</label>
											<para> may be crushed and dispersed in water or mixed with food; consume immediately</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3440">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3443">
					<section type="none" id="sidelem4x3444">
						<sec_title>CNS:</sec_title>
						<para> Headache, asthenia, poor concentration, <emphasis style="bold">seizures, suicidal ideation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3451">
						<sec_title>CV:</sec_title>
						<para> Bleeding</para>
					</section>
					<section type="none" id="sidelem4x3456">
						<sec_title>ENDO:</sec_title>
						<para> Hyperglycemia, hyperlipidemia</para>
					</section>
					<section type="none" id="sidelem4x3461">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea,</emphasis> anorexia, dyspepsia, <emphasis style="italic">nausea, flatulence,</emphasis><emphasis style="bold">hepatitis, pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3473">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Anemia, leukopenia, thrombocytopenia,</emphasis> Hgb abnormalities</para>
					</section>
					<section type="none" id="sidelem4x3481">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> dermatitis, <emphasis style="bold">anaphylaxis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3491">
						<sec_title>MS:</sec_title>
						<para> Pain, arthralgia, myalgia, myopathy</para>
					</section>
					<section type="none" id="sidelem4x3496">
						<sec_title>Other:</sec_title>
						<para> <emphasis style="bold">Hypoglycemia,</emphasis> redistribution/accumulation of body fat, <emphasis style="bold">immune reconstitution syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3506">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 3<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-5 hr, excreted in feces (87%), peak 2-4 hr, 98% protein binding; metabolized by CYP3A4 enzyme system; potent inhibitor of CYP3A4</para>
			</section>
			<section type="interactions" id="sidelem4x3517">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x3520">
					<section type="none" id="sidelem4x3521">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis alert="nurse">Increase: serious dysrhythmias: amiodarone, ergots, lovastatin, midazolam, pimozide, quiNIDine, simvastatin, triazolam, salmeterol</emphasis>
						</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> effect of—atorvastatin, azithromycin, rifabutin, indinavir, saquinavir, cycloSPORINE, tacrolimus, sirolimus, sildenafil, alfentanil, alosetron, buprenorphine, busPIRone, bortezomib, calcium channel blockers, cilostazol, disopyramide, dofetilide, DOCEtaxel, donepezil, ethosuximide, fentaNYL, galantamine, gefitinib, levomethadyl, systemic lidocaine, PACLitaxel, sibutramine, SUFentanil, vinca alkaloids, ziprasidone, zonisamide, traZODone, tricyclic antidepressants, sildenafil</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> nelfinavir levels—ketoconazole, indinavir, ritonavir; delavirdine, other HIV protease inhibitors</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> nelfinavir levels—rifamycins, nevirapine, PHENobarbital, phenytoin, carBAMazepine</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> effect of—didanosine, methadone, oral contraceptives, phenytoin</para>
					</section>
					<section type="none" id="sidelem4x3545">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis alert="nurse">Decrease: antiretroviral effect—St. John’s wort; do not use concurrently</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x3553">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> absorption with food</para>
					</section>
					<section type="none" id="sidelem4x3561">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT, alk phos, total bilirubin, CPK, LDH, lipids, uric acid</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> WBC, platelets</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3572">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3575">
					<section type="none" id="sidelem4x3576">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x3581">
								<item>
									<label>•</label>
									<para>Resistance testing at initiation, with failure of treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3586">
								<item>
									<label>•</label>
									<para>Signs of infection, anemia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3591">
								<item>
									<label>•</label>
									<para>Hepatic studies: ALT, AST</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3596">
								<item>
									<label>•</label>
									<para>Bowel pattern before, during treatment; if severe abdominal pain with bleeding occurs, product should be discontinued; monitor hydration</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3602">
								<item>
									<para>
										<emphasis alert="nurse">Immune reconstitution syndrome: occurs with combination therapy, including MAC, CMV, PCP TB requiring treatment</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3608">
								<item>
									<para>
										<emphasis alert="nurse">Anaphylaxis, hypersensitivity reaction: wheezing, flushing; swelling of lips, tongue, throat, skin eruptions, rash, urticaria, itching</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3616">
							<label>•</label>
							<sec_title>HIV</sec_title>
							<para>
								<list id="lidelem4x3616">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">HIV:</emphasis> serum lipid profile, plasma HIV RNA, blood glucose, viral load, CD4 cell counts at baseline and throughout treatment</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3620">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3625">
								<item>
									<label>•</label>
									<para>To avoid taking with other medications unless directed by prescriber</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3633">
							<label>•</label>
							<sec_title>
								<route>Diarrhea</route>
							</sec_title>
							<para>
								<list id="lidelem4x3633">
									<item>
										<label>•</label>
										<para> is most common side effect; may use loperamide to control</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3637">
								<item>
									<label>•</label>
									<para>That product does not cure but does manage symptoms; that product does not prevent transmission of HIV to others</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3642">
								<item>
									<label>•</label>
									<para>To use a nonhormonal form of birth control while taking this product if using contraceptives</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3647">
								<item>
									<label>•</label>
									<para>If dose is missed, to take as soon as remembered up to 1 hr before next dose; not to double dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3652">
								<item>
									<label>•</label>
									<para>To take with food</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3657">
								<item>
									<label>•</label>
									<para>To report symptoms of hyperglycemia, bleeding, abdominal pain; yellowing of skin, eyes</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3665">
							<label>•</label>
							<sec_title>Phenylketonuria<route> powder contains phenylalanine</route></sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="14" status="active" ru="yes">
			<mono_name>neomycin (Rx)</mono_name>
			<info>
				<pronunciation>(nee-oh-mye′sin)</pronunciation>
				<class type="func"> Antiinfective—aminoglycoside</class>
			</info>
			<section type="uses" id="sidelem4x3679">
				<sec_title>Uses:</sec_title>
				<para>Severe systemic infections of CNS, respiratory, GI, urinary tract, eye, bone, skin, soft tissues; hepatic coma, preoperatively to sterilize bowel, infectious diarrhea caused by enteropathogenic <emphasis style="italic">E. coli, Enterobacter</emphasis> sp., <emphasis style="italic">Escherichia coli, Klebsiella</emphasis> sp. May be effective for <emphasis style="italic">Acinetobacter</emphasis> sp., <emphasis style="italic">Bacillus anthracis, Citrobacter</emphasis> sp., <emphasis style="italic">Haemophilus influenzae</emphasis> (beta-lactamase negative), <emphasis style="italic">Haemophilus influenzae</emphasis> (beta-lactamase positive), <emphasis style="italic">Neisseria</emphasis> sp., <emphasis style="italic">Proteus mirabilis, Proteus vulgaris, Providencia</emphasis> sp., <emphasis style="italic">Salmonella</emphasis> sp., <emphasis style="italic">Serratia</emphasis> sp., <emphasis style="italic">Shigella</emphasis> sp., <emphasis style="italic">Staphylococcus aureus</emphasis> (MSSA), <emphasis style="italic">Staphylococcus epidermidis</emphasis></para>
			</section>
			<section type="contra" id="sidelem4x3722">
				<sec_title>Contraindications:</sec_title>
				<para>Infants, children, bowel obstruction (oral use), severe renal disease, hypersensitivity, GI disease</para>
				<section type="none" id="sidelem4x3727">
					<section type="none" id="sidelem4x3728">
						<sec_title>Precautions:</sec_title>
						<para> Dehydration, geriatric patients, respiratory insufficiency</para>
						<para>
							<bbw>Hearing impairment, neuromuscular disease, renal disease</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3743">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3746">
					<section type="none" id="sidelem4x3747">
						<sec_title>Hepatic encephalopathy</sec_title>
						<section type="none" id="sidelem4x3755">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3755">
									<item>
										<label>•</label>
										<para> 4-12 g/day in divided doses q6hr × 5-6 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3762">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3762">
									<item>
										<label>•</label>
										<para> 50-100 mg/kg/day in divided doses q6hr × 5-6 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3766">
						<sec_title>Preoperative intestinal antisepsis</sec_title>
						<section type="none" id="sidelem4x3774">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3774">
									<item>
										<label>•</label>
										<para> 1 g/hr × 4 hr, then 1 g q4hr for remaining 24 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="15" status="active">
			<mono_name>nepafenac ophthalmic</mono_name>
			<section type="none" id="sidelem4x3782">
				<para>
					<see refid="tra">See Appendix B</see>
				</para>
			</section>
		</monograph>
<monograph id="16" status="active" ha="yes">
			<mono_name>nesiritide (Rx)</mono_name>
			<info>
				<pronunciation>(neh-seer′ih-tide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x37920">Natrecor</tradename>
				</tradenames>
				<class type="func"> Vasodilator</class>
				<class type="chem"> Human B-type natriuretic peptide</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x3802">
				<sec_title>Action:</sec_title>
				<para>Uses DNA technology; human B-type natriuretic peptide binds to the receptor in vascular smooth muscle and endothelial cells, thereby leading to smooth muscle relaxation</para>
			</section>
			<section type="uses" id="sidelem4x3807">
				<sec_title>Uses:</sec_title>
				<para>Acutely decompensated CHF</para>
			</section>
			<section type="contra" id="sidelem4x3812">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or <emphasis style="italic">Escherichia coli</emphasis> protein; cardiogenic shock or B/P &lt;90 mm Hg as primary therapy</para>
				<section type="none" id="sidelem4x3820">
					<section type="none" id="sidelem4x3821">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>); breastfeeding; children; mitral stenosis; significant valvular stenosis, restriction, or obstructive cardiomyopathy, or any condition dependent on venous return; renal disease; constrictive pericarditis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3826">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3834">
					<label>•</label>
					<sec_title>Adult<route> IV BOL</route></sec_title>
					<para>
						<list id="lidelem4x3834">
							<item>
								<label>•</label>
								<para> 2 mcg/kg, then  0.01 mcg/kg/min</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x3841">
					<section type="none" id="sidelem4x3842">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj, 1.5-mg single-use vial</para>
					</section>
					<section type="none" id="sidelem4x3847">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x3850">
							<sec_title>IV route</sec_title>
							<section type="none" id="sidelem4x3858">
								<label>•</label>
								<sec_title>
									<route>Do not give through a central catheter containing other products; administer other products through separate catheter or central line heparin-coated catheter because nesiritide binds to heparin</route>
								</sec_title>
							</section>
							<para>
								<list id="lidelem4x3861">
									<item>
										<label>•</label>
										<para>Reconstitute one 1.5-mg vial/5 ml of diluent from prefilled 250-ml plastic IV bag with diluent of choice (preservative free D<emphasis style="inf">5</emphasis>, 0.9% NaCl, D<emphasis style="inf">5</emphasis>/<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> NaCl, D<emphasis style="inf">5</emphasis>/0.2% NaCl); do not shake vial; roll gently; use only clear sol</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x3881">
									<item>
										<label>•</label>
										<para>Withdraw all contents of reconstituted vial and add to 250-ml plastic IV bag (6 mcg/ml), invert bag several times</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x3886">
									<item>
										<label>•</label>
										<para>Use within 24 hr of reconstituting</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x3891">
									<item>
										<label>•</label>
										<para>Prime IV fluid with infusion of 5 ml before connecting to patient’s vascular access port and before bolus dose or IV infusion</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x3896">
								<sec_title>Direct IV route</sec_title>
								<para>
									<list id="lidelem4x3900">
										<item>
											<label>•</label>
											<para>Prime tubing with 5 ml infusion sol; calculate dose based on patient’s weight, 0.33 × patient weight (kg) = bolus vol (ml) (6 mcg/ml); withdraw prescribed bolus dose (volume) from prepared infusion bag; give over 1 min through IV port</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x3906">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x3910">
									<item>
										<label>•</label>
										<para>After bolus dose, use infusion, give at 0.1 ml/kg/hr (0.01 mcg/kg/min)</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfen-tanil, allopurinol, amifostine, aminocaproic acid, aminophylline, amiodarone, amphotericin B colloidal, amphotericin B lipid complex, amphotericin B liposome, anidulafungin, argatroban, atenolol, atracurium, azithromycin, aztreonam, bivalirudin, bleomycin, buprenorphine, busulfan, butorphanol, calcium acetate/chloride/gluconate, CARBOplatin, carmustine, ceFAZolin, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, cimetidine, ciprofloxacin, cisatracurium, CISplatin, clindamycin, cyclophosphamide, cycloSPORINE, cytarabine, dacarbazine, DACTINomycin, DAUNOrubicin, digoxin, diltiazem, diphenhydrAMINE, DOCEtaxel, dolasetron, doxacurium, DOXOrubicin, doxycycline, droperidol, ePHEDrine, epirubicin, ertapenem, erythromycin, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, filgrastim, fluconazole, fludarabine, fluorouracil, foscarnet, fosphenytoin, ganciclovir, gatifloxacin, gemcitabine, gemtuzumab, glycopyrrolate, granisetron, haloperidol, hydrocortisone, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, imipenem-cilastatin, irinotecan, ketorolac, leucovorin, levofloxacin, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, melphalan, meropenem, mesna, metaraminol, methohexital, methotrexate, methylPREDNISolone, metoclopramide, metroNIDAZOLE, midazolam, milrinone, minocycline, mitoMYcin, mitoXANtrone, mivacurium, moxifloxacin, mycophenolate, nalbuphine, naloxone, niCARdipine, nitroglycerin, nitroprusside, octreotide, ondansetron, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, PEMEtrexed, pentamidine, PENTobarbital, PHENobarbital, phentolamine, phenylephrine, polymyxin B sulfate, potassium chloride/phosphates, prochlorperazine, propranolol, quiNIDine, quinupristin-dalfopristin, ranitidine, remifentanil, rocuronium, sodium acetate/bicarbonate/phosphates, streptozocin, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiotepa, ticarcillin, tigecycline, tirofiban, tolazoline, topotecan, torsemide, trimethobenzamide, vancomycin, vasopressin, vecuronium, verap-amil, vinBLAStine, vinCRIStine, vinorelbine, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3922">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3925">
					<section type="none" id="sidelem4x3926">
						<sec_title>CNS:</sec_title>
						<para> Headache, insomnia, dizziness, anxiety, confusion, paresthesia, tremor</para>
					</section>
					<section type="none" id="sidelem4x3931">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Hypotension,</emphasis><emphasis style="bold">tachycardia,</emphasis> dysrhythmias, bradycardia, <emphasis style="bold">ventricular tachycardia, ventricular extrasystoles, atrial fibrillation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3943">
						<sec_title>GI:</sec_title>
						<para> Vomiting, nausea</para>
					</section>
					<section type="none" id="sidelem4x3948">
						<sec_title>INTEG:</sec_title>
						<para> Rash, sweating, pruritus, inj-site reaction</para>
					</section>
					<section type="none" id="sidelem4x3953">
						<sec_title>MISC:</sec_title>
						<para> Abdominal pain, back pain</para>
					</section>
					<section type="none" id="sidelem4x3958">
						<sec_title>RESP:</sec_title>
						<para> Increased cough, hemoptysis, <emphasis style="bold">apnea</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3965">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 18 min</para>
			</section>
			<section type="interactions" id="sidelem4x3970">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—ACE inhibitors, antihypertensives, IV nitrates</para>
			</section>
			<section type="considerations" id="sidelem4x3977">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3980">
					<section type="none" id="sidelem4x3981">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x3986">
								<item>
									<label>•</label>
									<para>PCWP, RAP, cardiac index, MPAP, respiratory rate, CUP, B/P, pulse during treatment until stable</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3991">
								<item>
									<label>•</label>
									<para>Daily serum creatinine, BUN</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3999">
							<label>•</label>
							<sec_title>CHF</sec_title>
							<para>
								<list id="lidelem4x3999">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">CHF:</emphasis> weight gain, dyspnea, crackles, I&amp;O ratios, peripheral edema</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4003">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4008">
								<item>
									<label>•</label>
									<para>Therapeutic response: improvement in CHF with improved PCWP, RAP, MPAP</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4016">
							<label>•</label>
							<sec_title>Allergic reactions to peptides<route> rash, pruritus, wheezing, discontinue immediately, keep emergency equipment available</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4019">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4023">
								<item>
									<label>•</label>
									<para>About purpose of medication, expected results; to report pain at IV site</para>
								</item>
								<item>
									<label>•</label>
									<para>To report dizziness, blurred vision, lightheadedness, sweating, allergic reaction</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="17" status="active">
			<mono_name>nevirapine (Rx)</mono_name>
			<info>
				<pronunciation>(ne-veer′a-peen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x40391">Viramune</tradename>
					<tradename id="tnidelem4x40390">Viramune XR</tradename>
				</tradenames>
				<class type="func"> Antiretroviral</class>
				<class type="chem"> Nonnucleoside reverse transcriptase inhibitor (NNRTI)</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x4049">
				<para>
					<confusion>
						<tradename id="tnidelem4x40490">nevirapine</tradename>
						<drug type="generic" refid="idelem4x40490">nelfinavir</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x4056">
				<sec_title>Action:</sec_title>
				<para>Binds directly to reverse transcriptase and blocks RNA, DNA, thus causing a disruption of the enzyme’s site</para>
			</section>
			<section type="uses" id="sidelem4x4061">
				<sec_title>Uses:</sec_title>
				<para>HIV-1 in combination with other highly active antiretroviral therapy (HAART)</para>
			</section>
			<section type="contra" id="sidelem4x4066">
				<sec_title>Contraindications:</sec_title>
				<para>
					<bbw>Hypersensitivity, hepatic disease</bbw>
				</para>
				<section type="none" id="sidelem4x4080">
					<section type="none" id="sidelem4x4081">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, renal disease, Hispanic patients</para>
						<para>
							<bbw>Females, hepatitis</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4096">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4099">
					<section type="none" id="sidelem4x4100">
						<sec_title>Treatment of HIV infection in combination with other antiretrovirals</sec_title>
						<section type="none" id="sidelem4x4108">
							<label>•</label>
							<sec_title>Adult and adolescent<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4108">
									<item>
										<label>•</label>
										<para> 200 mg/day × 2 wk, then 200 mg bid in combination;  tab (adults not currently taking immediate rel nevirapine) 200 mg/day (immediate rel tab) × 14 days with other antiretrovirals; if rash develops during lead-in periods and persists beyond 14 days, do not use ext rel tab; if no consistent rash present, then give 400 mg/day ext rel tab with other antiretrovirals; if interrupted &gt;7 days, restart 14 day lead-in dosing; for adults switched from immediate rel tab, give 400 mg/day ext rel tab</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4118">
							<label>•</label>
							<sec_title>Child/adolescent ≥6 yr<route> PO EXT REL</route></sec_title>
							<para>
								<list id="lidelem4x4118">
									<item>
										<label>•</label>
										<para> not currently taking immediate release 150 mg/m<emphasis style="sup">2</emphasis> (immediate release) daily (max 200 mg/day) × 14 days, then BSA 0.58-0.83 m<emphasis style="sup">2</emphasis> 200 mg/day; BSA 0.84-1.16 m<emphasis style="sup">2</emphasis> 300 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4134">
							<label>•</label>
							<sec_title>Child/infant/neonate ≥15 days old<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4134">
									<item>
										<label>•</label>
										<para> 150 mg/m<emphasis style="sup">2</emphasis>/day × 14 days, then 150 mg/m<emphasis style="sup">2</emphasis> bid, max 400 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4144">
						<sec_title>Perinatal transmission prophylaxis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x4152">
							<label>•</label>
							<sec_title>Females with no previous antiretroviral therapy<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4152">
									<item>
										<label>•</label>
										<para> 200 mg as a single dose at onset of labor with zidovudine 2 mg/kg over 1 hr followed by zidovudine 1 mg/kg/hr until delivery</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4159">
							<label>•</label>
							<sec_title>Neonate ≥34 wk gestation<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4159">
									<item>
										<label>•</label>
										<para> Nevirapine 12 mg (&gt;2 kg) or 8 mg (1.5-2 kg) × 3 doses; 1st dose 48 hr after birth, 2nd dose 48 hr after 1st dose, 3rd dose 96 hr after 2nd dose and  zidovudine</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4166">
						<sec_title>Hepatic Dose</sec_title>
						<section type="none" id="sidelem4x4174">
							<label>•</label>
							<sec_title>Adult<route> PO do not use with Child-Pugh grade B or C</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4177">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 200 mg; oral susp 50 mg/5 ml; ext rel 400 mg</para>
					</section>
					<section type="none" id="sidelem4x4182">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x4190">
							<label>•</label>
							<sec_title>
								<route>Do not initiate treatment in females when CD4 counts &gt;250 cells/mm3 or in males when &gt;400 cells/mm3 unless benefits outweigh risks</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x4199">
								<item>
									<label>•</label>
									<para>Without regard to meals</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4204">
								<item>
									<label>•</label>
									<para>Use in combination with at least 1 other antiretroviral</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4212">
							<label>•</label>
							<sec_title>
								<route>Oral susp</route>
							</sec_title>
							<para>
								<list id="lidelem4x4212">
									<item>
										<label>•</label>
										<para> should be shaken before giving</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4216">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4219">
					<section type="none" id="sidelem4x4220">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Paresthesia, headache, fever, peripheral neuropathy</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4227">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea,</emphasis> abdominal pain, <emphasis style="italic">nausea, stomatitis,</emphasis><emphasis style="bold">hepatotoxicity, hepatic failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4239">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia, anemia, thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4246">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis><emphasis style="bold">toxic epidermal necrolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4255">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Stevens-Johnson syndrome, anaphylaxis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4262">
						<sec_title>MS:</sec_title>
						<para> Pain, myalgia, <emphasis style="bold">rhabdomyolysis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4269">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly absorbed, peak 4 hr, 60% bound to plasma proteins, metabolized by liver; metabolized by hepatic P450 enzyme system, excreted 91% in urine, terminal half-life 25-30 hr, 50% removed by peritoneal dialysis; with hepatic disease and in Hispanic patients, African American patients, slower rate of clearance</para>
			</section>
			<section type="interactions" id="sidelem4x4274">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> nevirapine levels—cimetidine, macrolide antiinfectives</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of protease inhibitors, oral contraceptives, ketoconazole, methadone, itraconazole</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> nevirapine levels—rifamycins, anticonvulsants, clonazePAM, diazepam, warfarin</para>
				<section type="none" id="sidelem4x4289">
					<section type="none" id="sidelem4x4290">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> action of antiretroviral—St. John’s wort; do not use concurrently</para>
					</section>
					<section type="none" id="sidelem4x4297">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> ALT, AST, GGT, bilirubin, Hgb</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> neutrophil count</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4308">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4311">
					<section type="none" id="sidelem4x4312">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x4317">
								<item>
									<label>•</label>
									<para>Resistance testing before therapy and when therapy fails</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4324">
								<item>
									<para>
										<emphasis alert="nurse">Signs of infection, anemia, hepatotoxicity, immune reconstitution syndrome; hepatitis B or C, liver toxicity may occur</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4332">
							<label>•</label>
							<sec_title>HIV</sec_title>
							<para>
								<list id="lidelem4x4332">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">HIV:</emphasis> blood studies during treatment: ALT, AST, viral load, CD4, plasma HIV RNA, renal studies; if LFTs elevated significantly, product should be withheld; glucose levels in diabetic patients, if treatment is interrupted by &gt;1 wk, restart at initial dose</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x4337">
								<item>
									<para>
										<emphasis alert="nurse">Rhabdomyolysis: pain, tenderness, weakness, edema; product should be discontinued</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4345">
							<label>•</label>
							<sec_title>
								<route>Bowel pattern before, during treatment; if severe abdominal pain with bleeding occurs, product should be discontinued; monitor hydration</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x4349">
								<item>
									<para>
										<emphasis alert="nurse">Stevens-Johnson syndrome, toxic epidermal necrolysis, allergies before treatment, reaction to each medication; skin eruptions; rash, urticaria, itching; if rash is severe or systemic symptoms occur, discontinue immediately</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4354">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4358">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of AIDS-defining symptoms, improvement in quality of life; decreased viral load, increase in CD4 count</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4364">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4370">
								<item>
									<para>
										<emphasis alert="nurse">To report any right quadrant pain, yellowing of eyes or skin, dark urine, nausea, anorexia, muscle pain or tenderness, rash immediately</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4375">
								<item>
									<label>•</label>
									<para>That product may be taken with food, antacids</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4380">
								<item>
									<label>•</label>
									<para>To take as prescribed; if dose is missed, to take as soon as remembered up to 1 hr before next dose; not to double dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4385">
								<item>
									<label>•</label>
									<para>That product is not a cure, does not prevent transmission; controls symptoms of HIV</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4390">
								<item>
									<label>•</label>
									<para>To avoid OTC agents unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4395">
								<item>
									<label>•</label>
									<para>To use a nonhormonal form of contraception during treatment in those using contraceptives</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="18" status="active" ru="yes">
			<mono_name>niacin (<emphasis style="smallcaps">otc</emphasis>, Rx)</mono_name>
			<info>
				<pronunciation>(nye′a-sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x44103">Equaline Niacin</tradename>
					<tradename id="tnidelem4x44102">Niaspan</tradename>
					<tradename id="tnidelem4x44101">
						<country code="CAN">Ni-Odan </country>
					</tradename>
					<tradename id="tnidelem4x44100">Slo-Niacin</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="19" status="active">
			<mono_name>niacinamide (<emphasis style="smallcaps">otc</emphasis>, Rx)</mono_name>
			<info>
				<class type="func"> Vit B, antihyperlipidemic</class>
				<class type="chem"> Water-soluble vitamin</class>
			</info>
			<section type="uses" id="sidelem4x4432">
				<sec_title>Uses:</sec_title>
				<para>Pellagra, hyperlipidemias (types 4, 5), peripheral vascular disease that presents a risk for pancreatitis</para>
			</section>
			<section type="contra" id="sidelem4x4437">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding, hypersensitivity, peptic ulcer, hepatic disease, hemorrhage, severe hypotension</para>
			</section>
			<section type="doses" id="sidelem4x4442">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4445">
					<section type="none" id="sidelem4x4446">
						<sec_title>Niacin deficiency</sec_title>
						<section type="none" id="sidelem4x4454">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4454">
									<item>
										<label>•</label>
										<para> 100-500 mg/day in divided doses;  5-100 mg ≥5×/day;  25-100 mg bid or tid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4467">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4467">
									<item>
										<label>•</label>
										<para> ≤300 mg/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4471">
						<sec_title>Adjunct in hyperlipidemia</sec_title>
						<section type="none" id="sidelem4x4479">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4479">
									<item>
										<label>•</label>
										<para> 250 mg after evening meal; may increase dose at 1-4 wk intervals to 1-2 g tid, max 6 g/day;  500 mg at bedtime × 4 wk, then 1000 mg at bedtime for wk 5-8; do not increase by &gt;500 mg q4wk, max 2000 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4486">
						<sec_title>Pellagra</sec_title>
						<section type="none" id="sidelem4x4494">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4494">
									<item>
										<label>•</label>
										<para> 300-500 mg/day in divided doses;  50-100 mg 5×/day or  25-100 mg bid by slow </para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4509">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4509">
									<item>
										<label>•</label>
										<para> 100-300 mg/day in divided doses;  ≤300 mg/day by slow </para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4518">
						<sec_title>Peripheral vascular disease</sec_title>
						<section type="none" id="sidelem4x4526">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4526">
									<item>
										<label>•</label>
										<para> 250-800 mg/day in 3-5 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="20" status="active">
			<mono_name>niCARdipine (Rx)</mono_name>
			<info>
				<pronunciation>(nye-card′i-peen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x45362">Cardene</tradename>
					<tradename id="tnidelem4x45361">Cardene IV</tradename>
					<tradename id="tnidelem4x45360">Cardene SR</tradename>
				</tradenames>
				<class type="func"> Calcium channel blocker, antianginal, antihypertensive</class>
				<class type="chem"> Dihydropyridine</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x4546">
				<para>
					<confusion>
						<tradename id="tnidelem4x45460">niCARdipine</tradename>
						<drug type="generic" refid="idelem4x45460">NIFEdipine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x4556">
				<sec_title>Action:</sec_title>
				<para>Inhibits calcium ion influx across cell membrane during cardiac depolarization; produces relaxation of coronary vascular smooth muscle, peripheral vascular smooth muscle; dilates coronary vascular arteries; increases myocardial oxygen delivery in patients with vasospastic angina</para>
			</section>
			<section type="uses" id="sidelem4x4561">
				<sec_title>Uses:</sec_title>
				<para>Chronic stable angina pectoris, hypertension</para>
			</section>
			<section type="contra" id="sidelem4x4566">
				<sec_title>Contraindications:</sec_title>
				<para>Sick sinus syndrome, 2nd-/3rd-degree heart block; hypersensitivity to this product or dihydropyridine; advanced aortic stenosis</para>
				<section type="none" id="sidelem4x4571">
					<section type="none" id="sidelem4x4572">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, CHF, hypotension, hepatic injury, renal disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4577">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4580">
					<section type="none" id="sidelem4x4581">
						<sec_title>Hypertension</sec_title>
						<section type="none" id="sidelem4x4589">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4589">
									<item>
										<label>•</label>
										<para> 20 mg tid initially; may increase after 3 days (range 20-40 mg tid) or 30 mg bid  may increase to 60 mg bid or  5 mg/hr; may increase by 2.5 mg/hr q15min; max 15 mg/hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4599">
						<sec_title>Angina</sec_title>
						<section type="none" id="sidelem4x4607">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4607">
									<item>
										<label>•</label>
										<para> 20 mg tid; may be adjusted q3days; may use 20-40 mg tid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4611">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x4619">
							<label>•</label>
							<sec_title>Adult<route> PO adjust based on response</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4622">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x4630">
							<label>•</label>
							<sec_title>Adult<route> PO 20 mg bid</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4633">
						<sec_title>Available forms:</sec_title>
						<para> Caps 20, 30 mg; sus rel caps 30, 45, 60 mg; inj 2.5 mg/ml, premixed 20 mg/200 ml, 40 mg/200 ml</para>
					</section>
					<section type="none" id="sidelem4x4638">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x4641">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x4645">
									<item>
										<label>•</label>
										<para>Do not break, crush, chew, or open sus rel cap</para>
									</item>
									<item>
										<label>•</label>
										<para>Without regard to meals</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4656">
							<sec_title>IV route</sec_title>
							<para/>
						</section>
						<section type="none" id="sidelem4x4660">
							<sec_title>Continuous IV INFUSION</sec_title>
							<para>
								<list id="lidelem4x4664">
									<item>
										<label>•</label>
										<para>Dilute each 25 mg/240 ml of compatible sol (0.1 mg/ml), give slowly, titrate to patient response, change IV site q12hr</para>
									</item>
									<item>
										<label>•</label>
										<para>Stable at room temperature for 24 hr</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Solution compatibilities:</emphasis> D<emphasis style="inf">5</emphasis>W, D<emphasis style="inf">5</emphasis>/0.45% NaCl, D<emphasis style="inf">5</emphasis>/0.9% NaCl</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alemtuzumab, amikacin, aminophylline, aztreonam, bivalirudin, butorphanol, calcium gluconate, CARBOplatin, caspofungin, ceFAZolin, ceftizoxime, chloramphenicol, cimetidine, CISplatin, clindamycin, cytarabine, DAPTOmycin, dexmedetomidine, diltiazem, DOBUTamine, DOCEtaxel, DOPamine, DOXOrubicin hydrochloride, enalaprilat, EPINEPHrine, epirubicin, erythromycin, esmolol, famotidine, fenoldopam, fentaNYL, gentamicin, hydrocortisone, HYDROmorphone, labetalol, lidocaine, linezolid, LORazepam, magnesium sulfate, mechlorethamine, methylPREDNISolone, metroNIDAZOLE, midazolam, milrinone, morphine, nafcillin, nesiritide, nitroglycerin, nitroprusside, norepinephrine, octreotide, oxaliplatin, oxytocin, palonosetron, penicillin G potassium, potassium chloride/phosphate, quinupristin/dalfopristin, ranitidine, rocuronium, tacrolimus, tirofiban, tobramycin, trimethoprim/sulfamethoxazole, vancomycin, vasopressin, vecuronium, vinCRIStine, voriconazole, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4692">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4695">
					<section type="none" id="sidelem4x4696">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, dizziness,</emphasis> anxiety, depression, confusion, paresthesia, somnolence, <emphasis style="italic">flushing</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4707">
						<sec_title>CV:</sec_title>
						<para> Edema, bradycardia, hypotension, palpitations, <emphasis style="bold">pulmonary edema,</emphasis> chest pain, tachycardia, increased angina, <emphasis style="bold">arrhythmias, CHF</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4717">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, gastric upset, constipation, <emphasis style="bold">hepatitis,</emphasis> abdominal cramps, dry mouth, sore throat</para>
					</section>
					<section type="none" id="sidelem4x4725">
						<sec_title>GU:</sec_title>
						<para> Nocturia, polyuria</para>
					</section>
					<section type="none" id="sidelem4x4730">
						<sec_title>INTEG:</sec_title>
						<para> Rash, infusion-site discomfort, <emphasis style="bold">Stevens-Johnson syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4737">
						<sec_title>OTHER:</sec_title>
						<para> Blurred vision, flushing, sweating, SOB, impotence</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4742">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by liver, excreted in urine 60%, feces 35%, half-life 2-5 hr</para>
				<section type="none" id="sidelem4x4747">
					<section type="none" id="sidelem4x4748">
						<sec_title>PO:</sec_title>
						<para> Onset 20 min, peak 1-2 hr, duration 8 hr</para>
					</section>
					<section type="none" id="sidelem4x4753">
						<sec_title>PO-SR:</sec_title>
						<para> Onset unknown, duration 10-12 hr</para>
					</section>
					<section type="none" id="sidelem4x4758">
						<sec_title>Onset</sec_title>
						<para/>
					</section>
					<section type="none" id="sidelem4x4762">
						<sec_title>IV: </sec_title>
						<para>1 min, peak 45 min</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x4767">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of digoxin, neuromuscular blocking agents, theophylline, other antihypertensives, nitrates, alcohol, quiNIDine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> niCARdipine effects—cimetidine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity risk—cycloSPORINE, prazosin, carBAMazepine, quiNIDine, propranolol</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—NSAIDs, rifampin</para>
				<section type="none" id="sidelem4x4786">
					<section type="none" id="sidelem4x4787">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> effect—ginkgo, ginseng, hawthorn</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> effect—ephedra, melatonin, St. John’s wort, yohimbe</para>
					</section>
					<section type="none" id="sidelem4x4798">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> hypotensive effect—grapefruit juice</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs</para>
					</section>
					<section type="none" id="sidelem4x4809">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> potassium (IV), phosphate, platelets</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4816">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4819">
					<section type="none" id="sidelem4x4820">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x4826">
								<item>
									<para>
										<emphasis alert="nurse">Cardiac status: B/P often, pulse, respiration, ECG during long-term treatment</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4834">
							<label>•</label>
							<sec_title>Anginal pain</sec_title>
							<para>
								<list id="lidelem4x4834">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Anginal pain:</emphasis> intensity, location, duration; alleviating, precipitating factors</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x4838">
								<item>
									<label>•</label>
									<para>Potassium, renal, hepatic studies periodically</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4844">
								<item>
									<para>
										<emphasis alert="nurse">CHF: weight gain, crackles, jugular venous distention, dyspnea, I&amp;O</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4852">
							<label>•</label>
							<sec_title>Allergic reactions (Stevens-Johnson syndrome)<route> if rash is severe and joint aches, mouth lesions, discontinue immediately</route></sec_title>
						</section>
						<section type="none" id="sidelem4x4858">
							<label>•</label>
							<sec_title>Hypertension</sec_title>
							<para>
								<list id="lidelem4x4858">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypertension:</emphasis> decreasing B/P; assess salt in diet, smoking, exercise, weight, monitor B/P often</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4862">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4866">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased anginal pain, decreased B/P</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4872">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4877">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until stabilized on product, dizziness is no longer a problem</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4882">
								<item>
									<label>•</label>
									<para>To limit caffeine consumption; to avoid alcohol products; to take without regard to food, avoid high-fat foods; to swallow sus rel product whole</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4887">
								<item>
									<label>•</label>
									<para>To avoid OTC products, grapefruit juice unless directed by prescriber</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4895">
							<label>•</label>
							<sec_title>Hypertension</sec_title>
							<para>
								<list id="lidelem4x4895">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypertension:</emphasis> comply in all areas of medical regimen: diet, exercise, stress reduction, product therapy</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x4900">
								<item>
									<para>
										<emphasis alert="nurse">To notify prescriber of irregular heartbeat, SOB, swelling of feet and hands, pronounced dizziness, constipation, nausea, hypotension, change in severity/pattern/incidence of angina</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="21" status="active">
			<mono_name>nicotine</mono_name>
			<info>
				<pronunciation>(nik′o-teen)</pronunciation>
			</info>
		</monograph>
<monograph id="22" status="active">
			<mono_name>nicotine chewing gum</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x49201">Thrive</tradename>
					<tradename id="tnidelem4x49200">Nicorette</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="23" status="active">
			<mono_name>nicotine inhaler (<emphasis style="smallcaps">otc</emphasis>, Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x49280">Nicotrol</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="24" status="active">
			<mono_name>nicotine lozenge (<emphasis style="smallcaps">otc</emphasis>)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x49361">Commit</tradename>
					<tradename id="tnidelem4x49360">Nicorette</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="25" status="active">
			<mono_name>nicotine nasal spray (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x49410">Nicotrol NS</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="26" status="active">
			<mono_name>nicotine transdermal (<emphasis style="smallcaps">otc</emphasis>, Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x49490">Nicoderm CQ</tradename>
				</tradenames>
				<class type="func"> Smoking deterrent</class>
				<class type="chem"> Ganglionic cholinergic agonist</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg> <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x4959">
				<sec_title>Action:</sec_title>
				<para>Agonist at nicotinic receptors in peripheral, central nervous systems; acts at sympathetic ganglia, on chemoreceptors of aorta, carotid bodies; also affects adrenalin-releasing catecholamines</para>
			</section>
			<section type="uses" id="sidelem4x4964">
				<sec_title>Uses:</sec_title>
				<para>Deter cigarette smoking</para>
				<section type="none" id="sidelem4x4969">
					<section type="none" id="sidelem4x4970">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Gilles de la Tourette’s syndrome, ulcerative colitis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x4975">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>) (transdermal, inhaler); hypersensitivity, immediate post-MI recovery period, severe angina pectoris</para>
				<section type="none" id="sidelem4x4980">
					<section type="none" id="sidelem4x4981">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>) (gum); breastfeeding, vasospastic disease, dysrhythmias, diabetes mellitus, hyperthyroidism, pheochromocytoma, esophagitis, peptic ulcer, coronary/renal/hepatic disease; MRI (patch); soy hypersensitivity (mint lozenge)</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4986">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4989">
					<section type="none" id="sidelem4x4990">
						<sec_title>Nicotine chewing gum</sec_title>
						<section type="none" id="sidelem4x4998">
							<label>•</label>
							<sec_title>Adult</sec_title>
							<para>
								<list id="lidelem4x4998">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult:</emphasis> chew 1 piece of gum (2 mg nicotine) whenever urge to smoke occurs; dose varies; usually 20 mg/day during first mo, max 24 pieces/day, max 3 mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5002">
						<sec_title>Nicotine inhaler</sec_title>
						<section type="none" id="sidelem4x5010">
							<label>•</label>
							<sec_title>Adult<route> INH</route></sec_title>
							<para>
								<list id="lidelem4x5010">
									<item>
										<label>•</label>
										<para> 6 cartridges/day for first 3-6 wk, max 16 cartridges/day × 12 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5014">
						<sec_title>Nicotine lozenge</sec_title>
						<section type="none" id="sidelem4x5022">
							<label>•</label>
							<sec_title>Adult</sec_title>
							<para>
								<list id="lidelem4x5022">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult:</emphasis> if cigarette is desired &gt;30 min after awakening, start with 2-mg lozenge; if &lt;30 min after awakening, start with 4-mg lozenge, then again q1-2hr, max 20 lozenges/day or 5 lozenges/6 hr × 6 wk, then 1 lozenge q2-4hr × 2 wk, then 1 lozenge q4-8hr × 2 wk, then discontinue</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5026">
						<sec_title>Nicotine nasal spray</sec_title>
						<section type="none" id="sidelem4x5034">
							<label>•</label>
							<sec_title>Adult</sec_title>
							<para>
								<list id="lidelem4x5034">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult:</emphasis> 1 spray in each nostril 1-2×/hr, max 5×/hr or 40×/day, max 3 mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5038">
						<sec_title>Nicotine transdermal/inhaler system</sec_title>
						<section type="none" id="sidelem4x5046">
							<label>•</label>
							<sec_title>Nicoderm</sec_title>
							<para>
								<list id="lidelem4x5046">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Nicoderm:</emphasis> 21 mg/day × 4-8 wk; 14 mg/day × 2-4 wk; 7 mg/day × 2-4 wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5053">
							<label>•</label>
							<sec_title>Nicotrol</sec_title>
							<para>
								<list id="lidelem4x5053">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Nicotrol:</emphasis> 15 mg/day × 12 wk; 10 mg/day × 2 wk; 5 mg/day × 2 wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5060">
							<label>•</label>
							<sec_title>Nicotrol inhaler</sec_title>
							<para>
								<list id="lidelem4x5060">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Nicotrol inhaler:</emphasis> delivers 30% of nicotine that smoker receives from an actual cigarette</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5064">
						<sec_title>Gilles de la Tourette’s syndrome (unlabeled)</sec_title>
						<section type="none" id="sidelem4x5072">
							<label>•</label>
							<sec_title>Adult and child<route> chewing gum</route></sec_title>
							<para>
								<list id="lidelem4x5072">
									<item>
										<label>•</label>
										<para> 2 mg chewed × 30 min bid for 1-6 mo;  7- or 10-mg patch daily × 2 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5079">
						<sec_title>Available forms:</sec_title>
						<para> <emphasis style="bold">Transdermal patch</emphasis> (Habitrol <country code="CAN">FIX_STRUCTURE(Habitrol </country>, Nicoderm, nicotine transdermal system) delivering 7, 14, 21 mg/day; (Nicoderm) 5, 10, 15 mg/day; <emphasis style="bold">nicotine inhaler</emphasis> 4 mg delivered; <emphasis style="bold">nasal spray</emphasis> 0.5 mg nicotine/actuation; <emphasis style="bold">gum</emphasis> 2, 4 mg/piece; <emphasis style="bold">lozenge</emphasis> 2 mg, 4 mg</para>
					</section>
					<section type="none" id="sidelem4x5102">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x5110">
							<label>•</label>
							<sec_title>Gum</sec_title>
							<para>
								<list id="lidelem4x5110">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Gum:</emphasis> chew gum slowly for 30 min to promote buccal absorption of product; do not chew &gt;45 min</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x5114">
								<item>
									<label>•</label>
									<para>Begin product withdrawal after 3 mo of use; do not exceed 6 mo</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5122">
							<label>•</label>
							<sec_title>Transdermal patch</sec_title>
							<para>
								<list id="lidelem4x5122">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Transdermal patch:</emphasis> 1 × day to nonhairy, clean, dry area of skin on upper body or upper outer arm; rotate sites to prevent skin irritation</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5130">
							<label>•</label>
							<sec_title>Inhaler</sec_title>
							<para>
								<list id="lidelem4x5130">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Inhaler:</emphasis> puffing on mouthpiece delivers nicotine through mouth</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5134">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5137">
					<section type="none" id="sidelem4x5138">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, vertigo, insomnia, headache, confusion, seizures, depression, euphoria, numbness, tinnitus, strange dreams</para>
					</section>
					<section type="none" id="sidelem4x5143">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Dysrhythmias,</emphasis> tachycardia, palpitations, edema, flushing, hypertension</para>
					</section>
					<section type="none" id="sidelem4x5151">
						<sec_title>EENT:</sec_title>
						<para> Jaw ache, irritation in buccal cavity</para>
					</section>
					<section type="none" id="sidelem4x5156">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, indigestion,</emphasis> diarrhea, abdominal pain, constipation, eructation, irritation</para>
					</section>
					<section type="none" id="sidelem4x5164">
						<sec_title>RESP:</sec_title>
						<para> Breathing difficulty, cough, hoarseness, sneezing, wheezing, bronchial spasm</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5169">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset 15-30 min, metabolized in liver, excreted in urine, half-life 2-3 hr, 30-120 hr (terminal)</para>
			</section>
			<section type="interactions" id="sidelem4x5174">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> vasoconstriction—ergots, bromocriptine, cabergoline</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of—adenosine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> B/P—buPROPion</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of—α-blockers, insulin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> nicotine clearance—cimetidine</para>
				<section type="none" id="sidelem4x5197">
					<section type="none" id="sidelem4x5198">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x5202">
								<item>
									<label>•</label>
									<para>Avoid use of gum with acidic foods (colas, coffee) and for 15 min after</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5208">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5211">
					<section type="none" id="sidelem4x5212">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x5220">
							<label>•</label>
							<sec_title>Smoking</sec_title>
							<para>
								<list id="lidelem4x5220">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Smoking:</emphasis> number of cigarettes smoked, years used; <emphasis style="bold">withdrawal:</emphasis> headache, cravings, restlessness, irritation, drowsiness, insomnia, sore throat, increased appetite</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5230">
							<label>•</label>
							<sec_title>Adverse reaction</sec_title>
							<para>
								<list id="lidelem4x5230">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adverse reaction:</emphasis> irritation of buccal cavity, dislike of taste, jaw ache</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5234">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5238">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in urge to smoke, decreased need for gum after 3-6 mo</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5244">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x5252">
							<label>•</label>
							<sec_title>Gum</sec_title>
							<para>
								<list id="lidelem4x5252">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Gum:</emphasis> about all aspects of product use; give package insert to patient and explain</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x5256">
								<item>
									<label>•</label>
									<para>That gum will not stick to dentures, dental appliances</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5261">
								<item>
									<label>•</label>
									<para>That gum is as toxic as cigarettes; that it is to be used only to deter smoking, call prescriber immediately, stop use if difficulty breathing or rash occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5266">
								<item>
									<label>•</label>
									<para>To avoid use during pregnancy</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5274">
							<label>•</label>
							<sec_title>Transdermal patch</sec_title>
							<para>
								<list id="lidelem4x5274">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Transdermal patch:</emphasis> that patch is as toxic as cigarettes; to be used only to deter smoking</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x5278">
								<item>
									<label>•</label>
									<para>Not to use during pregnancy because birth defects may occur; not to breastfeed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5283">
								<item>
									<label>•</label>
									<para>To keep used and unused system out of reach of children and pets</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5288">
								<item>
									<label>•</label>
									<para>To stop smoking immediately when beginning patch treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5293">
								<item>
									<label>•</label>
									<para>To apply promptly after removing from protective patch because system may lose strength</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5301">
							<label>•</label>
							<sec_title>Nasal spray</sec_title>
							<para>
								<list id="lidelem4x5301">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Nasal spray:</emphasis> to tilt head back; not to swallow or inhale during administration; after smoking is stopped, to use spray up to 8 wk, then discontinue over 6 wk by tapering</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5308">
							<label>•</label>
							<sec_title>Lozenges</sec_title>
							<para>
								<list id="lidelem4x5308">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Lozenges:</emphasis> to allow to dissolve; to avoid swallowing</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5315">
							<label>•</label>
							<sec_title>Inhalation</sec_title>
							<para>
								<list id="lidelem4x5315">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Inhalation:</emphasis> to use by inhaler for 20 min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="27" status="active">
			<mono_name>NIFEdipine (Rx)</mono_name>
			<info>
				<pronunciation>(nye-fed′i-peen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x53244">Adalat CC</tradename>
					<tradename id="tnidelem4x53243">
						<country code="CAN">Adalat XL</country>
					</tradename>
					<tradename id="tnidelem4x53242">Afeditab CR</tradename>
					<tradename id="tnidelem4x53241">Procardia</tradename>
					<tradename id="tnidelem4x53240">Procardia XL</tradename>
				</tradenames>
				<class type="func"> Calcium channel blocker, antianginal, antihypertensive</class>
				<class type="chem"> Dihydropyridine</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x5337">
				<para>
					<confusion>
						<tradename id="tnidelem4x53370">NIFEdipine</tradename>
						<drug type="generic" refid="idelem4x53370">niCARdipine/niMODipine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x5341">
				<sec_title>Action:</sec_title>
				<para>Inhibits calcium ion influx across cell membrane during cardiac depolarization; relaxes coronary vascular smooth muscle; dilates coronary arteries; increases myocardial oxygen delivery in patients with vasospastic angina; dilates peripheral arteries</para>
			</section>
			<section type="uses" id="sidelem4x5346">
				<sec_title>Uses:</sec_title>
				<para>Chronic stable angina pectoris, variant angina, hypertension</para>
				<section type="none" id="sidelem4x5353">
					<section type="none" id="sidelem4x5354">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Migraines, migraine prophylaxis; preterm labor, chronic/acute hypertension (pediatrics), diabetic nephropathy, proteinuria, hiccups</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x5359">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or dihydropyridine; cardiogenic shock</para>
				<section type="none" id="sidelem4x5364">
					<section type="none" id="sidelem4x5365">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, hypotension, sick sinus syndrome, 2nd-/3rd-degree heart block, hypotension &lt;90 mm Hg systolic, hepatic injury, renal disease, acute MI, aortic stenosis, GERD, heart failure</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5370">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5378">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x5378">
							<item>
								<label>•</label>
								<para> Immediate release 10 mg tid, increase in 10-mg increments q7-14days, max 180 mg/24 hr or single dose of 30 mg;  30-60 mg/day, may increase q7-14days, max 90 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5385">
					<section type="none" id="sidelem4x5386">
						<sec_title>Hypertension</sec_title>
						<section type="none" id="sidelem4x5394">
							<label>•</label>
							<sec_title>Adult<route> PO EXT REL</route></sec_title>
							<para>
								<list id="lidelem4x5394">
									<item>
										<label>•</label>
										<para> 30-60 mg daily, titrate upward as needed, max 90 mg/day (Adalat CC), 120 mg/day (Procardia XL)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5401">
							<label>•</label>
							<sec_title>Child/adolescent (unlabeled)<route> PO EXT REL</route></sec_title>
							<para>
								<list id="lidelem4x5401">
									<item>
										<label>•</label>
										<para> 0.25-0.5 mg/kg/day, max 3 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5405">
						<sec_title>Acute hypertensive episodes in pediatric patients (unlabeled)</sec_title>
						<section type="none" id="sidelem4x5413">
							<label>•</label>
							<sec_title>Adolescent/child/infant<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5413">
									<item>
										<label>•</label>
										<para> 0.2-0.5 mg/kg/dose up to 10 mg (total dose)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5417">
						<sec_title>Migraine prophylaxis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x5425">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5425">
									<item>
										<label>•</label>
										<para> 30-180 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5429">
						<sec_title>Preterm labor (unlabeled)</sec_title>
						<section type="none" id="sidelem4x5437">
							<label>•</label>
							<sec_title>Pregnant female<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5437">
									<item>
										<label>•</label>
										<para> Immediate release (Procardia, Adalat) 30-mg loading dose, then 10-20 mg q4-6hr; use in monitored settings</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5441">
						<sec_title>Hiccups (unlabeled)</sec_title>
						<section type="none" id="sidelem4x5449">
							<label>•</label>
							<sec_title>Adult</sec_title>
							<para>
								<list id="lidelem4x5449">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult:</emphasis> 10-20 mg tid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5453">
						<sec_title>Available forms:</sec_title>
						<para> Caps 10, 20 mg; ext rel tabs (CC, XL) 30, 60, 90 mg</para>
					</section>
					<section type="none" id="sidelem4x5458">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x5462">
								<item>
									<label>•</label>
									<para>Do not break, crush, or chew ext rel tabs, do not use immediate release caps within 7 days of MI, coronary syndrome</para>
								</item>
								<item>
									<label>•</label>
									<para>Without regard to meals; avoid grapefruit juice</para>
								</item>
								<item>
									<label>•</label>
									<para>Protect caps from direct light, keep in dry area, do not freeze</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5478">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5481">
					<section type="none" id="sidelem4x5482">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis> fatigue, drowsiness, <emphasis style="italic">dizziness,</emphasis> anxiety, depression, weakness, insomnia, light-headedness, paresthesia, tinnitus, blurred vision, nervousness, tremor, <emphasis style="italic">flushing</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5495">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Dysrhythmias,</emphasis> edema, hypotension, palpitations, tachycardia</para>
					</section>
					<section type="none" id="sidelem4x5503">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, diarrhea, gastric upset, constipation, increased LFTs, dry mouth, flatulence, gingival hyperplasia</para>
					</section>
					<section type="none" id="sidelem4x5508">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Nocturia, polyuria</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5515">
						<sec_title>HEMA:</sec_title>
						<para> Bruising, bleeding, petechiae</para>
					</section>
					<section type="none" id="sidelem4x5520">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, flushing, hair loss, <emphasis style="bold">Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5527">
						<sec_title>MISC:</sec_title>
						<para> Sexual difficulties, cough, fever, chills</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5532">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by liver; excreted in urine 60%-80% (metabolites), feces 15%; protein binding 92%-98%, half-life 2-5 hr, well absorbed</para>
				<section type="none" id="sidelem4x5537">
					<section type="none" id="sidelem4x5538">
						<sec_title>PO:</sec_title>
						<para> Onset 20 min, duration 6-8 hr</para>
					</section>
					<section type="none" id="sidelem4x5543">
						<sec_title>PO-ER:</sec_title>
						<para> Duration 24 hr</para>
					</section>
					<section type="none" id="sidelem4x5548">
						<sec_title>PO-CC, PA, XL: </sec_title>
						<para>Peak 6 hr, duration 24 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x5553">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Contraindicated with strong CYP3A4 inducers</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> level of digoxin, phenytoin, cycloSPORINE, prazosin, carBAMazepine</para>
				<para>
					<emphasis alert="nurse">Increase: NIFEdipine, toxicity—cimetidine, ranitidine</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of β-blockers, antihypertensives</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—NSAIDs</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of quiNIDine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> NIFEdipine level—smoking</para>
				<section type="none" id="sidelem4x5586">
					<section type="none" id="sidelem4x5587">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> effect—ginkgo biloba, ginseng, hawthorn</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> effect—ephedra, melatonin, St. John’s wort, yohimbe</para>
					</section>
					<section type="none" id="sidelem4x5598">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> NIFEdipine level—grapefruit juice</para>
					</section>
					<section type="none" id="sidelem4x5606">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CPK, LDH, AST</para>
						<para>
							<emphasis style="bold">Positive:</emphasis> ANA, direct Coombs’ test</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5617">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5620">
					<section type="none" id="sidelem4x5621">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x5629">
							<label>•</label>
							<sec_title>Anginal pain</sec_title>
							<para>
								<list id="lidelem4x5629">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Anginal pain:</emphasis> location, intensity, duration, character, alleviating, aggravating factors</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x5633">
								<item>
									<label>•</label>
									<para>Cardiac status: B/P, pulse, respiration, ECG at baseline and periodically, in those taking antihypertensives, β-blockers, monitor B/P often</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5638">
								<item>
									<label>•</label>
									<para>Potassium, renal, hepatic studies periodically during treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5643">
								<item>
									<label>•</label>
									<para>For bruising, petechiae, bleeding</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5651">
							<label>•</label>
							<sec_title>GI obstruction<route> Ext rel products have been associated with rare reports of obstruction in those with strictures and no known GI disease</route></sec_title>
						</section>
						<section type="none" id="sidelem4x5657">
							<label>•</label>
							<sec_title>Serious skin disorders<route> rash that starts suddenly, fever, cutaneous lesions that may have pustules present; discontinue product</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x5660">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5664">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased anginal pain, B/P, activity tolerance</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5670">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5675">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until stabilized on product, dizziness is no longer a problem</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5680">
								<item>
									<label>•</label>
									<para>To limit caffeine consumption; to avoid alcohol products</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5685">
								<item>
									<label>•</label>
									<para>To avoid OTC products unless directed by prescriber without regard to meals, Adelat CC should be taken on empty stomach</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5690">
								<item>
									<label>•</label>
									<para>That empty tab shells may appear in stools and is not significant</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5698">
							<label>•</label>
							<sec_title>Hypertension</sec_title>
							<para>
								<list id="lidelem4x5698">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypertension:</emphasis> to comply with all areas of medical regimen: diet, exercise, stress reduction, product therapy</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x5702">
								<item>
									<label>•</label>
									<para>To change position slowly because orthostatic hypotension is common</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5708">
								<item>
									<para>
										<emphasis alert="nurse">To notify prescriber of dyspnea, edema of extremities, nausea, vomiting, severe ataxia, severe rash; changes in pattern, frequency, severity of angina</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5713">
								<item>
									<label>•</label>
									<para>To increase fluid intake to prevent constipation</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5718">
								<item>
									<label>•</label>
									<para>To check for gingival hyperplasia and report promptly</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5726">
							<label>•</label>
							<sec_title>
								<route>Not to discontinue abruptly; to gradually taper</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="28" status="active" ha="yes">
			<mono_name>nilotinib (Rx)</mono_name>
			<info>
				<pronunciation>(nye-loe′ti-nib)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x57410">Tasigna</tradename>
				</tradenames>
				<class type="func"> Antineoplastic—miscellaneous</class>
				<class type="chem"> Protein-tyrosine kinase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x5751">
				<sec_title>Action:</sec_title>
				<para>Inhibits BCR-ABL tyrosine kinase created in patients with chronic myeloid leukemia (CML)</para>
			</section>
			<section type="uses" id="sidelem4x5756">
				<sec_title>Uses:</sec_title>
				<para>Chronic phase/accelerated phase Philadelphia-chromosome–positive CML that is resistant or intolerant to imatinib</para>
			</section>
			<section type="contra" id="sidelem4x5761">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, hypersensitivity</para>
				<para>
					<bbw>Hypokalemia, hypomagnesemia, QT prolongation</bbw>
				</para>
				<section type="none" id="sidelem4x5776">
					<section type="none" id="sidelem4x5777">
						<sec_title>Precautions:</sec_title>
						<para> Children, females, geriatric patients, active infections, anemia, cardiac disease, bone marrow suppression, cholestasis, diabetes, gelatin hypersensitivity, infertility, galactose-free diet, lactase deficiency, neutropenia, pancreatitis, thrombocytopenia</para>
						<para>
							<bbw>Hepatic disease</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5792">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5800">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x5800">
							<item>
								<label>•</label>
								<para> 400 mg q12hr, continue until disease progression or unacceptable toxicity</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5804">
					<section type="none" id="sidelem4x5805">
						<sec_title>Adjustment after discontinuation of a strong CYP3A4 inducer</sec_title>
						<section type="none" id="sidelem4x5813">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5813">
									<item>
										<label>•</label>
										<para> reduce to 400 mg/bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5818">
						<sec_title>For those taking a strong CYP3A4 inhibitor</sec_title>
						<section type="none" id="sidelem4x5826">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5826">
									<item>
										<label>•</label>
										<para> reduce dose to 300 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5830">
						<sec_title>QT prolongation</sec_title>
						<section type="none" id="sidelem4x5838">
							<label>•</label>
							<sec_title>QTcF &gt;480 msec<route> withhold dose</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x5841">
						<sec_title>Myelosuppression</sec_title>
						<section type="none" id="sidelem4x5849">
							<label>•</label>
							<sec_title>ANC 1 × 109/L or platelets &lt;50 × 109/L</sec_title>
							<para>
								<list id="lidelem4x5849">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">ANC 1 × 10<emphasis style="sup">9</emphasis>/L or platelets &lt;50 × 10<emphasis style="sup">9</emphasis>/L:</emphasis> withhold dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5859">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x5867">
							<label>•</label>
							<sec_title>Adult<route> PO (Child-Pugh A/B/C) newly diagnosed CML 200 mg bid, then escalation to 300 mg bid initially</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x5870">
						<sec_title>Available forms:</sec_title>
						<para> Caps 150, 200 mg</para>
					</section>
					<section type="none" id="sidelem4x5875">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x5879">
								<item>
									<label>•</label>
									<para>Do not break, crush, or chew caps; if whole capsule cannot be swallowed, disperse capsule contents in 1 tsp. applesauce</para>
								</item>
								<item>
									<label>•</label>
									<para>Without regard to meals; separate doses by 12 hr; make-up dose should not be taken if dose is missed</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at 59° F-86° F (15° C- 30° C)</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5895">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5898">
					<section type="none" id="sidelem4x5899">
						<sec_title>CNS:</sec_title>
						<para> Headache, dizziness, fatigue, fever, flushing, paresthesia</para>
					</section>
					<section type="none" id="sidelem4x5904">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">QT prolongation,</emphasis> palpitations, <emphasis style="bold">torsades de pointes,</emphasis> AV block</para>
					</section>
					<section type="none" id="sidelem4x5915">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis><emphasis style="bold">hepatotoxicity,</emphasis> vomiting, dyspepsia, <emphasis style="italic">anorexia, abdominal pain,</emphasis> constipation, <emphasis style="bold">pancreatitis,</emphasis> diarrhea, xerostomia</para>
					</section>
					<section type="none" id="sidelem4x5931">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia, thrombocytopenia, anemia, pancytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5938">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> alopecia, erythema</para>
					</section>
					<section type="none" id="sidelem4x5946">
						<sec_title>META:</sec_title>
						<para> Hyperamylasemia, hyperbilirubinemia, hyperglycemia, hyperkalemia, hypocalcemia, hyponatremia, hypomagnesemia</para>
					</section>
					<section type="none" id="sidelem4x5951">
						<sec_title>MISC:</sec_title>
						<para> Diaphoresis, anxiety</para>
					</section>
					<section type="none" id="sidelem4x5956">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, myalgia, back or bone pain, muscle cramps</para>
					</section>
					<section type="none" id="sidelem4x5961">
						<sec_title>RESP:</sec_title>
						<para> Cough, dyspnea</para>
					</section>
					<section type="none" id="sidelem4x5966">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Bleeding, tumor lysis syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5973">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Protein binding 98%, metabolized by CYP3A4, plasma levels 3 hr, elimination half-life 17 hr</para>
			</section>
			<section type="interactions" id="sidelem4x5978">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x5986">
					<label>•</label>
					<sec_title>
						<route>Product interactions are numerous</route>
					</sec_title>
				</section>
				<section type="none" id="sidelem4x5992">
					<label>•</label>
					<sec_title>
						<route>Do not use with phenothiazines, pimozide, ziprasidone</route>
					</sec_title>
				</section>
				<para>
					<list id="lidelem4x5996">
						<item>
							<para>
								<emphasis alert="nurse">Increase: QT prolongation—class IA/III antidysrhythmics, some phenothiazines, β agonists, local anesthetics, tricyclics, haloperidol, chloroquine, droperidol, pentamidine; CYP3A4 inhibitors (amiodarone, clarithromycin, erythromycin, telithromycin, troleandomycin), arsenic trioxide, levomethadyl; CYP3A4 substrates (methadone, pimozide, QUEtiapine, quiNIDine, risperiDONE, zipra sidone)</emphasis>
							</para>
						</item>
					</list>
				</para>
				<para>
					<list id="lidelem4x6002">
						<item>
							<para>
								<emphasis alert="nurse">Increase: hepatotoxicity—acetaminophen</emphasis>
							</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> concentrations—ketoconazole, itraconazole, erythromycin, clarithromycin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> plasma concentrations of simvastatin, calcium channel blockers</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> plasma concentration of warfarin; avoid use with warfarin, use low-molecular-weight anticoagulants instead</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> concentrations—dexamethasone, phenytoin, carBAMazepine, rifampin, PHENobarbital</para>
				<section type="none" id="sidelem4x6023">
					<section type="none" id="sidelem4x6024">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> concentration—St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x6031">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> plasma concentrations—grapefruit juice</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6038">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6041">
					<section type="none" id="sidelem4x6042">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x6050">
							<label>•</label>
							<sec_title>Tumor lysis syndrome<route> maintain hydration, correct uric acid before use with this product</route></sec_title>
						</section>
						<section type="none" id="sidelem4x6079">
							<label>•</label>
							<sec_title>Myelosuppression</sec_title>
							<para>
								<list id="lidelem4x6079">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Myelosuppression:</emphasis> Monitor CBC ×2 mo, then monthly, differential, platelet count; for bleeding: epistaxis, rectal, gingival, upper GI, genital and wound bleeding; </para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6085">
								<item>
									<label>•</label>
									<para>ANC and platelets; if ANC &lt;1 ×10<emphasis style="sup">9</emphasis>/L and/or platelets &lt;50 ×10<emphasis style="sup">9</emphasis>/L, stop until ANC &gt;1.5 ×10<emphasis style="sup">9</emphasis>/L and platelets &gt;75 ×10<emphasis style="sup">9</emphasis>/L</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6105">
							<label>•</label>
							<sec_title>Electrolytes</sec_title>
							<para>
								<list id="lidelem4x6105">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Electrolytes:</emphasis> calcium, potassium, magnesium, sodium; lipase, phosphate; hypokalemia, hypomagnesemia should be corrected before use</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6110">
								<item>
									<label>•</label>
									<para>AST/ALT/Bilirubin/Lipase/Amylase if increased to grade 3, withhold product, resume at 400 mg daily when levels return to grade 1 or below</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6116">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6120">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in progression of disease</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6126">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6130">
								<item>
									<label>•</label>
									<para>To report adverse reactions immediately: SOB, bleeding</para>
								</item>
								<item>
									<label>•</label>
									<para>About reason for treatment, expected results</para>
								</item>
								<item>
									<label>•</label>
									<para>That many adverse reactions may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid persons with known upper respiratory tract infections; immunosuppression is common</para>
								</item>
								<item>
									<label>•</label>
									<para>To watch for signs, symptoms of low potassium or magnesium</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="29" status="active">
			<mono_name>nisoldipine (Rx)</mono_name>
			<info>
				<pronunciation>(nye-sole′dih-peen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x61610">Sular</tradename>
				</tradenames>
				<class type="func"> Calcium channel blocker, antihypertensive</class>
				<class type="chem"> Dihydropyridine</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x6171">
				<para>
					<confusion>
						<tradename id="tnidelem4x61710">nisoldipine</tradename>
						<drug type="generic" refid="idelem4x61710">NIFEdipine/niMODipine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x6175">
				<sec_title>Action:</sec_title>
				<para>Inhibits calcium ion influx across the cell membrane, thereby resulting in the dilation of peripheral arteries</para>
			</section>
			<section type="uses" id="sidelem4x6180">
				<sec_title>Uses:</sec_title>
				<para>Essential hypertension, alone or in combination with other antihypertensives</para>
				<section type="none" id="sidelem4x6185">
					<section type="none" id="sidelem4x6186">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Variant (Prinzmetal’s) angina, stable angina pectoris</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x6191">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or dihydropyridines; sick sinus syndrome; 2nd-/3rd-degree heart block; aortic stenosis</para>
				<section type="none" id="sidelem4x6196">
					<section type="none" id="sidelem4x6197">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, CHF, hypotension &lt;90 mm Hg systolic, hepatic injury, renal disease, acute MI, unstable angina, CAD, cardiogenic shock</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6202">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6205">
					<section type="none" id="sidelem4x6206">
						<sec_title>Hypertension</sec_title>
						<section type="none" id="sidelem4x6214">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6214">
									<item>
										<label>•</label>
										<para> 17 mg/day initially, may increase by 8.5 mg/wk, usual dose 17-34 mg/day, max 34 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6221">
							<label>•</label>
							<sec_title>Geriatric/hepatic dose<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6221">
									<item>
										<label>•</label>
										<para> 8.5 mg/day, increase based on patient response</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6225">
						<sec_title>Variant (Prinzmetal’s) angina/stable angina pectoris (unlabeled)</sec_title>
						<section type="none" id="sidelem4x6233">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6233">
									<item>
										<label>•</label>
										<para> 17-34 mg/day, max 34 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6237">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x6245">
							<label>•</label>
							<sec_title>Adult<route> PO 8.5 mg/day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x6248">
						<sec_title>Available forms:</sec_title>
						<para> Ext rel tabs 8.5, 17, 20, 25.5, 30, 34, 40 mg</para>
					</section>
					<section type="none" id="sidelem4x6253">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x6256">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x6260">
									<item>
										<label>•</label>
										<para>Swallow whole; do not break, crush, or chew</para>
									</item>
									<item>
										<label>•</label>
										<para>Once daily as whole tablet; avoid high-fat foods, grapefruit juice</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6271">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6274">
					<section type="none" id="sidelem4x6275">
						<sec_title>CNS:</sec_title>
						<para> Headache, fatigue, drowsiness, dizziness, anxiety, depression, nervousness, insomnia, lightheadedness, paresthesia, tinnitus, psychosis, somnolence, ataxia, confusion, malaise, migraine, flushing</para>
					</section>
					<section type="none" id="sidelem4x6280">
						<sec_title>CV:</sec_title>
						<para> Dysrhythmia, edema, <emphasis style="bold">CHF,</emphasis> hypotension, palpitations, <emphasis style="bold">MI, pulmonary edema,</emphasis> tachycardia, syncope, AV block, angina, chest pain, ECG abnormalities</para>
					</section>
					<section type="none" id="sidelem4x6292">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, diarrhea, gastric upset, constipation, increased LFTs, dry mouth, dyspepsia, dysphagia, flatulence</para>
					</section>
					<section type="none" id="sidelem4x6297">
						<sec_title>GU:</sec_title>
						<para> Nocturia, hematuria, dysuria</para>
					</section>
					<section type="none" id="sidelem4x6302">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Anemia, leukopenia,</emphasis> petechiae</para>
					</section>
					<section type="none" id="sidelem4x6310">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus</para>
					</section>
					<section type="none" id="sidelem4x6315">
						<sec_title>MISC:</sec_title>
						<para> Sexual difficulties, cough, nasal congestion, SOB, wheezing, epistaxis, dyspnea, gingival hyperplasia, chills, fever, gout, sweating</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6320">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by liver, excreted in urine, peak 6-12 hr, protein binding 99%, half-life 7-12 hr</para>
			</section>
			<section type="interactions" id="sidelem4x6325">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of β-blockers, antihypertensives, digoxin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> nisoldipine level—CYP3A4 inhibitors, cimetidine, ranitidine, azole antifungals</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> nisoldipine effect—CYP3A4 inducers, hydantoins</para>
				<section type="none" id="sidelem4x6340">
					<section type="none" id="sidelem4x6341">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> B/P—ephedra, melatonin</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> B/P—hawthorn</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> nisoldipine effect—St. John’s wort, ginseng, ginkgo biloba</para>
					</section>
					<section type="none" id="sidelem4x6356">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> nisoldipine level—high-fat foods</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> hypotensive effect—grapefruit juice</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6367">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6370">
					<section type="none" id="sidelem4x6371">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x6376">
								<item>
									<label>•</label>
									<para>Cardiac status: B/P, pulse, respiration, ECG before treatment and periodically</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6384">
							<label>•</label>
							<sec_title>CHF</sec_title>
							<para>
								<list id="lidelem4x6384">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">CHF:</emphasis> weight gain, jugular venous distention, edema, crackles, I&amp;O ratios</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6391">
							<label>•</label>
							<sec_title>Angina</sec_title>
							<para>
								<list id="lidelem4x6391">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Angina:</emphasis> frequency, severity of attacks, if angina worsens, report immediately</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6395">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6399">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased B/P</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6405">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6409">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until stabilized on product, dizziness is no longer a problem</para>
								</item>
								<item>
									<label>•</label>
									<para>To report nausea, dizziness, swelling, SOB, palpitations, severe headache</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid OTC products unless directed by prescriber; to avoid grapefruit juice</para>
								</item>
								<item>
									<label>•</label>
									<para>About the importance of complying with all areas of the medical regimen: diet, exercise, stress reduction, product therapy</para>
								</item>
								<item>
									<label>•</label>
									<para>To rise slowly to prevent orthostatic hypotension</para>
								</item>
								<item>
									<label>•</label>
									<para>If dose is missed, to take as soon as remembered; not to double dose</para>
								</item>
								<item>
									<label>•</label>
									<para>How to perform B/P monitoring at home</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="30" status="active" ru="yes">
			<mono_name>nitazoxanide (Rx)</mono_name>
			<info>
				<pronunciation>(nye-taz-ox′a-nide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x64570">Alinia</tradename>
				</tradenames>
				<class type="func"> Antiprotozoal</class>
			</info>
			<section type="uses" id="sidelem4x6463">
				<sec_title>Uses:</sec_title>
				<para>Diarrhea caused by <emphasis style="italic">Cryptosporidium parvum</emphasis> or <emphasis style="italic">Giardia lamblia</emphasis></para>
			</section>
			<section type="contra" id="sidelem4x6473">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
			</section>
			<section type="doses" id="sidelem4x6478">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6486">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x6486">
							<item>
								<label>•</label>
								<para> 500 mg q12hr × 3 days</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6493">
					<label>•</label>
					<sec_title>Child 4-11 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x6493">
							<item>
								<label>•</label>
								<para> 10 ml (200 mg) q12hr × 3 days</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6500">
					<label>•</label>
					<sec_title>Child 12-47 mo<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x6500">
							<item>
								<label>•</label>
								<para> 5 ml (100 mg) q12hr × 3 days</para>
							</item>
						</list>
					</para>
				</section>
			</section>
		</monograph>
<monograph id="31" status="active">
			<mono_name>nitrofurantoin (Rx)</mono_name>
			<info>
				<pronunciation>(nye-troe-fyoor′an-toyn)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x65103">Furadantin</tradename>
					<tradename id="tnidelem4x65102">Macrobid</tradename>
					<tradename id="tnidelem4x65101">Macrodantin</tradename>
					<tradename id="tnidelem4x65100">
						<country code="CAN">Novo-Furantoin </country>
					</tradename>
				</tradenames>
				<class type="func"> Urinary tract antiinfective</class>
				<class type="chem"> Synthetic nitrofuran derivative</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x6522">
				<sec_title>Action:</sec_title>
				<para>Inhibits bacterial acetyl-CoA inteference with carbohydrate metabolism</para>
			</section>
			<section type="uses" id="sidelem4x6527">
				<sec_title>Uses:</sec_title>
				<para>Urinary tract infections caused by <emphasis style="italic">Escherichia coli, Klebsiella, Pseudomonas, Proteus vulgaris, Proteus morganii, Serratia, Citrobacter, Staph ylococcus aureus, Staphylococcus epidermidis, Enterococcus, Salmonella, Shigella</emphasis></para>
			</section>
			<section type="contra" id="sidelem4x6534">
				<sec_title>Contraindications:</sec_title>
				<para>Infants &lt;1 mo, hypersensitivity, anuria, severe renal disease CCr &lt;60 ml/min, at term pregnancy (38-42 wk), labor, delivery, cholestatic jaundice due to nitrofurantoin therapy</para>
				<section type="none" id="sidelem4x6539">
					<section type="none" id="sidelem4x6540">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, geriatric patients, G6PD deficiency, GI disease, diabetes</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6545">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6548">
					<section type="none" id="sidelem4x6549">
						<sec_title>Active infections</sec_title>
						<section type="none" id="sidelem4x6557">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6557">
									<item>
										<label>•</label>
										<para> 50-100 mg qid after meals</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6564">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6564">
									<item>
										<label>•</label>
										<para> 5-7 mg/kg/day in 4 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6568">
						<sec_title>Chronic suppression</sec_title>
						<section type="none" id="sidelem4x6576">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6576">
									<item>
										<label>•</label>
										<para> 50-100 mg q <emphasis style="smallcaps">pm</emphasis></para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6585">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6585">
									<item>
										<label>•</label>
										<para> 1-2 mg/kg/day in <emphasis style="smallcaps">pm</emphasis> or 0.5-1 mg/kg q12hr if dose not well tolerated</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6592">
						<sec_title>Available forms:</sec_title>
						<para> Caps 25, 50, 100 mg; susp 25 mg/5 ml; macrocrystal caps (Macrodantin) 25, 50, 100 mg; Macrobid cap 100 mg (25 macrocrystals, 75 monohydrate)</para>
					</section>
					<section type="none" id="sidelem4x6597">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x6600">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x6604">
									<item>
										<label>•</label>
										<para>Give with meals</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not break, crush, chew, or open tabs, caps, store in original container</para>
									</item>
									<item>
										<label>•</label>
										<para>Two daily doses if urine output is high or if patient diabetic</para>
									</item>
									<item>
										<label>•</label>
										<para>Use calibrated device to measure liquid product; may mix water, fruit juice; rinse mouth after liquid product; staining of teeth may occur</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6625">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6628">
					<section type="none" id="sidelem4x6629">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, headache,</emphasis> drowsiness, peripheral neuropathy, chills, confusion, vertigo</para>
					</section>
					<section type="none" id="sidelem4x6637">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Bundle branch block,</emphasis> chest pain</para>
					</section>
					<section type="none" id="sidelem4x6645">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, abdominal pain, diarrhea,</emphasis><emphasis style="bold">cholestatic jaundice,</emphasis> loss of appetite, <emphasis style="bold">pseudomembranous colitis, hepatitis, pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6657">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Anemia, agranulocytosis, hemolytic anemia, leukopenia, thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6664">
						<sec_title>INTEG:</sec_title>
						<para> Pruritus, rash, urticaria, angioedema, alopecia, tooth staining, <emphasis style="bold">exfoliative dermatitis, Stevens-Johnson syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6671">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, myalgia, numbness, peripheral neuropathy</para>
					</section>
					<section type="none" id="sidelem4x6676">
						<sec_title>RESP:</sec_title>
						<para> Cough, dyspnea, <emphasis style="bold">pneumonitis, pulmonary fibrosis or infiltrate</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6683">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Superinfection,</emphasis> SLE-like syndrome</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6691">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x6694">
					<section type="none" id="sidelem4x6695">
						<sec_title>PO:</sec_title>
						<para> Half-life 20-60 min; crosses blood-brain barrier, placenta; enters breast milk; excreted as inactive metabolites in liver, unchanged in urine; protein binding 60%-90%</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x6700">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> antagonistic effect—norfloxacin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of nitrofurantoin—probenecid</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption of magnesium trisilicate antacid</para>
				<section type="none" id="sidelem4x6715">
					<section type="none" id="sidelem4x6716">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> BUN, alk phos, bilirubin, creatinine, blood glucose</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6724">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6727">
					<section type="none" id="sidelem4x6728">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x6733">
								<item>
									<label>•</label>
									<para>Blood count during chronic therapy, LFTs, pulmonary function tests</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6741">
							<label>•</label>
							<sec_title>Urinary tract infection</sec_title>
							<para>
								<list id="lidelem4x6741">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Urinary tract infection:</emphasis> burning, pain on urination; fever; cloudy, foul-smelling urine; I&amp;O ratio: C&amp;S before treatment, after completion; serum creatinine, BUN</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6748">
							<label>•</label>
							<sec_title>Pseudomembraneous colitis<route> diarrhea with mucus, abdominal pain, fever, fatigue, anorexia; may be treated with vancomycin or metroNIDAZOLE</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x6751">
								<item>
									<label>•</label>
									<para>CNS symptoms: insomnia, vertigo, headache, drowsiness, seizures</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6757">
								<item>
									<para>
										<emphasis alert="nurse">Hepatotoxicity: yellowing of skin or eyes, dark urine, clay-colored stools; monitor AST, ALT</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6763">
								<item>
									<para>
										<emphasis alert="nurse">Pulmonary fibrosis, pneumonitis: dyspnea, tachypnea, persistent cough</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6769">
								<item>
									<para>
										<emphasis alert="nurse">Serious skin disorders: fever, flushing, rash, urticaria, pruritus</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6777">
							<label>•</label>
							<sec_title>Peripheral neuropathy</sec_title>
							<para>
								<list id="lidelem4x6777">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Peripheral neuropathy:</emphasis> paresthesias (more common in diabetes mellitus, electrolyte imbalances, vit B deficiency, debilitated patients)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6781">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6785">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased dysuria, fever; negative C&amp;S</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6791">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6796">
								<item>
									<label>•</label>
									<para>To notify prescriber of continued symptoms of UTI, fever, myalgias, arthralgias, numbness or tingling of extremities</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6801">
								<item>
									<label>•</label>
									<para>To take with food or milk; to avoid alcohol</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6806">
								<item>
									<label>•</label>
									<para>To protect susp from freezing; shake well before taking</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6811">
								<item>
									<label>•</label>
									<para>That product may cause drowsiness; to seek aid with walking, other activities; not to drive or operate machinery while taking medication</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6816">
								<item>
									<label>•</label>
									<para>That diabetics should monitor blood glucose levels</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6821">
								<item>
									<label>•</label>
									<para>That product may turn urine rust-yellow to brown</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6827">
								<item>
									<para>
										<emphasis alert="nurse">Pseudomembranous colitis: fever; diarrhea with mucus, pus, or blood; report immediately</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="32" status="active" ha="yes">
			<mono_name>nitroglycerin (Rx)</mono_name>
			<info>
				<pronunciation>(nye-troe-gli′ser-in)</pronunciation>
			</info>
		</monograph>
<monograph id="33" status="active">
			<mono_name>extended release caps (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x68421">Nitro-Time</tradename>
					<tradename id="tnidelem4x68420">
						<country code="CAN">Nitrogard SR</country>
					</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="34" status="active">
			<mono_name>topical ointment (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x68490">Nitro-Bid</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="35" status="active">
			<mono_name>rectal ointment</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x68540">Rectiv</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="36" status="active">
			<mono_name>SL (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x68590">Nitrostat</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="37" status="active">
			<mono_name>translingual spray (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x68641">Nitrolingual</tradename>
					<tradename id="tnidelem4x68640">NitroMist</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="38" status="active">
			<mono_name>transdermal (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x68691">Minitran</tradename>
					<tradename id="tnidelem4x68690">Nitro-Dur</tradename>
				</tradenames>
				<class type="func"> Coronary vasodilator, antianginal</class>
				<class type="chem"> Nitrate</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x6879">
				<para>
					<confusion>
						<tradename id="tnidelem4x68790">Nitro-Bid</tradename>
						<drug type="generic" refid="idelem4x68790">Nicobid</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x6883">
				<sec_title>Action:</sec_title>
				<para>Decreases preload and afterload, which are responsible for decreasing left ventricular end-diastolic pressure, systemic vascular resistance; dilates coronary arteries, improves blood flow through coronary vasculature, dilates arterial and venous beds systemically</para>
			</section>
			<section type="uses" id="sidelem4x6888">
				<sec_title>Uses:</sec_title>
				<para>Chronic stable angina pectoris, prophylaxis of angina pain, CHF, acute MI, controlled hypotension for surgical procedures, anal fissures</para>
				<section type="none" id="sidelem4x6893">
					<section type="none" id="sidelem4x6894">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Pulmonary hypertension, hemorrhoids, retained placenta</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x6899">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or nitrites; severe anemia, increased intracranial pressure, cerebral hemorrhage, closed-angle glaucoma, cardiac tamponade, cardiomyopathy, constrictive pericarditis</para>
				<section type="none" id="sidelem4x6906">
					<section type="none" id="sidelem4x6907">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, postural hypotension, severe renal/hepatic disease, acute MI, abrupt discontinuation, hyperthyroidism</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6912">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6920">
					<label>•</label>
					<sec_title>Adult<route> SL</route></sec_title>
					<para>
						<list id="lidelem4x6920">
							<item>
								<label>•</label>
								<para> Dissolve tab under tongue when pain begins; may repeat q5min until relief occurs; take ≤3 tabs/15 min; use 1 tab prophylactically 5-10 min before activities;  q6-12hr on empty stomach;  1-2 in q8hr, increase to 4 in q4hr as needed;  5 mcg/min, then increase by 5 mcg/min q3-5min; if no response after 20 mcg/min, increase by 10-20 mcg/min until desired response;  apply a patch daily to a site free of hair; remove patch at bedtime to provide 10-12 hr nitrate-free interval to avoid tolerance</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6939">
					<label>•</label>
					<sec_title>Child<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x6939">
							<item>
								<label>•</label>
								<para> Initially 0.25-0.5 mcg/kg/min, titrate to patient response, usual dose 1-3 mcg/kg/min transmucosal</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6943">
					<section type="none" id="sidelem4x6944">
						<sec_title>Anal fissures (Rectiv)</sec_title>
						<section type="none" id="sidelem4x6952">
							<label>•</label>
							<sec_title>Adult<route> Rectal</route></sec_title>
							<para>
								<list id="lidelem4x6952">
									<item>
										<label>•</label>
										<para> Apply 1 inch of 0.4% ointment q12hr × 3 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6956">
						<sec_title>Available forms:</sec_title>
						<para> Translingual aero 0.4 mg/metered spray; sus rel tabs 2.5, 6.5, 9 mg; SL tabs 0.3, 0.4, 0.6 mg; topical oint 2%; trans syst 0.1, 0.2, 0.3, 0.4, 0.6, 0.8 mg/hr; inj sol 25 mg/250 ml, 50 mg/250 ml, 50 mg/500 ml, 100 mg/250 ml, 200 mg/500 ml; rectal ointment 0.4% (Rectiv)</para>
					</section>
					<section type="none" id="sidelem4x6961">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x6969">
							<label>•</label>
							<sec_title>
								<route>Topical ointment</route>
							</sec_title>
							<para>
								<list id="lidelem4x6969">
									<item>
										<label>•</label>
										<para> should be measured on papers supplied; use paper to spread on nonhairy area of chest, abdomen, thigh skin; thin layer spread over 2-3 inches; do not rub</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6973">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x6978">
									<item>
										<label>•</label>
										<para>Swallow sus rel products whole; do not break, crush, or chew</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x6983">
									<item>
										<label>•</label>
										<para>With 8 oz water on empty stomach (oral tablet) 1 hr before or 2 hr after meals</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x6991">
								<label>•</label>
								<sec_title>SL</sec_title>
								<para>
									<list id="lidelem4x6991">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">SL:</emphasis> should be dissolved under tongue, not swallowed</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x6998">
								<label>•</label>
								<sec_title>
									<route>Aerosol</route>
								</sec_title>
								<para>
									<list id="lidelem4x6998">
										<item>
											<label>•</label>
											<para> sprayed under tongue  not inhaled; prime before 1st-time use or if product has not been used in &gt;6 wk; press valve head with forefinger</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x7005">
							<sec_title>Transdermal route</sec_title>
							<para>
								<list id="lidelem4x7009">
									<item>
										<label>•</label>
										<para>Apply new TD patch daily; remove after 12-14 hr to prevent tolerance</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7015">
							<sec_title>Rectal route</sec_title>
							<para>
								<list id="lidelem4x7019">
									<item>
										<label>•</label>
										<para>Cover finger with plastic wrap, disposable glove, or finger cot; lay finger alongside 1-inch dosing line on carton; squeeze tube until equal to 1-inch dosing line; insert covered finger gently into anal canal no further than 1st finger joint and apply to sides; wash hands thoroughly; if too painful, apply directly to outside of anus</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7025">
							<sec_title>Continuous IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x7029">
									<item>
										<label>•</label>
										<para>Diluted in D<emphasis style="inf">5</emphasis>, D<emphasis style="inf">5</emphasis>W, 0.9% NaCl for infusion to 200-400 mcg/ml, depending on patient’s fluid status; common dilution 50 mg/250 ml, use controlled infusion device; use glass infusion bottles, non–polyvinyl-chloride infusion tubing; titrate to patient response; do not use filters</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfen-tanil, amikacin, aminocaproic acid, aminophylline, amiodarone, amphotericin B cholesteryl, amphotericin B lipid complex, amphotericin B liposome, anidulafungin, argatroban, ascorbic acid, atenolol, atracurium, atropine, azaTHIOprine, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, caspofungin, cefamandole, ceFAZolin, cefmetazole, cefonicid, cefoperazone, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, cephalothin, cephapirin, chloramphenicol, chlorproMAZINE, cimetidine, cisatracurium, CISplatin, clindamycin, cloNIDine, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, dexamethasone, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doxacurium, DOXOrubicin, doxycycline, drotrecogin alfa, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, ertapenem, erythromycin, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, fluorouracil, folic acid, ganciclovir, gati floxacin, gemcitabine, gemtuzumab, gentamicin, glycopyrrolate, granisetron, heparin, hydrocortisone, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, imipenem-cilastatin, indomethacin, insulin (regular), irinotecan, isoproterenol, ketorolac, labetalol, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, meperidine, metaraminol, methicillin, methotrexate, methoxamine, methyldopate, methylPREDNISolone, metoclopramide, metroNIDAZOLE, mezlocillin, micafungin, miconazole, midazolam, milrinone, minocycline, mitoXANtrone, morphine, moxalactam, mycophenolate, nafcillin, nalbuphine, naloxone, nesiri-tide, netilmicin, niCARdipine, nitroprusside, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, pantoprazole, papaverine, PEMEtrexed, penicillin G potassium/ sodium, pentamidine, pentazocine, PENTobarbital, PHENobarbital, phentolamine, phenylephrine, phytonadione, piperacillin, piperacillin-tazobactam, polymyxin B, potassium chloride, procainamide, prochlorperazine, promethazine, propofol, propranolol, protamine, pyridoxine, quiNIDine, quinupristin-dalfopristin, ranitidine, remifentanil, ritodrine, rocuronium, sodium bicarbonate, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiamine, thiopental, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, tobramycin, tolazoline, trimetaphan, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, voriconazole, warfarin, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7047">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7050">
					<section type="none" id="sidelem4x7051">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, flushing, dizziness</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7058">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Postural hypotension,</emphasis> tachycardia, <emphasis style="bold">collapse,</emphasis> syncope, palpitations</para>
					</section>
					<section type="none" id="sidelem4x7069">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting</para>
					</section>
					<section type="none" id="sidelem4x7074">
						<sec_title>INTEG:</sec_title>
						<para> Pallor, sweating, rash</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7079">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by liver, excreted in urine, half-life 1-4 min</para>
				<section type="none" id="sidelem4x7084">
					<section type="none" id="sidelem4x7085">
						<sec_title>SUS REL:</sec_title>
						<para> Onset 20-45 min, duration 3-8 hr</para>
					</section>
					<section type="none" id="sidelem4x7090">
						<sec_title>SL:</sec_title>
						<para> Onset 1-3 min, duration 30 min</para>
					</section>
					<section type="none" id="sidelem4x7095">
						<sec_title>TRANSDERMAL:</sec_title>
						<para> Onset 30 min-1 hr, duration 12-24 hr</para>
					</section>
					<section type="none" id="sidelem4x7100">
						<sec_title>AEROSOL:</sec_title>
						<para> Onset 2 min, duration 30-60 min</para>
					</section>
					<section type="none" id="sidelem4x7105">
						<sec_title>TOPICAL OINT:</sec_title>
						<para> Onset 30-60 min, duration 2-12 hr</para>
					</section>
					<section type="none" id="sidelem4x7110">
						<sec_title>IV:</sec_title>
						<para> Onset 1-2 min, duration 3-5 min</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x7115">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x7123">
					<label>•</label>
					<sec_title>Severe hypotension, CV collapse<route> alcohol</route></sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of β-blockers, diuretics, antihypertensives, calcium channel blockers</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> fatal hypotension—sildenafil, tadalafil, vardenafil; do not use together</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> nitrate level—aspirin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> heparin—IV nitroglycerin</para>
				<section type="none" id="sidelem4x7142">
					<section type="none" id="sidelem4x7143">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> urine catecholamine, urine VMA</para>
						<para>
							<emphasis style="bold">False increase:</emphasis> cholesterol</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7154">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7157">
					<section type="none" id="sidelem4x7158">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x7166">
							<label>•</label>
							<sec_title>Pain</sec_title>
							<para>
								<list id="lidelem4x7166">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pain:</emphasis> duration, time started, activity being performed, character</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x7170">
								<item>
									<label>•</label>
									<para>Orthostatic B/P, pulse before and after administration</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7175">
								<item>
									<label>•</label>
									<para>Tolerance if taken over long period</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7180">
								<item>
									<label>•</label>
									<para>Headache, lightheadedness, decreased B/P; may indicate a need for decreased dosage</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7185">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7189">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease, prevention of anginal pain</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7195">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x7200">
								<item>
									<label>•</label>
									<para>To place buccal tab between lip and gum above incisors or between cheek and gum</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7205">
								<item>
									<label>•</label>
									<para>To keep tabs in original container; to replace q6mo because effectiveness is lost; to keep away from heat, moisture, light</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7211">
								<item>
									<label>•</label>
									<para>That if 3 SL tabs in 15 min do not relieve pain, to seek immediate medical attention</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7216">
								<item>
									<label>•</label>
									<para>To avoid alcohol</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7221">
								<item>
									<label>•</label>
									<para>That product may cause headache; that tolerance usually develops; to use nonopioid analgesic</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7226">
								<item>
									<label>•</label>
									<para>That product may be taken before stressful activity: exercise, sexual activity</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7231">
								<item>
									<label>•</label>
									<para>That SL may sting when product comes in contact with mucous membranes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7236">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities if dizziness occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7241">
								<item>
									<label>•</label>
									<para>To comply with complete medical regimen</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7246">
								<item>
									<label>•</label>
									<para>To make position changes slowly to prevent fainting</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7252">
								<item>
									<para>
										<emphasis alert="nurse">Never to use erectile dysfunction products (sildenafil, tadalafil, vardenafil); may cause severe hypotension, death</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="39" status="active" ha="yes">
			<mono_name>nitroprusside (Rx)</mono_name>
			<info>
				<pronunciation>(nye-troe-pruss′ide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x72640">Nitropress</tradename>
				</tradenames>
				<class type="func"> Antihypertensive, vasodilator</class>
			</info>
			<section type="actions" id="sidelem4x7270">
				<sec_title>Action:</sec_title>
				<para>Directly relaxes arteriolar, venous smooth muscle, thereby resulting in reduction in cardiac preload and afterload</para>
			</section>
			<section type="uses" id="sidelem4x7275">
				<sec_title>Uses:</sec_title>
				<para>Hypertensive crisis/urgency/ induction; to decrease bleeding by creating hypotension during surgery; acute CHF</para>
				<section type="none" id="sidelem4x7280">
					<section type="none" id="sidelem4x7281">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Postoperative hypertension, mitral regurgitation</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x7286">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, hypertension (compensatory) due to aortic coarctation or AV shunting, acute CHF associated with reduced peripheral vascular resistance, AV shunt, Leber’s disease, toxic amblyopia</para>
				<para>
					<bbw>Cyanide toxicity, do not use in hypothyroidism</bbw>
				</para>
				<section type="none" id="sidelem4x7301">
					<section type="none" id="sidelem4x7302">
						<sec_title>Precautions:</sec_title>
						<para> Anemia, increased intracranial pressure, pregnancy (C), breastfeeding, children, geriatric patients, hypovolemia, electrolyte imbalances, renal/hepatic disease, hypothyroidism</para>
						<para>
							<bbw>Hypotension</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7317">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7325">
					<label>•</label>
					<sec_title>Adult and child<route> IV INFUSION</route></sec_title>
					<para>
						<list id="lidelem4x7325">
							<item>
								<label>•</label>
								<para> 0.25-10 mcg/kg/min; max 10 mcg/kg/min × 10 min</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x7329">
					<section type="none" id="sidelem4x7330">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x7338">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x7338">
									<item>
										<label>•</label>
										<para> CCr &lt;60 ml/min, maintain doses &lt;3 mcg/kg/min to reduce thiocyanate accumulation</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7342">
						<sec_title>Available forms:</sec_title>
						<para> Inj 50 mg/2 ml</para>
					</section>
					<section type="none" id="sidelem4x7347">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x7351">
								<item>
									<label>•</label>
									<para>Antidote is sodium thiosulfate</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7357">
							<sec_title>Continuous IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x7361">
									<item>
										<label>•</label>
										<para>Depending on B/P reading q15min</para>
									</item>
									<item>
										<label>•</label>
										<para>Reconstitute 50 mg/2-3 ml of D<emphasis style="inf">5</emphasis>W, further dilute in 250, 500, or 1000 ml of D<emphasis style="inf">5</emphasis>W to 200, 100, 50 mcg/ml, respectively; use infusion pump only; wrap bottle with aluminum foil to protect from light; observe for color change in infusion; discard if highly discolored (blue, green, dark red); titrate to patient response, protect from light</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alfentanil, alprostadil, amikacin, aminocaproic acid, aminophylline, amphotericin B lipid compex, amphotericin B liposome, anidulafungin, argatroban, atenolol, atropine, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, cefamandole, ceFAZolin, cefmetazole, cefonicid, cefoperazone, cefotaxime, cefoTEtan, ce fOXitin, cefTAZidime, ceftizoxime, cef TRIAXone, cefuroxime, cephalothin, chloramphenicol, cimetidine, CISplatin, clindamycin, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, digoxin, diltiazem, DOCEtaxel, DOPamine, doxacurium, DOXOrubicin, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, ertapenem, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, fluorouracil, folic acid, furosemide, ganciclovir, gatifloxacin, gemcitabine, gemtuzumab, gentamicin, glycopyrrolate, granisetron, heparin, hydrocortisone, HYDROmorphone, IDArubicin, ifosfamide, inamrinone, indomethacin, insulin (regular), isoproterenol, ketorolac, labetalol, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, meperidine, metaraminol, methicillin, methoxamine, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, mezlocillin, micafungin, miconazole, midazolam, milrinone, minocycline, morphine, moxalactam, multiple vitamins injection, nafcillin, nalbuphine, naloxone, nesiritide, netilmicin, niCARdipine, nitroglycerin, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, pantoprazole, penicillin G potassium/sodium, pentamidine, PENTobarbital, PHENobarbital, phentolamine, phenylephrine, phytonadione, piperacillin, piperacillin-tazobactam, polymyxin B, potassium chloride/phosphates, procainamide, propofol, propranolol, protamine, pyridoxine, ranitidine, ritodrine, rocuronium, sodium acetate/bicarbonate, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiamine, ticarcillin, ticarcillin-clavulanate, tigecy cline, tirofiban, tobramycin, tolazoline, trimetaphan, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7384">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7387">
					<section type="none" id="sidelem4x7388">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, headache,</emphasis> agitation, twitching, decreased reflexes, <emphasis style="italic">restlessness</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7398">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Bradycardia,</emphasis> ECG changes, tachycardia, <emphasis style="italic">hypotension</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7408">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, abdominal pain</para>
					</section>
					<section type="none" id="sidelem4x7413">
						<sec_title>INTEG:</sec_title>
						<para> Pain, irritation at inj site, sweating</para>
					</section>
					<section type="none" id="sidelem4x7418">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Cyanide, thiocyanate toxicity,</emphasis> flushing, hypothyroidism</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7426">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x7429">
					<section type="none" id="sidelem4x7430">
						<sec_title>IV:</sec_title>
						<para> Onset 1-2 min, duration 1-10 min, half-life 2 min; metabolized in liver, excreted in urine</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x7435">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: severe hypotension—ganglionic blockers, volatile liquid anesthetics, halothane, enflurane, circulatory depressants</emphasis>
				</para>
				<section type="none" id="sidelem4x7441">
					<section type="none" id="sidelem4x7442">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> antihypertensive effect—hawthorn</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7449">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7452">
					<section type="none" id="sidelem4x7453">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x7458">
								<item>
									<label>•</label>
									<para>Electrolytes: potassium, sodium, chloride, CO<emphasis style="inf">2</emphasis>, CBC, serum glucose, serum methemoglobin if pulmonary O<emphasis style="inf">2</emphasis> levels are decreased; use IV 1-2 mg/kg methylene blue given over several min for methemoglobinemia, ABGs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7469">
								<item>
									<label>•</label>
									<para>Renal studies: catecholamines, BUN, creatinine</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7477">
							<para>
								<list id="lidelem4x7477">
									<item>
										<label>•</label>
										<para>Hepatic studies: AST, ALT, alk phos
<bbw>
												<emphasis alert="lifethreat">Hypotension:</emphasis> B/P by direct means if possible; check ECG continuously; pulse, jugular venous distention; PCWP; rebound hypertension may occur after nitroprusside is discontinued, give only with emergency equipment nearby, rapid decrease in B/P may occur</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x7490">
								<item>
									<label>•</label>
									<para>Weight daily, I&amp;O</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7496">
								<item>
									<para>
										<emphasis alert="nurse">Thiocyanate, lactate, cyanide toxicity: obtain levels daily if infusion &gt;3 mcg/kg/min; thiocyanate toxicity occurs at plasma levels of 50-100 mcg/ml; thiocyanate toxicity includes confusion, weakness, seizures, hyperreflexia, psychosis, tinnitus, coma</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7501">
								<item>
									<label>•</label>
									<para>Nausea, vomiting, diarrhea</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7506">
								<item>
									<label>•</label>
									<para>Edema in feet, legs daily; skin turgor, dryness of mucous membranes for hydration status</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7511">
								<item>
									<label>•</label>
									<para>Crackles, dyspnea, orthopnea q30min</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7516">
								<item>
									<label>•</label>
									<para>For decrease in bicarbonate, P<emphasis style="smallcaps">co</emphasis><emphasis style="inf">2</emphasis> blood pH, acidosis</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7527">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7531">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased B/P, decreasing symptoms of cardiogenic shock or cardiac pump failure</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7537">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x7541">
								<item>
									<label>•</label>
									<para>To report headache, dizziness, loss of hearing, blurred vision, dyspnea, faintness, pain at IV site</para>
								</item>
								<item>
									<label>•</label>
									<para>About the reason for giving product and expected results</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="40" status="active">
			<mono_name>nizatidine (<emphasis style="smallcaps">otc</emphasis>, Rx)</mono_name>
			<info>
				<pronunciation>(ni-za′ti-deen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x75601">Axid</tradename>
					<tradename id="tnidelem4x75600">Axid AR</tradename>
				</tradenames>
				<class type="func"> H-receptor antagonist</class>
				<class type="chem"> Substituted thiazole</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x7573">
				<sec_title>Action:</sec_title>
				<para>Blocks H<emphasis style="inf">2</emphasis>-receptors, thereby reducing gastric acid output</para>
			</section>
			<section type="uses" id="sidelem4x7581">
				<sec_title>Uses:</sec_title>
				<para>Benign gastric and duodenal ulceration, prevention of duodenal ulcer recurrence, symptomatic relief of gastroesophageal reflux, heartburn prevention</para>
			</section>
			<section type="contra" id="sidelem4x7586">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x7591">
					<section type="none" id="sidelem4x7592">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, renal/hepatic impairment (reduce dose in renal impairment)</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7597">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7600">
					<section type="none" id="sidelem4x7601">
						<sec_title>Gastric and duodenal ulcer</sec_title>
						<section type="none" id="sidelem4x7609">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7609">
									<item>
										<label>•</label>
										<para> 300 mg at night or 150 mg bid for 4-8 wk; maintenance 150 mg at night</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7613">
						<sec_title>Prophylaxis of duodenal ulcer</sec_title>
						<section type="none" id="sidelem4x7621">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7621">
									<item>
										<label>•</label>
										<para> 150 mg/day at bedtime</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7625">
						<sec_title>Gastroesophageal reflux</sec_title>
						<section type="none" id="sidelem4x7633">
							<label>•</label>
							<sec_title>Adult and child ≥12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7633">
									<item>
										<label>•</label>
										<para> 150 mg bid × ≤12 wk, max 300 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7637">
						<sec_title>Heartburn prevention</sec_title>
						<section type="none" id="sidelem4x7645">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7645">
									<item>
										<label>•</label>
										<para> 75 mg before eating bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7649">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x7657">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 20-50 ml/min, give 150 mg every other day; CCr &lt;20 ml/min, give 150 mg q72hr</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x7660">
						<sec_title>Available forms:</sec_title>
						<para> Caps 150, 300 mg; tabs 75 mg</para>
					</section>
					<section type="none" id="sidelem4x7665">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x7669">
								<item>
									<label>•</label>
									<para>With meals for prolonged product effect; antacids 1 hr before or 1 hr after product; at bedtime if taken daily</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7675">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7678">
					<section type="none" id="sidelem4x7679">
						<sec_title>CNS:</sec_title>
						<para> Headache, somnolence, confusion, abnormal dreams, dizziness</para>
					</section>
					<section type="none" id="sidelem4x7684">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Cardiac dysrhythmias, cardiac arrest</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7691">
						<sec_title>ENDO:</sec_title>
						<para> Gynecomastia</para>
					</section>
					<section type="none" id="sidelem4x7696">
						<sec_title>GI:</sec_title>
						<para> Elevated hepatic enzymes, <emphasis style="bold">hepatitis,</emphasis> jaundice, nausea</para>
					</section>
					<section type="none" id="sidelem4x7704">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, agranulocytosis, aplastic anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7711">
						<sec_title>INTEG:</sec_title>
						<para> Pruritus, sweating, urticaria, <emphasis style="bold">exfoliative dermatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7718">
						<sec_title>METAB:</sec_title>
						<para> Hyperuricemia</para>
					</section>
					<section type="none" id="sidelem4x7723">
						<sec_title>MS:</sec_title>
						<para> Myalgia</para>
					</section>
					<section type="none" id="sidelem4x7728">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Bronchospasm, laryngeal edema, pneumonia</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7735">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Partially metabolized by liver, excreted by kidneys, plasma half-life 1-2.8 hr, 70% absorbed orally, small amount (0.1% of plasma concentration) enters breast milk, 35% bound to plasma proteins</para>
			</section>
			<section type="interactions" id="sidelem4x7740">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase:</emphasis>
					<emphasis alert="lifethreat">GI obstruction risk—NIFEdipine (ext rel tabs)</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of—mefloquine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of—ketoconazole, itraconazole, atazanavir, cefditoren, cefpodoxime, delavirdine, gefitinib, raltegravir</para>
				<section type="none" id="sidelem4x7756">
					<section type="none" id="sidelem4x7757">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> ALT, AST, serum creatinine</para>
						<para>
							<emphasis style="bold">False negative:</emphasis> allergy skin tests</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7768">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7771">
					<section type="none" id="sidelem4x7772">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x7780">
							<label>•</label>
							<sec_title>GI pain</sec_title>
							<para>
								<list id="lidelem4x7780">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">GI pain:</emphasis> epigastric, abdominal, character, alleviating factors, hematemesis, occult blood in stool, heartburn, GERD</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x7785">
								<item>
									<para>
										<emphasis alert="nurse">Agranulocytosis: CBC with differential if patient receiving long-term therapy</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7790">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7794">
								<item>
									<label>•</label>
									<para>Decreased GI pain, heartburn, GERD; resolution of gastric, duodenal ulcers</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7801">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x7805">
								<item>
									<label>•</label>
									<para>That gynecomastia, impotence may occur, are reversible</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid driving or other hazardous activities until stabilized on product; that dizziness may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid black pepper, caffeine, alcohol, harsh spices, extremes in temperature of food</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid OTC preparations: aspirin, cough, cold preparations</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="41" status="active" ha="yes">
			<mono_name>norepinephrine (Rx)</mono_name>
			<info>
				<pronunciation>(nor-ep-i-nef′rin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x78380">Levophed</tradename>
				</tradenames>
				<class type="func"> Adrenergic</class>
				<class type="chem"> Catecholamine</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x7848">
				<para>
					<confusion>
						<tradename id="tnidelem4x78480">norepinephrine</tradename>
						<drug type="generic" refid="idelem4x78480">EPINEPHrine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x7852">
				<sec_title>Action:</sec_title>
				<para>Causes increased contractility and heart rate by acting on β-receptors in heart; also acts on α-receptors, thereby causing vasoconstriction in blood vessels; B/P is elevated, coronary blood flow improves, and cardiac output increases</para>
			</section>
			<section type="uses" id="sidelem4x7857">
				<sec_title>Uses:</sec_title>
				<para>Acute hypotension, shock</para>
			</section>
			<section type="contra" id="sidelem4x7862">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or cyclopropane/halothane anesthesia, sulfites; ventricular fibrillation, tachydysrhythmias, pheochromocytoma, hypotension, hypovolemia</para>
				<section type="none" id="sidelem4x7867">
					<section type="none" id="sidelem4x7868">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, arterial embolism, peripheral vascular disease, hypertension, hyperthyroidism, cardiac disease</para>
						<para>
							<bbw>Extravasation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7883">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7891">
					<label>•</label>
					<sec_title>Adult<route> IV INFUSION</route></sec_title>
					<para>
						<list id="lidelem4x7891">
							<item>
								<label>•</label>
								<para> 0.5-1 mcg/min titrated to B/P; maintenance 2-4 mcg/min; max 30 mcg/min</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x7898">
					<label>•</label>
					<sec_title>Child<route> IV INFUSION</route></sec_title>
					<para>
						<list id="lidelem4x7898">
							<item>
								<label>•</label>
								<para> 0.1 mcg/kg/min titrated to B/P; max 2 mcg/kg/min</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x7902">
					<section type="none" id="sidelem4x7903">
						<sec_title>Available forms:</sec_title>
						<para> Inj 1 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x7908">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x7912">
								<item>
									<label>•</label>
									<para>Plasma expanders for hypovolemia</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7918">
							<sec_title>Continuous IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x7922">
									<item>
										<label>•</label>
										<para>Dilute with 500-1000 ml D<emphasis style="inf">5</emphasis>W or D<emphasis style="inf">5</emphasis>/0.9% NaCl; average dilution 4 mg/1000 ml diluent (4 mcg base/ml); give as infusion 2-3 ml/min; titrate to response</para>
									</item>
									<item>
										<label>•</label>
										<para>Store reconstituted sol in refrigerator ≤24 hr, protect from light, store unopened product at room temperature, do not use discolored sol</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alemtuzumab, alfentanil, amikacin, amiodarone, anidulafungin, argatroban, ascorbic acid, atenolol, atracurium, atropine, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, caspo fungin, cefamandole, ceFAZolin, cefmetazole, cefonicid, cefoperazone, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, ceftobiprole, cef TRIAXone, cefuroxime, cephalothin, chloramphenicol, chlorproMAZINE, cimetidine, cisatracurium, CISplatin, clindamycin, cloNIDine, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DAPTOmycin, dexamethasone, digoxin, diltiazem, diphen hydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doripenem, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, ertapenem, erythromycin, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, heparin, hydrocortisone, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, imipenem-cilastatin, irinotecan, isoproterenol, ketorolac, labetalol, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, meperidine, meropenem, metaraminol, methicillin, methotrexate, methoxamine, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, mezlocillin, micafungin, miconazole, midazolam, milrinone, minocycline, mitoXANtrone, morphine, moxalactam, multiple vitamins injection, mycophenolate, nafcillin, nalbuphine, naloxone, netilmicin, niCARdipine, nitroglycerin, nitroprusside, octreotide, ondansetron, oxacillin, oxalipla tin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, papaverine, PEMEtrexed, penicillin G potassium/ sodium, pentamidine, pentazocine, phenylephrine, phytonadione, piperacillin, piperacillin-tazobactam, polymyxin B, potassium chloride, procainamide, prochlorperazine, promethazine, propofol, propranolol, protamine, pyridoxine, quiNIDine, ranitidine, remifentanil, ritodrine, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiamine, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, tobramycin, tolazoline, trimetaphan, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, vitamin B complex with C, voriconazole, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7945">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7948">
					<section type="none" id="sidelem4x7949">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis> anxiety, dizziness, insomnia, restlessness, tremor, <emphasis style="bold">cerebral hemorrhage</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7959">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Palpitations, tachycardia, hypertension, ectopic beats, angina</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7966">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7973">
						<sec_title>GU:</sec_title>
						<para> Decreased urine output</para>
					</section>
					<section type="none" id="sidelem4x7978">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="bold">Necrosis, tissue sloughing with extravasation, gangrene</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7985">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea</para>
					</section>
					<section type="none" id="sidelem4x7990">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7997">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x8000">
					<section type="none" id="sidelem4x8001">
						<sec_title>IV:</sec_title>
						<para> Onset 1-2 min; metabolized in liver; excreted in urine (inactive metabolites); crosses placenta</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x8006">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x8017">
					<label>•</label>
					<sec_title>Incompatible with alkaline solutions<route> sodium, bicarbonate</route></sec_title>
				</section>
				<section type="none" id="sidelem4x8023">
					<label>•</label>
					<sec_title>Severe hypertension<route> guanethidine</route></sec_title>
				</section>
				<para>
					<list id="lidelem4x8027">
						<item>
							<para>
								<emphasis alert="nurse">Do not use within 2 wk of MAOIs, antihistamines, ergots, methyldopa, oxytocics, tricyclics, guanethidine because hypertensive crisis may result</emphasis>
							</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> B/P—oxytocics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> pressor effect—tricyclics, MAOIs</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> norepinephrine action—α-blockers</para>
			</section>
			<section type="considerations" id="sidelem4x8044">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8047">
					<section type="none" id="sidelem4x8048">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x8053">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; notify prescriber if output &lt;30 ml/hr</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8058">
								<item>
									<label>•</label>
									<para>B/P, pulse q2-3min after parenteral route, ECG during administration continuously; if B/P increases, product is decreased, CVP or PWP during infusion if possible</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8066">
							<para>
								<list id="lidelem4x8066">
									<item>
										<label>•</label>
										<para>Paresthesias and coldness of extremities; peripheral blood flow may decrease
<bbw>
												<emphasis alert="lifethreat">Extravasation:</emphasis> inj site: tissue sloughing</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8082">
							<label>•</label>
							<sec_title>
								<route>Sulfite sensitivity, which may be life-threatening</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x8085">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8089">
								<item>
									<label>•</label>
									<para>Therapeutic response: increased B/P with stabilization, adequate tissue perfusion</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8095">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x8099">
								<item>
									<label>•</label>
									<para>About the reason for product administration; to report dyspnea, dizziness, chest pain</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="42" status="active">
			<mono_name>norethindrone (Rx)</mono_name>
			<info>
				<pronunciation>(nor-eth-in′drone)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x811712">Aygestin</tradename>
					<tradename id="tnidelem4x811711">Camila</tradename>
					<tradename id="tnidelem4x811710">Deblitane</tradename>
					<tradename id="tnidelem4x81179">
						<country code="CAN">Errin </country>
					</tradename>
					<tradename id="tnidelem4x81178">Heather</tradename>
					<tradename id="tnidelem4x81177">Jencycla</tradename>
					<tradename id="tnidelem4x81176">Jolivette</tradename>
					<tradename id="tnidelem4x81175">Lyza</tradename>
					<tradename id="tnidelem4x81174">Micronor</tradename>
					<tradename id="tnidelem4x81173">Nora-BE</tradename>
					<tradename id="tnidelem4x81172">Norlyroc</tradename>
					<tradename id="tnidelem4x81171">Nor-QD</tradename>
					<tradename id="tnidelem4x81170">Sharobel</tradename>
				</tradenames>
				<class type="func"> Progestogen</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="actions" id="sidelem4x8126">
				<sec_title>Action:</sec_title>
				<para>Inhibits the secretion of pituitary gonadotropins, which prevents follicular maturation and ovulation; stimulates growth of mammary tissue; antineoplastic action against endometrial cancer</para>
			</section>
			<section type="uses" id="sidelem4x8131">
				<sec_title>Uses:</sec_title>
				<para>Uterine bleeding (abnormal), amenorrhea, endometriosis, contraception</para>
			</section>
			<section type="contra" id="sidelem4x8136">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>), breast cancer, hypersensitivity, thromboembolic disorders, reproductive cancer, genital bleeding (abnormal, undiagnosed), liver tumors, hepatic disease</para>
				<section type="none" id="sidelem4x8141">
					<section type="none" id="sidelem4x8142">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, hypertension, asthma, blood dyscrasias, CHF, diabetes mellitus, depression, migraine headache, seizure disorders, bone/gallbladder/renal/hepatic disease, family history of breast or reproductive tract cancer, smoking, HIV</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8147">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8150">
					<section type="none" id="sidelem4x8151">
						<sec_title>Amenorrhea, abnormal uterine bleeding (Aygestin)</sec_title>
						<section type="none" id="sidelem4x8159">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8159">
									<item>
										<label>•</label>
										<para> 2.5-10 mg/day on days 5-25 of menstrual cycle</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8163">
						<sec_title>Endometriosis (Aygestin)</sec_title>
						<section type="none" id="sidelem4x8171">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8171">
									<item>
										<label>•</label>
										<para> 5 mg/day × 2 wk, then increased by 2.5 mg/day × 2 wk up to 15 mg/day, may continue for 6-9 mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8175">
						<sec_title>Contraception</sec_title>
						<section type="none" id="sidelem4x8183">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8183">
									<item>
										<label>•</label>
										<para> 0.35 mg on 1st day of menses, then 0.35 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8187">
						<sec_title>Available forms:</sec_title>
						<para> Tabs (Aygestin) 5 mg; tabs 0.35 mg</para>
					</section>
					<section type="none" id="sidelem4x8192">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x8196">
								<item>
									<label>•</label>
									<para>Titrated dose; use lowest effective dose</para>
								</item>
								<item>
									<label>•</label>
									<para>One dose in <emphasis style="smallcaps">am</emphasis>; do not interrupt between pill packs; give at roughly same time of day</para>
								</item>
								<item>
									<label>•</label>
									<para>Without regard to meals</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in dark area</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8220">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8223">
					<section type="none" id="sidelem4x8224">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, headache,</emphasis> migraines, depression, fatigue</para>
					</section>
					<section type="none" id="sidelem4x8232">
						<sec_title>CV:</sec_title>
						<para> Hypotension, <emphasis style="bold">thrombophlebitis,</emphasis> edema, <emphasis style="bold">thromboembolism, CVA, stroke, PE, MI</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8242">
						<sec_title>EENT:</sec_title>
						<para> Diplopia</para>
					</section>
					<section type="none" id="sidelem4x8247">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> vomiting, anorexia, cramps, increased weight, <emphasis style="bold">cholestatic jaundice</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8257">
						<sec_title>GU:</sec_title>
						<para> Amenorrhea, cervical erosion, breakthrough bleeding, dysmenorrhea, vaginal candidiasis, breast changes, (gynecomastia, testicular atrophy, impotence), endometriosis, <emphasis style="bold">spontaneous abortion,</emphasis><emphasis style="italic">breast tenderness</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8266">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, acne, hirsutism, alopecia, oily skin, seborrhea, purpura, melasma</para>
					</section>
					<section type="none" id="sidelem4x8271">
						<sec_title>META:</sec_title>
						<para> Hyperglycemia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8276">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Excreted in urine, feces; metabolized in liver, half-life 5-14 hr</para>
			</section>
			<section type="interactions" id="sidelem4x8281">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Decrease:</emphasis> progestin effect—barbiturates, carBAMazepine, fosphenytoin, phenytoin, rifampin</para>
				<section type="none" id="sidelem4x8288">
					<section type="none" id="sidelem4x8289">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis alert="lifethreat">Decrease: contraception—St. John’s wort</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x8295">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> caffeine level—caffeine</para>
					</section>
					<section type="none" id="sidelem4x8302">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LDL</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> GTT, HDL, alk phos</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x8313">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8316">
					<section type="none" id="sidelem4x8317">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x8321">
								<item>
									<label>•</label>
									<para>Weight daily: notify prescriber of weekly weight gain &gt;5 lb</para>
								</item>
								<item>
									<label>•</label>
									<para>B/P at beginning of treatment and periodically</para>
								</item>
								<item>
									<label>•</label>
									<para>I&amp;O ratio; be alert for decreasing urinary output, increasing edema</para>
								</item>
								<item>
									<label>•</label>
									<para>Hepatic studies: ALT, AST, bilirubin periodically during long-term therapy</para>
								</item>
								<item>
									<label>•</label>
									<para>Edema, hypertension, cardiac symptoms, jaundice, thromboembolism</para>
								</item>
								<item>
									<label>•</label>
									<para>Mental status: affect, mood, behavioral changes, depression</para>
								</item>
								<item>
									<label>•</label>
									<para>Hypercalcemia</para>
								</item>
								<item>
									<label>•</label>
									<para>Breast exam, pap smear</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8363">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8367">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased abnormal uterine bleeding, absence of amenorrhea</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8373">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x8378">
								<item>
									<label>•</label>
									<para>About cushingoid symptoms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8384">
								<item>
									<para>
										<emphasis alert="nurse">To report breast lumps, vaginal bleeding, amenorrhea, edema, jaundice, dark urine, clay-colored stools, dyspnea, headache, blurred vision, abdominal pain, numbness or stiffness in legs, chest pain; impotence or gynecomastia (men)</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8389">
								<item>
									<label>•</label>
									<para>To take at same time of day; not to interrupt between pill packs</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8397">
							<label>•</label>
							<sec_title>
								<route>To report suspected pregnancy immediately, to wait ≥3 mo after stopping product to become pregnant, pregnancy (X); to use backup contraception methods for 48 hr if treatment is not begun on the first day of menstruation</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x8400">
								<item>
									<label>•</label>
									<para>To avoid smoking; CV reactions may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8405">
								<item>
									<label>•</label>
									<para>That product does not protect against HIV, STDs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8410">
								<item>
									<label>•</label>
									<para>That product may mask onset of menopause</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="43" status="active">
			<mono_name>nortriptyline (Rx)</mono_name>
			<info>
				<pronunciation>(nor-trip′ti-leen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x84201">
						<country code="CAN">Arentyl </country>
					</tradename>
					<tradename id="tnidelem4x84200">Pamelor</tradename>
				</tradenames>
				<class type="func"> Antidepressant, tricyclic</class>
				<class type="chem"> Dibenzocycloheptene—secondary amine</class>
			</info>
			<section type="confusion" id="sidelem4x8433">
				<para>
					<confusion>
						<tradename id="tnidelem4x84330">nortriptyline</tradename>
						<drug type="generic" refid="idelem4x84330">amitriptyline</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x8437">
				<sec_title>Action:</sec_title>
				<para>Blocks reuptake of norepinephrine and serotonin into nerve endings, thereby increasing action of norepinephrine and serotonin in nerve cells</para>
			</section>
			<section type="uses" id="sidelem4x8442">
				<sec_title>Uses:</sec_title>
				<para>Major depression</para>
				<section type="none" id="sidelem4x8447">
					<section type="none" id="sidelem4x8448">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Chronic pain management, PMDD, social phobia, panic disorder, enuresis, migraine prophylaxis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x8453">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to tricyclics, recovery phase of MI, seizure disorders, prostatic hypertrophy</para>
				<section type="none" id="sidelem4x8458">
					<section type="none" id="sidelem4x8459">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, suicidal patients, severe depression, increased intraocular pressure, closed-angle glaucoma, urinary retention, cardiac/hepatic disease, hyperthyroidism, electroshock therapy, elective surgery, pregnancy (C), carBAMazepine hypersensitivity</para>
						<para>
							<bbw>Children, suicidal ideation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8474">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8482">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x8482">
							<item>
								<label>•</label>
								<para> 25 mg tid or qid; may increase to 150 mg/day; may give daily dose at bedtime</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x8489">
					<label>•</label>
					<sec_title>Adolescent<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x8489">
							<item>
								<label>•</label>
								<para> 1-3 mg/kg/day in 3-4 divided doses or daily at bedtime, max 150 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x8496">
					<label>•</label>
					<sec_title>Child 6-12 yr (unlabeled)<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x8496">
							<item>
								<label>•</label>
								<para> 1-3 mg/kg/day in 3-4 divided doses, max 150 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x8503">
					<label>•</label>
					<sec_title>Geriatric<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x8503">
							<item>
								<label>•</label>
								<para> 10-25 mg at bedtime, increase by 10-25 mg at weekly intervals to desired dose; usual maintenance 75 mg/day, max 150 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x8507">
					<section type="none" id="sidelem4x8508">
						<sec_title>Available forms:</sec_title>
						<para> Caps 10, 25, 50, 75 mg; sol 10 mg/5 ml</para>
					</section>
					<section type="none" id="sidelem4x8513">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x8518">
								<item>
									<label>•</label>
									<para>Store in tight, light-resistant container at room temperature</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8523">
								<item>
									<label>•</label>
									<para>Increased fluids, bulk in diet if constipation occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8528">
								<item>
									<label>•</label>
									<para>Without regard to meals</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8533">
								<item>
									<label>•</label>
									<para>Dosage at bedtime for oversedation during day; may take entire dose at bedtime; geriatric patients may not tolerate once-daily dosing</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8538">
								<item>
									<label>•</label>
									<para>Gum, hard candy, frequent sips of water for dry mouth</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8546">
							<label>•</label>
							<sec_title>Oral solution</sec_title>
							<para>
								<list id="lidelem4x8546">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Oral solution:</emphasis> with fruit juice, water, or milk to disguise taste</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8551">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8554">
					<section type="none" id="sidelem4x8555">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, drowsiness,</emphasis> confusion, headache, anxiety, tremors, stimulation, weakness, insomnia, nightmares, EPS (geriatric patients), increased psychiatric symptoms, <emphasis style="bold">seizures</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8565">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Orthostatic hypotension,</emphasis><emphasis style="bold">ECG changes,</emphasis><emphasis style="italic">tachycardia,</emphasis><emphasis style="bold">hypertension,</emphasis> palpitations, <emphasis style="bold">dysrhythmias</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8581">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Blurred vision,</emphasis> tinnitus, mydriasis, dry eyes</para>
					</section>
					<section type="none" id="sidelem4x8589">
						<sec_title>ENDO:</sec_title>
						<para> SIADH, hyponatremia, hypothyroidism</para>
					</section>
					<section type="none" id="sidelem4x8594">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Constipation, dry mouth,</emphasis> nausea, vomiting, <emphasis style="bold">paralytic ileus,</emphasis> increased appetite, cramps, epigastric distress, jaundice, <emphasis style="bold">hepatitis,</emphasis> stomatitis, weight gain</para>
					</section>
					<section type="none" id="sidelem4x8608">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Urinary retention,</emphasis><emphasis style="bold">acute renal failure,</emphasis> sexual dysfunction</para>
					</section>
					<section type="none" id="sidelem4x8618">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, thrombocytopenia, eosinophilia, leukopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8625">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, sweating, pruritus, photosensitivity</para>
					</section>
					<section type="none" id="sidelem4x8630">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Serotonin syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8637">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x8640">
					<section type="none" id="sidelem4x8641">
						<sec_title>PO:</sec_title>
						<para> Steady-state 4-19 days; metabolized by liver; excreted by kidneys; crosses placenta; excreted in breast milk; half-life 18-28 hr, protein binding 93%-95%</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x8646">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x8652">
						<item>
							<para>
								<emphasis alert="nurse">Increase: QT prolongation—class IA/III antidysrhythmics, some phenothiazines, β agonists, local anesthetics, tricyclics, haloperidol, chloroquine, droperidol, pentamidine; CYP3A4 inhibitors (amiodarone, clarithromycin, erythromycin, telithromycin, troleandomycin), arsenic trioxide, levomethadyl; CYP3A4 substrates (methadone, pimozide, QUEtiapine, quiNIDine, risperiDONE, ziprasidone)</emphasis>
							</para>
						</item>
					</list>
				</para>
				<para>
					<list id="lidelem4x8657">
						<item>
							<label>•</label>
							<para>Heavy smoking: decreased product effect</para>
						</item>
					</list>
				</para>
				<para>
					<list id="lidelem4x8663">
						<item>
							<para>
								<emphasis alert="nurse">Hyperpyretic crisis, seizures, hypertensive episode: MAOI</emphasis>
							</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of direct-acting sympathomimetics (EPINEPHrine), alcohol, barbiturates, benzodiazepines, CNS depressants, products increasing QT interval, other anticholinergics</para>
				<para>
					<emphasis alert="nurse">Increase: serotonin syndrome, neuroleptic malignant syndrome—SSRIs, SNRIs, serotonin receptor agonists, linezolid; methylene blue (IV)</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of guanethidine, cloNIDine, indirect-acting sympathomimetics (ePHEDrine)</para>
				<section type="none" id="sidelem4x8681">
					<section type="none" id="sidelem4x8682">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS effect—kava, valerian</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> nortriptyline level—St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x8693">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> serum bilirubin, blood glucose, alk phos</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> VMA, 5-HIAA</para>
						<para>
							<emphasis style="bold">False increase:</emphasis> urinary catecholamines</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x8708">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8711">
					<section type="none" id="sidelem4x8712">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Suicidal thoughts/ behaviors in children/young adults:</emphasis> not approved for children, monitor for suicidal ideation in depression, adolescents, young adults</bbw>
						</para>
						<para>
							<list id="lidelem4x8728">
								<item>
									<label>•</label>
									<para>Monitor for glaucoma exacerbation and paralytic ileus</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8733">
								<item>
									<label>•</label>
									<para>B/P (lying, standing), pulse q4hr; if systolic B/P drops 20 mm Hg, hold product, notify prescriber; VS q4hr in patients with CV disease</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8738">
								<item>
									<label>•</label>
									<para>Blood studies: thyroid function tests, LFTs, serum nortriptyline level/target 50-150 mg/ml if patient is receiving long-term therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8743">
								<item>
									<label>•</label>
									<para>Weight weekly; appetite may increase with product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8749">
								<item>
									<para>
										<emphasis alert="nurse">PR, QT prolongation: ECG for flattening of T wave, bundle branch block, AV block, QT prolongation, dysrhythmias in cardiac patients; assess for chest pain, palpitations, dyspnea</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8754">
								<item>
									<label>•</label>
									<para>EPS primarily in geriatric patients: rigidity, dystonia, akathisia, preferred tricyclic in geriatric patients</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8759">
								<item>
									<label>•</label>
									<para>Mental status changes: mood, sensorium, affect, suicidal tendencies, increase in psychiatric symptoms, depression, panic</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8764">
								<item>
									<label>•</label>
									<para>Urinary retention, constipation; constipation is more likely to occur in children</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8771">
								<item>
									<para>
										<emphasis alert="nurse">Withdrawal symptoms: headache, nausea, vomiting, muscle pain, weakness; do not usually occur unless product was discontinued abruptly</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8776">
								<item>
									<label>•</label>
									<para>Alcohol intake; if alcohol is consumed, hold dose until <emphasis style="smallcaps">am</emphasis></para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8786">
							<label>•</label>
							<sec_title>Serotonin syndrome, neuroleptic malignant syndrome<route> assess for increased heart rate, shivering, sweating, dilated pupils, tremors, high B/P, hyperthermia, headache, confusion; if these occur, stop product, administer serotonin antagonist if needed (rare)</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x8789">
								<item>
									<label>•</label>
									<para>Assistance with ambulation during beginning therapy because drowsiness/dizziness occurs; safety measures including side rails, primarily for geriatric patients</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8794">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8798">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased depression</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8804">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x8809">
								<item>
									<label>•</label>
									<para>That therapeutic effects may take 2-3 wk; only small quantities may be dispersed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8814">
								<item>
									<label>•</label>
									<para>To use caution when driving, during other activities requiring alertness because of drowsiness, dizziness, blurred vision</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8819">
								<item>
									<label>•</label>
									<para>To avoid alcohol ingestion, other CNS depressants; to avoid MAOIs within 14 days</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8824">
								<item>
									<label>•</label>
									<para>Not to discontinue medication quickly after long-term use; may cause nausea, headache, malaise</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8829">
								<item>
									<label>•</label>
									<para>To wear sunscreen or large hat because photosensitivity occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8835">
								<item>
									<para>
										<emphasis alert="nurse">To immediately report urinary retention, worsening depression, suicidal thoughts/behaviors</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="44" status="active">
			<mono_name>nystatin (Rx)</mono_name>
			<info>
				<pronunciation>(nye-stat′in)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x88504">Bio-Statin</tradename>
					<tradename id="tnidelem4x88503">Mycostatin</tradename>
					<tradename id="tnidelem4x88502">
						<country code="CAN">Nadostine</country>
					</tradename>
					<tradename id="tnidelem4x88501">Nilstat</tradename>
					<tradename id="tnidelem4x88500">Nyamyc</tradename>
				</tradenames>
				<class type="func"> Antifungal</class>
				<class type="chem"> Amphoteric polyene</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x8863">
				<sec_title>Action:</sec_title>
				<para>Interferes with fungal DNA replication; binds sterols in fungal cell membrane, which increases permeability, leaking of cell nutrients</para>
			</section>
			<section type="uses" id="sidelem4x8868">
				<sec_title>Uses:</sec_title>
				<para>
					<emphasis style="italic">Candida</emphasis> species causing oral, intestinal infections</para>
			</section>
			<section type="contra" id="sidelem4x8875">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x8880">
					<section type="none" id="sidelem4x8881">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>)</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8886">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8889">
					<section type="none" id="sidelem4x8890">
						<sec_title>Oral infection</sec_title>
						<section type="none" id="sidelem4x8898">
							<label>•</label>
							<sec_title>Adult/adolescent/child<route> SUSP</route></sec_title>
							<para>
								<list id="lidelem4x8898">
									<item>
										<label>•</label>
										<para> 400,000-600,000 units qid; use <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> dose in each side of mouth; swish and swallow; use for at least 48 hr after symptoms resolved</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8911">
							<label>•</label>
							<sec_title>Infant<route> SUSP</route></sec_title>
							<para>
								<list id="lidelem4x8911">
									<item>
										<label>•</label>
										<para> 200,000 units qid (100,000 units in each side of mouth)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8918">
							<label>•</label>
							<sec_title>Newborn and premature infant<route> SUSP</route></sec_title>
							<para>
								<list id="lidelem4x8918">
									<item>
										<label>•</label>
										<para> 100,000 units qid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8925">
							<label>•</label>
							<sec_title>Adult/child<route> TROCHES</route></sec_title>
							<para>
								<list id="lidelem4x8925">
									<item>
										<label>•</label>
										<para> 200,000-400,000 units qid × ≤2 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8929">
						<sec_title>GI infection</sec_title>
						<section type="none" id="sidelem4x8937">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8937">
									<item>
										<label>•</label>
										<para> 500,000-1,000,000 units tid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8941">
						<sec_title>Cutaneous candidiasis</sec_title>
						<section type="none" id="sidelem4x8949">
							<label>•</label>
							<sec_title>Adult/child<route> Top cream/ointment</route></sec_title>
							<para>
								<list id="lidelem4x8949">
									<item>
										<label>•</label>
										<para> apply to affected area bid;  apply to affected area bid-tid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8956">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 500,000 units; oral caps 500,000, 1,000,000 units, bulk powder; suspension 100,000 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x8961">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x8965">
								<item>
									<label>•</label>
									<para>Store at room temperature for oral susp; tabs in tight, light-resistant containers at room temperature</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8972">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x8976">
									<item>
										<label>•</label>
										<para>Oral susp dose by placing <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> in each cheek, then swallow; do not mix with food</para>
									</item>
									<item>
										<label>•</label>
										<para>Topical dose after cleansing area; mouth may be swabbed; very moist lesions best treated with topical powder</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8993">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8996">
					<section type="none" id="sidelem4x8997">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, anorexia, diarrhea, cramps</para>
					</section>
					<section type="none" id="sidelem4x9002">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria (rare)</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9007">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x9010">
					<section type="none" id="sidelem4x9011">
						<sec_title>PO:</sec_title>
						<para> Little absorption, excreted in feces</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x9016">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9019">
					<section type="none" id="sidelem4x9020">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x9028">
							<label>•</label>
							<sec_title>Allergic reaction</sec_title>
							<para>
								<list id="lidelem4x9028">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Allergic reaction:</emphasis> rash, urticaria, irritated oral mucous membranes; product may have to be discontinued</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x9032">
								<item>
									<label>•</label>
									<para>Obtain culture, histologic tests to confirm organism</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9037">
								<item>
									<label>•</label>
									<para>Predisposing factors: antibiotic therapy, pregnancy, diabetes mellitus, sexual partner infection (vaginal infections)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9042">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x9046">
								<item>
									<label>•</label>
									<para>Therapeutic response: culture negative for <emphasis style="italic">Candida</emphasis></para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9054">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x9058">
								<item>
									<label>•</label>
									<para>That long-term therapy may be needed to clear infection; to complete entire course of medication</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid commercial mouthwashes for mouth infection</para>
								</item>
								<item>
									<label>•</label>
									<para>To shake susp before measuring each dose</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber of irritation; product may have to be discontinued</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="45" status="active">
			<mono_name>nystatin topical</mono_name>
			<section type="none" id="sidelem4x9082">
				<para>
					<see refid="tra">See Appendix B</see>
				</para>
			</section>
		</monograph>
</alpha>
</drug_guide>